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Abstract
Phage Selection Against Antibiotic Resistance or Virulence in Opportunistic Bacterial Pathogens
Kaitlyn E. Kortright
2021

Bacteriophages (phages) are prolific, ubiquitous viruses that infect bacterial cells. Phages have
proven to be invaluable tools of the biological sciences enabling the discovery and description of
some of the foundations of molecular biology and genetics; excellent systems for the study of
evolutionary dynamics; and their seemingly limitless diversity promises to produce interesting
new biology for many years to come. As natural predators of bacteria, phages might additionally
be employed for phage therapy, the therapeutic use of phages to treat bacterial infections. Lytic
phages impose strong selective pressure on bacteria to evolve resistance to phage infection. Under
certain environmental conditions this selection pressure can result in the evolution of phage
resistance at reduced fitness; this is an example evolutionary trade-off, or the evolution of a certain
trait at the detriment of the fitness. In particular, it is possible that phage-imposed selection on
bacterial surface expressed molecules may result in reduced antibiotic resistance and/or attenuated
virulence of opportunistic bacterial pathogens. In this thesis, we will examine the idea of phageimposed trade-offs on opportunistic bacterial pathogens.
A published review paper serves as the first chapter and an introduction to phage biology
and phage therapy. We present the history of the discovery of phages as well as the early reports
of phage therapy. We highlight recent animal studies, case reports and clinical trials that have
investigated the therapeutic use of phage. Finally, we discuss new approaches to phage therapy as
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well as identify interesting question and potential hurdles that will likely underscore a modern
approach to phage therapy.
In chapter 2, transposon insertion sequencing (INSeq) is used as a high-throughput method
to identify phage receptors to find new phage that use antibiotic resistance or virulence factors as
receptors. Preliminary experiments using characterized phages T2, T4, T6 and T7 demonstrate that
the top results of INSeq screens with phage are involved in phage binding. These screens were
extended to enable receptor identification for five newly isolated phages, R3, U115, EC35, EC14
and 8S. Adsorption assays and efficiency of plaquing assays to demonstrate phage binding and
infection are used to validate the results of the INSeq screens with uncharacterized phage. In
summary, this chapter establishes the use of INSeq screens as a high-throughput method to
determine phage receptors which should allow for identification of phage that target virulence
factors or molecules contributing to antibiotic resistance.
Evolutionary dynamics between Pseudomonas aeruginosa and a lytic phage, OMKO1 that
selects against antibiotic resistance, are examined in a short-term coevolution experiment in
chapter 3. Time shift assays showed that coevolution of the three treatment populations followed
arms race dynamic. Interestingly, only one treatment population demonstrated the predicted tradeoff between phage resistance and antibiotic resistance. Sequencing of bacterial population allowed
for identification of mutations underlying bacterial evolution and the trade-off. Results from this
study demonstrate that evolution may not be as repeatable or predictable as previous experimental
evolution studies have suggested.
In chapter 4, we identify a new Shigella flexneri phage that selects for phage-resistant
bacteria that are attenuated for virulence. We isolate and characterize a new Myoviridae phage,
A1-1 which uses OmpA of S. flexneri as a receptor. Assays to interrogate membrane permeability
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including, live-dead staining, minimum inhibitory concentrations to various antibiotics and
measurements of total lipopolysaccharide (LPS) quantity demonstrated that phage A1-1 selects for
two different phenotypes of resistant mutants: OmpA deficient and altered LPS. Whole genome
sequencing revealed that the five phage-resistant mutants examined in this study have mutations
either in ompA or in genes involved in LPS biosynthesis genes. Using bacterial plaque assays, we
showed that all five resistant mutants are attenuated for intercellular spread, indicating that in the
case of phage A1-1, phage resistance trades off with bacterial virulence.
While the previous two chapter highlight phage selection resulting in a trade-off, the final
chapter involves a system in which phage selection resulted in a trade-up with antibiotic resistance.
Tsx is a nucleoside porin in Escherichia coli which also serves as a receptor for phage T6, phage
U115 and albicidin, a DNA gyrase inhibitor. We showed that selection for resistance to any of
these three antibacterials resulted in cross-resistance to the other two. Competition assays showed
resistance to these antibacterials does not result in a fitness cost relative to wild-type. In all 29 of
the resistant mutants observed in this study, mutations in tsx were found. The trade-up between
phage resistance and antibiotic resistance in this study highlights the need for rigorous studies of
phage-bacteria interactions prior to deployment of phage therapy.
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Preface
Chapter 1 has been adapted from a review article that has previously published: Kortright, K. E.,
Chan, B. K., Koff, J. L., & Turner, P. E. (2019). Phage therapy: a renewed approach to combat
antibiotic-resistant bacteria. Cell host & microbe, 25(2), 219-232. Kaitlyn Kortright and Dr. Paul
Turner planned, conceptualized and prepared the manuscript. Dr. Benjamin Chan and Dr. Jon
Koff provided useful feedback, comments and edits. We thank Caeul Lim and three anonymous
reviewers for helpful comments on the manuscript. This work was supported by a Pilot Award
from the Cystic Fibrosis Foundation.
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Abstract
Phage therapy, long overshadowed by chemical antibiotics, is garnering renewed interest in
Western medicine. This stems from the rise in frequency of multidrug resistant bacterial infections
in humans. There also have been recent case reports of phage therapy demonstrating clinical utility
in resolving these otherwise intractable infections. Nevertheless, bacteria can readily evolve phage
resistance too, making it crucial for modern phage therapy to develop strategies to capitalize on
this inevitability. Here, we review the history of phage therapy research. We compare and contrast
phage therapy and chemical antibiotics, highlighting their potential synergies when used in
combination. We also examine the use of animal models, case studies and results from clinical
trials. Throughout, we explore how the modern scientific community works to improve the
reliability and success of phage therapy in the clinic, and discuss how to properly evaluate the
potential for phage therapy to combat antibiotic resistant bacteria.
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Chapter Introduction
Soon after Alexander Fleming’s 1928 discovery of penicillin and Western medicine’s widespread
use of antibiotics since the 1940’s, Fleming himself warned that misuses of these drugs could result
in antibiotic resistant bacteria 1. As predicted, clinical reports of antibiotic resistance followed,
such as the evolution of resistant Mycobacterium tuberculosis in early clinical trials for
streptomycin efficacy in treating tuberculosis 2. Nevertheless, the discovery and development of
novel antibiotics flourished for many decades 3. However, in the latter 20th century, antibiotic
discovery slowed and the alarming increase in rates of antibiotic resistance signaled that the golden
age of antibiotics had perhaps ended. Indeed, aside from three new antibiotic classes discovered
between 2005 and 2018, no novel drug classes have been developed since the 1980s 4-6. Similar
mechanism of action among these newer drugs has led to potential evolution of cross resistance in
bacteria. While synthetic modifications to some pre-existing antibiotics have temporarily extended
their clinical usefulness 7, this approach has also selected for broader resistance mechanisms such
as extended spectrum beta lactamases 8, adaptive changes that are perhaps more easily evolved
compared to de novo resistance mechanisms.
In 2017, the World Health Organization (WHO) highlighted the particular threat of Gramnegative pathogens resistant to multiple antibiotics 9. Discovery, design, and development of new
and alternative antibacterial therapies are crucial. This review concerns the therapeutic use of
bacteriophages (phages): viruses that exclusively infect bacteria and can act as bactericidal agents.
This approach of ‘phage therapy’ is an old idea that is recently regaining popularity. Efforts are
buoyed by development of easier methods for engineering phages for different purposes in
biotechnology

10

. Also, the extreme biodiversity of phages in nature

11, 12

can be leveraged for

‘bioprospecting’: discovery and development of naturally evolved phages with properties that are
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ideal for phage therapy use

13

. Below we examine the past, present and future uses of phage

therapy, especially addressing how this newly energized field may proceed with modern, rational
therapeutic approaches.
Phage Biology
During a lytic infection cycle (Figure 1.1) a phage will: (1) attach to receptor(s) on the surface of
a bacterium; (2) deliver the genomic content into the bacterium; (3) undergo viral replication in
the cytosol via bacterial transcription, translation and replication; and (4) upon formation of new
phage particles, escape the cytoplasm through lysis of the bacterium. This process is then repeated
by the new phage particles as they infect additional susceptible cells. This highlights a longunderstood benefit of phage therapy: utilizing lytic viruses as self-amplifying ‘drugs’ that target
and kill susceptible cells may be more efficient than applying antibiotics that are incapable of selfamplification.
Obligately lytic (or ‘virulent’) phages seem to be the best candidates for development of
phage therapy (hereafter we refer to such phages simply as ‘lytic’). However, for completeness we
briefly remind that lysogenic (or temperate) phages are also prevalent in nature. Lysogenic phages
integrate into the host genome, and are inherited by daughter cells during binary fission; however,
at a later time, under environmental perturbation or other physiological stressor, lysogenic phages
excise from the bacterial genome and enter a lytic infection cycle. While lysogenic phages might
be preferred in certain biotechnology applications, lytic phages are more akin to antibiotic drugs
lethal to bacteria, which suggests an easier path to approval for treating bacterial infections.
In the mid-20th century bacteria and lytic phages were used in classic experiments to
elucidate fundamentals of biology and genetics, including demonstration of the spontaneous nature
of mutations, DNA as hereditary material, and triplet nature of the amino-acid code 14-16. Beyond
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these studies, it is increasingly recognized that phage biodiversity is immense. Importantly,
whereas some phages are highly specific to a single species or even genotypic strain of bacteria 17,
other phages have naturally broad host ranges or can easily mutate to infect bacterial genotypes
and species other than the typical host 18. The aforementioned first step of lytic phages infection is
attachment to the receptor(s) on the cell surface. These receptor binding sites are most commonly
proteins or sugar moieties on the bacterial cell, which are recognized by phage proteins that are
effectively responsible for phage host specificity (Figure 1.2). There are many well characterized
examples of phage binding, especially the morphological structures used for these purposes. For
instance, phage T4 uses two sets of tail fibers, long and short, to bind to susceptible Escherichia
coli bacteria 19; phage SPP1 uses a tail spike to attach to Bacillus subtilis hosts 20; the Siphoviridae
family of phages generally use baseplate proteins to initiate infection of Lactococcus lactis bacteria
21

; and Cystoviridae phages such as phi-6 infect Pseudomonas syringae via attachment proteins

embedded within an envelope that surrounds the nucleocapsid

22

. However, the immensity of

phage biodiversity suggests that the basic biology of phage binding to bacterial proteins remains a
vastly untapped science, ripe for new discoveries. The presence of phage-binding sites and their
possible structural variation should affect specialized versus generalized ability for phage
attachment. Nevertheless, in the following sections we highlight that historical efforts in phage
therapy have not always investigated and characterized the receptor binding site(s) used by phages
to initiate infection. Clearly, current development of phage therapy candidates could include: an
investigation of the receptor binding site(s) used by phages when infecting bacteria; whether
phage-imposed selection for changes in these structures alters therapy success; and how the
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evolution of bacterial resistance to therapeutic phages may affect bacterial fitness components,
such as rates of cell division and expression of pathogenicity traits.
Early Phage Therapy
The discovery of phages is attributed to the independent work of two microbiologists: Frederik
Twort in 1915 and Félix d’Hérelle in 1917. While Twort was the first to observe and describe the
effects of a ‘transparent material’ that inhibited bacterial growth

23

, it was not until 1917 when

d’Hérelle isolated an anti-Shigella microbe, that the idea of an obligate parasite of bacteria was
termed bacteriophage or “bacteria-eater”

24

. Almost immediately after his discovery, d’Hérelle

recognized the therapeutic potential of phages as a treatment for bacterial diseases. In 1919, he
successfully used phages to treat chickens infected with Salmonella gallinarum 25, 26. This success
in animals soon led d’Hérelle to attempt treating human infections with phages. In 1921, five
patients with bacillary dysentery were successfully treated with a phage that infects Shigella
dysenteriae 26, 27. In 1927, clinical trials treating cholera in India showed that mortality decreased
from 62.8% in control groups to 8.1% in phage-treated groups 28. Furthermore, d’Hérelle noted
that introducing anti-cholera phages into drinking wells of villages during an outbreak prevented
additional infections from occurring 28.
Early-identified challenges
Soon after d’Hérelle’s initial successes, many other scientists recognized the therapeutic and
prophylactic potential of phages and began to target other infections, though with varying success.
Among criticisms surrounding the design and quality of early phage therapy trials, scientists
started identifying some potential challenges of phage therapy. (1) The possible drawback of
extreme phage specificity was recognized early on, indicating that a phage may not be useful
without prior characterization of bacterial susceptibility. For example, in 1923, Beckerish and
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Hauduroy used phages successfully to reduce bacterial load in the blood of patients with typhoid
fever

29

, whereas a year later Smith (1924) unsuccessfully used phages on a similar patient

population; Hadley (1928) speculated Smith’s failure stemmed from unknowingly using phages
with a narrow host-range. d’Hérelle himself acknowledged this weakness, attributing the success
of his early trials to careful choice of phages capable of infecting the causative bacterial agent 26.
(2) The early methods used to bulk-manufacture therapeutic phages were likely heavily
contaminated with lysed bacteria. With limited and unreliable filtering and purification steps, the
possible beneficial effects of phages were difficult to separate from the confounding effects of
contaminating bacterial antigens

30

. (3) Early pharmacokinetic experiments showed that phages

were rapidly removed from the body via the spleen, calling into question the sustained efficacy of
phages over time 31. (4) In 1943, Luria and Delbruck used selection by lytic phages to calculate
spontaneous mutation rates of bacteria, and in doing so, demonstrated that bacteria are readily
capable of evolving resistance to lytic phage attack 16. (5) Lastly, early studies showed that in vitro
laboratory experiments with phages and bacteria did not always match with experimental
outcomes observed in vivo 32-34. As these perceived problems were identified, in Western medicine,
the interest in phage therapy waned relative to newly discovered chemotherapeutics, antibiotics,
and the trend away from phage therapy in the West was firmly cemented through the 1970s. This
sentiment was in stark contrast to vested interests of physicians and scientists in the then USSR,
Poland and elsewhere who continued to develop phage therapy in earnest; the legacy continues to
be evident in locales such as the G. Eliava Institute of Bacteriophages in Tbilisi, Georgia. This
important work has been the focus of numerous prior reviews and will not be discussed

35

.

However, as new antibiotic resistance mechanisms arose for every novel class and compound, and
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the incidence of antibiotic resistant infections increased globally, phage therapy was re-considered
by the West.
Smith and Huggins’ pioneering studies
This interest was propelled forward in the 1980s with a series of well-designed experiments by
Smith and Huggins. These experiments addressed many of the historic criticisms of phage therapy
described above, while demonstrating safety and efficacy in animal models. Smith and Huggins
began by showing that phage effectiveness in vitro could correlate with in vivo efficacy and
ultimately chose phage R, which demonstrated the greatest in vitro virulence, for further
characterization

36

. Phage R appears limited in host range, only infecting K1+ E. coli and likely

uses the K1 capsule as a receptor. Through a series of lethal bacterial challenges in mice, Smith
and Huggins demonstrated that a single dose of phage R was as effective as eight doses of
streptomycin 36. In the same experiment, they showed that bacterial lysate, free of phages, provided
no therapeutic effect. After intramuscular inoculation of mice with no bacterial challenge, they
observed that phages persisted in the inoculated muscle and spleen 28 days after the original
inoculation while it was cleared relatively rapidly from the liver and blood at 16 and 20 hours post
inoculation, respectively. Smith and Huggins noted that all phage-resistant mutants, observed at a
frequency of ~0.01, were K1- variants that had been previously shown to be avirulent. In a single
paper, Smith and Huggins were able to address many previous criticisms. Furthermore, they
observed phage therapy to be potentially more effective than chemical antibiotics.
Smith and Huggins further investigated factors that could influence the effectiveness of
phage therapy in an E. coli diarrhea model in calves. They cleverly employed a rational multiphage approach to combat the emergence of resistant mutants 37. Specifically, after choosing lytic
phage B44/1 that only infected K85+ strains of E. coli, they isolated phage-resistant mutants in
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vitro. Subsequently, they chose a second phage B44/3 for its ability to infect bacteria that were
resistant to the first phage B44/1, and additionally selected for B44/3-resistant mutants that were
susceptible to phage B44/1 infection. By examining phage resistance prior to the therapeutic use
of these phages, Smith and Huggins were able to anticipate the evolution of phage resistance and
use a dual-phage approach that might limit the emergence of phage-resistant bacteria. In 1987,
Smith and Huggins examined the stability of phages during orally administered therapy and
observed that poor phage stability in the acidic environment of the stomach could be countered by
administering calcium carbonate prior to phages

38

. These revolutionary studies by Smith and

Huggins determined that the many perceived criticisms of phage therapy were unfounded or less
concerning than believed, paving the way for new and rational approaches to phage therapy.
Other scientists have since re-examined and expanded on Smith and Huggins’ studies.
Rapid clearance of phages in vivo was originally deemed a negative aspect of phage therapy, but
Merril et al. (1996) demonstrated that it is possible to select for phage variants that are long
circulating in blood 39. Following Smith and Huggins favorable results in phage treatment of mice
infected with E. coli, Soothill et al. (1992) demonstrated efficacy of phage treatment in mice
infected with either Pseudomonas aeruginosa or Acinetobacter baumanii

40

. In 2002, Bull and

Levin et al. revisited Smith and Huggins’ original experiments comparing the efficacy of K1
antigen targeting phages versus a non-K1 targeting phages against E. coli in mice

41

. The K1-

antigen targeting phage was observed to protect 100% of mice treated immediately, while the nonK1 targeting phage resulted in 60% mortality. In a second experiment, phage therapy resulted in
9% mortality compared to streptomycin which resulted in 54% mortality. These data confirm
Smith and Huggins results that K1-capsule targeting phages are more effective in treatment than
non-K1 targeting phages or antibiotic treatment 41.
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Phage Therapy: A Renewed Approach
The ability to characterize and test phages as antibacterial therapies has advanced immensely. The
current era offers inexpensive whole-genome sequencing, automated technology for measuring the
growth of microbes, and efficient high-throughput methods for screening hundreds or even
thousands of samples simultaneously. Meanwhile, it is increasingly recognized that modern
clinical trials should be carefully designed to be safer, more inclusive, and (if possible) to generate
valuable data, compared to earlier attempts. An appropriately conducted phage therapy trial should
be double-blinded and placebo-controlled with large diverse cohorts, and perhaps designed to
generate relevant longitudinal data from clinical isolates. For example, researchers could conduct
follow-up lab studies and whole-genome sequencing of phages and/or bacteria taken during
treatment, to test a myriad of basic and clinical microbiology as well as evolutionary hypotheses.
Also, our increased understanding of the human microbiome and its interactions with human
immunology warrant closer investigation of possible phage and immune system interactions in
clearing infections.
However, one obvious limitation to phage therapy is the inevitable evolution of phage
resistance in bacteria

42

. Modern approaches to phage therapy should both acknowledge and

capitalize on this certainty. Evolutionary biology describes how genetic trade-offs should be
widely observed in biological systems; organisms sometimes evolve one trait that improves fitness
(a relative advantage in survival or reproduction), while simultaneously suffering reduced
performance in another trait 43-48. Phage therapy would thus benefit from utilizing certain phages,
which select for the target bacterial pathogen to suffer specific genetic trade-offs 49. In particular,
if the proximate binding of a lytic phage is known to associate with a virulence factor or
mechanism for antibiotic resistance in the target bacteria, this should exert strong selection for the
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bacteria to mutate or down regulate the phage-binding target(s). This approach should be
especially useful in the case of opportunistic bacterial pathogens, because the bacteria could evolve
reduced virulence or antibiotic resistance and still thrive in a different ecological setting (e.g., soil)
as opposed to ‘arms-race’ selection for escalating virulence in an obligate pathogen such as in
response to vaccine pressure (e.g., Marek’s Disease virus in chickens 50). Thus, this approach to
phage therapy should be doubly effective; success is achieved when phages lyse the target
bacterium, but also when bacteria evolve phage resistance because they suffer reduced virulence
or increased sensitivity to antibiotics. In the following sections we return to this paradigm of phageimposed genetic trade-offs.
A phage that requires a virulence factor to attach to and infect a bacterium may select
against the expression of that virulence factor (Figure 1.3). Selection against virulence factors
could be multiply effective as some virulence factors such as capsules have been shown to hide
antigenic sites

51

, provide some degree of antibiotic resistance

52

, and prevent phagocytosis by

macrophages 51. Phages that use components of LPS as receptors select against the expression of
these components typically resulting in ‘rough’ colony-forming mutants through phase variable
expression of LPS, point mutations or even large chromosomal deletions in LPS biosynthesis
genes 53-57. Bacterial mutants that evolve resistance to LPS targeting phages are typically have both
reduced fitness and virulence 58. Selection against other virulence factors that can serve as phage
receptors such as adhesins, pili or secretion systems could prevent bacterial attachment and
invasion of epithelial cells 59-62.
Similarly, phages that attach to an antibiotic efflux pump to infect may select against the
expression of the efflux pump, rendering the bacteria more sensitive to antibiotics that were
previously effluxed (Figure 1.3). For example, phage TLS selected for tolC and rfa mutants in E.
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coli at a typical frequency of 10-5 to 10-6 63. The TLS-resistant mutants with altered TolC were
hyper-sensitive to novobiocin. Additionally, when phage-resistant mutants were selected in the
presence of novobiocin, the frequency of recovered mutants decreased 1000-fold. More recently,
it was demonstrated that phage OMKO1 associates with the outer membrane protein M (OprM) of
MexAB- and Mex-XY-OprM efflux pumps of the opportunistic pathogen P. aeruginosa 64. This
interaction selects for phage-resistant mutants that are sensitive to antibiotics, as a ‘genetic tradeoff’. Chan et al. demonstrated that phage-resistant mutants, in both lab strains and clinical isolates
of P. aeruginosa, were more sensitive to antibiotics including ceftazidime 64. This was likely due
to mutations or deletions in the operon encoding for the multidrug efflux pump resulting in
nonfunctional gene products. Hypothetically, this promising result might also occur in other
bacterial pathogens with similar modes of achieving broad antibiotic resistance via homologous or
convergent efflux pump mechanisms. Overall, thoughtful consideration of the inevitable evolution
of phage resistance during treatment could greatly benefit phage therapy efforts.
Animal Models for Efficacy
Animal studies can help bridge the gap between in vitro studies and actual clinical application of
phage therapy. Unfortunately, most animal models investigate acute infections, which may not be
the ideal analog for phage therapy targeting chronic infections in humans. Many of these studies
observe best results when phages are applied simultaneously with the bacterial challenge, which
will not necessarily be applicable in the clinic. In many cases, no measures were taken to check
for the in vivo evolution of phage resistance by bacteria. Also, the comparison of phage treatment
to antibiotic treatment or even a combination of phage and antibiotic treatments are only beginning
to be investigated in animal models. Nevertheless, animal models provide vitally useful data on
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efficacy and safety of phage therapy in living hosts, and are crucial for further development of the
approach.
Systemic Infections
Several studies have investigated the efficacy of phage therapy for treatment of systemic
infections. In a gut-derived model of P. aeruginosa sepsis, Watanabe et al. (2007) observed 67%
survival of infected mice when phage therapy was administered orally one day post infection 65.
Capparelli et al. (2007) observed that successful protection of mice with a systemic
Staphylococcus aureus infection depended on phage dose 66; Biswas et al. (2002) observed similar
results of dose dependent success in a mouse model of vancomycin-resistant Enterococcus faecium
bacteremia 67. In a systemic disease model of Vibrio vulnificus, successful control of disease was
only achieved when bacterial infection and phage treatment were administered simultaneously 68.
The determinants of success for phage therapy to treat systemic infections are likely dependent on
multiple factors which need to be thoroughly examined prior to the widespread use of phages as a
treatment for sepsis in humans.
Local Infections
Phage therapy for localized infections (e.g., otitis, urinary tract infections, infected burns) is
recognized for its potential to entirely circumvent the use of chemical antibiotics. Furthermore,
use of chemical antibiotics for surgical and hospital acquired infections is limited as these often
constitute the strains with greatest antibiotic resistance. Watanabe et al. (2007) observed 92%
survival of mice with an intraperitoneal P. aeruginosa infection treated simultaneously with
phages 65. A similar study of S. aureus abscesses in mice by Capparelli et al. (2007) enumerated
the reduction in bacterial load resulting from phage therapy, and observed that phages applied
concurrently with bacteria prevented the formation of abscesses 66. When administered four days

14

after bacterial challenge, a single dose of phages resulted in a 100-fold reduction in bacterial load,
whereas multiple doses of phages resulted in a 10,000-fold reduction 66. In a mouse model of P.
aeruginosa infection of burn wounds, phage treatment improved survival rate from 6% in the
untreated controls to 88% when phages were administered via intraperitoneal injection 72 hours
post infection

69

. In contrast, phage treatment only resulted in 22% or 28% survival when

administered subcutaneously or intramuscularly. Further pharmacokinetic studies demonstrated
that phages delivered intraperitoneally persisted at higher levels in the liver, spleen and blood than
phages delivered intramuscularly or subcutaneously69. Finally, a murine model was used to
investigate the ability of phages to treat an E. coli urinary tract infection 70. Phages administered
intraperitoneally 24 hours after bacterial challenge resulted in a 100-fold reduction in bacterial
load in the kidneys 48 hours after phage treatment. The same phages resulted in a significant
reduction in bacterial load in an E. coli pneumonia model, but was ineffective in an E. coli model
of sepsis.
Gastrointestinal Infections
Applying phage therapy to gastrointestinal bacterial infections could potentially reduce or prevent
colonization of virulent bacteria without disrupting the natural gut flora. Galtier et al. (2017)
observed that a preventative treatment of phages, four days after an adherent-invasive E. coli
challenge, was able to reduce bacterial colonization in the gut of dextran sodium sulfate treated
mice and prevented the progression of colitis symptoms

71

. In an insect model of Clostridium

difficile colonization, prophylactic treatment with phages two hours prior to bacterial challenge
resulted in 100% survival, while simultaneous administration of phages and bacteria resulted in
72% survival, and phage administration two hours post bacterial challenge resulted in 30%
survival 72. Yen et al. (2017) observed that prophylactic treatment with a phage cocktail was able
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to reduce V. cholerae colonization in the small intestine of infant mice when phages were provided
three and six hours prior to bacterial challenge 73. However, phage-resistant bacterial mutants were
recovered after treatment, and effects of phage treatment were reduced when administered more
than six hours before bacterial challenge and when mice were challenged with a higher dose of V.
cholerae 73. While the result of prophylactic treatment of gastrointestinal infections with phages
are generally favorable, more studies that provide treatment after bacterial challenge, such as
Galtier et al. (2017), are needed as prophylactic treatment is not always possible in the clinic 71.
Lung Infections
Phage therapy for the treatment of lung infections, particularly chronic lung infections which are
common in those with cystic fibrosis (CF), has seen renewed interest recently with the increase in
MDR bacteria associated with the lung. Waters et al. (2017) observed complete eradication of a
CF strain of P. aeruginosa in mice when two doses of phages were administered intranasally to
infected mice 24/36 or 48/60 hours after infection74. Treatment at 144/156 hours post infection
resulted in complete eradication of infection in 70% of mice and a significant reduction in the
remaining 30%. In another CF lung infection model, phage treatment significantly improved the
survival rate of mice when administered intranasally at two hours post infection 75. Interestingly,
a high dose of phages administered 4 days prior to bacterial challenge provided complete
protection to mice, indicating that prophylactic treatment with phages could prevent chronic
infections. Semler et al. (2014) investigated different routes of administration of phages in a mouse
model of Burkholderia cepacia complex respiratory infection 76. A 100-fold decrease in bacterial
load was observed when phages were administered via nebulization while no decrease was
observed when administered via intraperitoneal injection

76

. Promising results for both
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prophylactic and curative treatment of lung infections with phages indicate that these types of
infections may be a reliable target for effective phage therapy.
Antibiotic and Phages in Combination
While there have been many in vivo studies on the efficacy of phage therapy, not many recent
studies have compared the in vivo efficacy of phage therapy to that of antibiotics or even combined
phages and antibiotic treatment. Huff et al. (2004) investigated the efficacy of traditional
antibiotics, phage treatment, or a combination of both in a head-to-head trial in an E. coli challenge
in broiler chickens

77

. The standard of care treatment, enrofloxacin (fluoroquinolone), reduced

mortality from 68% in untreated birds to 3%, while phage treatment alone reduced mortality to
15%. A combination therapy of phages and enrofloxacin resulted in no mortality

77

. Similarly,

Oechslin et al. (2016) observed that phages in combination with ciprofloxacin resulted in a 10,000fold greater reduction in bacterial load as compared to phages or ciprofloxacin treatment alone in
rats with experimental endocarditis due to P. aeruginosa

78

. Furthermore, they noted that this

particular combination of phages and antibiotics resulted in synergistic killing of P. aeruginosa
both in vitro and in vivo 78. As the future of phage therapy will likely be that of combined therapy
with chemical antibiotics, additional studies examining potential synergy between phages and
antibiotics both in vitro and in vivo are needed.
Compared to phage therapy studies in vivo animal models, there have been relatively few
reports on the clinical use of phages and even fewer controlled clinical trials. As summarized in
Table 1.1, below we describe some notable case studies and clinical trials that have been
performed; the lists are not exhaustive and other examples can be found in the literature 79, 80.
Case Reports of Emergency Phage Therapy
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Case 1: Pseudomonas Sepsis Case Report
A child with DiGeorge syndrome and congenital heart disease presented with P. aeruginosa
bacteremia following multiple surgeries that included insertion of a pacemaker

81

. Anti-

pseudomonal antibiotics initially controlled the infection but ultimately failed. Adverse reactions
to cephalosporins and fluoroquinolones further limited antibiotic options. Phages provided by the
US Navy were screened for lytic activity against the infectious strain and a cocktail of two phages
was created. After intravenous phage administration, blood cultures fluctuated between positive
for P. aeruginosa and below the limit of detection for several days. Phage therapy was resumed
on day 11, following a temporary cessation due to decompensation attributed to progressive heart
failure, which coincided with four days of blood cultures negative for P. aeruginosa. In this case,
phage therapy appeared to reduce the infection in the blood, though was apparently ineffective at
source control as blood cultures reverted to positive upon termination of therapy.
Case 2: Urinary Tract Infection Case Report
Khawaldeh et al. (2011) reported treating a P. aeruginosa urinary tract infection associated with a
bilateral ureteral stent

82

. Following cessation of antibiotic therapy, the infection consistently

recurred within a week. Libraries of phages from the Eliava Institute were screened against the
bacterial isolate and a suitable commercial phage product identified. This phage cocktail contained
phages with activity against Streptococcus pyogenes, S. aureus, E. coli, P. aeruginosa, Proteus
vulgaris and Proteus mirabilis. On day six of the treatment, antibiotic therapy with meropenem
and colistin was initiated. Khawaldeh et al. (2011) reported 10-fold reduction of bacteria in the
urine after five days of phage treatment. Two days of subsequent antibiotic treatment resulted in
apparent clearance of the infection at which point culturable P. aeruginosa was below the limit of
detection 82. Following completion of the 30-day course of meropenem, both stents were removed
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and one was replaced. Urine samples remained sterile for one year after treatment, at which point
observations were concluded.
Case 3: Surgical Site Infection Case Report
LaVergne et al. (2018) reported a postoperative A. baumanii infection in an individual following
a craniectomy 83. Strains of A. baumannii isolated from the infection were resistant to almost all
antibiotics and antibiotic combination therapy. Phages provided by the US Navy were screened
for lytic activity against the infectious strain and a cocktail of five phages was chosen for
therapeutic use. Five minutes after phage administration, the concentration of phages in blood was
approximately 100 PFU/mL. This was approximately 100-fold lower than expected if the phages
were simply diluted into an average human blood volume 10 minutes after administration, phages
were undetectable. Despite initial improvements, the lack of significant improvement led to
withdrawal of care. Unfortunately, bacterial load was not measured during the course of treatment
and it is difficult to attribute any clinical improvement to the administration of phages. It appears
that in this case, phages were actively removed from the blood, either through adsorption to
bacteria in vivo, or active removal by the body.
Case 4: Pancreatitis Case Report
Phage therapy was utilized in a case of necrotizing pancreatitis complicated by an MDR A.
baumannii infected pseudocyst

84

. Phages from several institutions were screened against the

isolated infectious strains and two cocktails each consisting of four different phages were
formulated. The first cocktail was administered via lavage at the site of the pancreatic pseudocyst.
The following day, the second cocktail was administered intravenously. Resistance emerged
against all of the phages used in both cocktails by eight days after the first administration of phages,
suggesting phage selection occurred in vivo. A third phage cocktail was formulated that was active
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against the resistant strains and was again administered intravenously. Resistance to the original
cocktails correlated with increased presence of encapsulated bacteria, further suggesting bacterial
response to phage administration. Phage therapy was continued for approximately 12 weeks, over
the course of which clinical improvement was observed and the infection was eventually resolved.
Case 5: Aortic Graft Infection Case Report
Surgical intervention to repair an aortic aneurysm with a Dacron graft resulted in a P. aeruginosa
infection that was refractory to standard treatment

13

. This chronic infection resulted in the

formation of an aorto-cutaneous fistula with purulent discharge. Infection control was attempted
with intravenous ceftazidime followed by oral ciprofloxacin. Resistance to ciprofloxacin evolved
during the course of treatment, debridement and irrigation were unsuccessful in resolving the
infection, and surgical replacement of the graft was not an option. After three years of suppressive
chemical antibiotic therapy which failed to eradicate the infection other options for infection
control were considered. A recent report of P. aeruginosa phage OMKO1 that had demonstrated
synergy when used in combination with ceftazidime 64 was screened for lytic activity against the
strain. Instillation of a single dose of phage OMKO1 and ceftazidime was applied topically at the
site of fistular discharge while continuing the existing therapy of intravenous ceftazidime. Four
weeks after the administration of phages, partial graft excision and replacement was required
following bleeding from the fistula. Cultures taken at the time of surgery were negative for P.
aeruginosa and the course of ceftazidime was discontinued. Two years after phage treatment, there
was no recurrence of the infection in the absence of any antibiotic therapy. The favorable outcome
of this case underscores the rational choice of phages and route of administration for this particular
infection; thoughtful selection of a phage that had previously demonstrated synergism with the
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clinically relevant antibiotics applied in proximity to the source of infection undoubtedly
contributed to the positive outcome.
Clinical Trials of Phage Therapy
Trial 1: Otitis Clinical Trial
In 2009, a clinical trial was designed to investigate the safety and preliminary efficacy of phage
therapy for treating chronic P. aeruginosa otitis 85. Wright et al. (2009) utilized a cocktail of six
phages with lytic activity against P. aeruginosa in individuals with chronic otitis

85

. While the

authors report a significant accumulated reduction of bacterial counts in the phage treatment group
and no significant accumulated change of bacterial counts in the placebo group, three individuals
from each group had undetectable levels of P. aeruginosa by day 42. Phages were isolated for an
average of 23 days from individuals in the phage treatment group suggesting that phages were
either cleared upon resolution of the infection, phages were unable to reach the site of infection,
or the bacteria became phage-resistant. There were no serious adverse events reported in either
group, indicating the safety of phage therapy for the treatment of otitis.
Trial 2: Diarrheal-Disease Clinical Trial
A clinical trial was conducted in Bangladesh to test safety and efficacy of two different phage
cocktails that target pathogenic E. coli in diarrheal diseases 86. Individuals presenting with acute
onset of dehydrating diarrhea were admitted to the study. Phage treatment consisted of oral
administration of one of two different phage cocktails that had been previously characterized: a
T4-like phage cocktail (T) containing 11 phages and a commercial phage cocktail (M) from Russia
consisting of at least 17 different phages in oral rehydration solution. Standard treatment of oral
rehydration solution was given to the placebo group. There were no adverse effects reported and
no significant differences between the phage treatment and placebo groups. It was unclear if the
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phages were lytic against the specific E. coli strains causing disease and no actions were taken to
buffer the stomach prior to the administration of phages. It is possible, therefore, that significant
numbers of phage particles were unable to survive the low-pH environment of the stomach, and
that the surviving particles were unable to amplify due to the lack of an appropriate host 87.
Trial 3: PhagoBurn Burn Wound Clinical Trial
The most recent clinical trial to date, PhagoBurn, evaluated the safety and efficacy of phage
therapy to treat P. aeruginosa infected burn wounds 88. A phage cocktail of 12 phages with lytic
activity against P. aeruginosa were added to an alginate template that was applied directly to the
wound. The control group received standard of care treatment which consisted of 1% sulfadiazine
silver applied topically. The average time to sterilization for the phage treated group and control
group was 144 hours and 47 hours, respectively. These unexpectedly poor results could be
explained by administration of a lower phage dose than intended. The concentration of the phage
cocktail had dropped over the course of the study and a dose of 200 to 2000 PFU was used instead
of the expected 2 × 107 PFU dose. With concentrations of phages 4-5 orders of magnitude lower
than expected it is possible, if not probable, that the lack of efficacy can be attributed to this
unintended change in the treatment protocol.
Perspectives and Future Directions
Will Phages Ever Replace Antibiotics?
A rational approach to phage therapy has many potential advantages over a traditional chemical
antibiotic approach (Table 1.2). (1) The non-lethal nature of some bacteriostatic antibiotics may
permit antibiotic resistance to evolve more easily, as well as accommodate the emergence of
persistor cells that are genotypically equivalent to wild-type bacteria yet physiologically capable
of withstanding antibiotic exposure

89

. On the other hand, lytic phages are always bactericidal,
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lysing cells at the completion of their replication cycle. Furthermore, phages (unlike antibiotics)
hijack most essential cellular processes including DNA replication, transcription and translation
upon infection and are perhaps harder targets for evolution of bacterial resistance

90

. (2) The

popular broad-spectrum antibiotics may disrupt the normal balance of the microbiome which
might otherwise provide a protective effect by occupying niche sites that prevent or constrain
bacterial pathogens from invading the body 91. (3) Phages can be specific to species and even single
strains of bacteria, making them an ideal therapeutic to selectively target and kill pathogens 90. The
clinical use of phages will likely require preliminary laboratory assays to identify sensitivity of
strains to therapeutic phages. Phage sensitivity could be determined in parallel with antibiotic
sensitivity to ensure a better match between the proposed drug (phage) and the target bacterial
strain. Relatedly, this may explain why the above-described case reports have been generally more
successful than clinical trials to date (see case studies and clinical trials summarized in Table 1.1).
(4) In addition, while antibiotics must be continually dosed to clear infection, phages are able to
amplify at the site of infection (suggesting fewer doses should be needed) and will be cleared from
the body when the susceptible bacteria are gone. (5) Resistance to antimicrobials is inevitable 16.
However, unlike antibiotic therapy, phage therapy can take advantage of this outcome via careful
choice of therapeutic phages that select for resistant bacterial mutants with lower fitness, especially
reduced virulence or impaired antibiotic efflux (see above section on Phage Therapy: A Renewed
Approach). (6) Furthermore, as phages co-evolve with bacteria over time, it is possible that the
administered phage population will evolve to infect the phage-resistant bacteria (an arms race),
which is not possible for antibiotics. (7) Phage treatment of biofilms may prove more promising
than antibiotic treatment of biofilms
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; however, this difference may depend on the target

bacterium and the general benefits of using phages in treating biofilms merits further investigation

23

92

. (8) Finally, while novel antibiotic discovery has stagnated in recent years, discovery of new

phages has proven expeditious due to the vast biodiversity of phages in nature that have useful
properties in biotechnology 7, 90.
However, even with this more rational phage therapy approach, phages still have some
limitations compared to traditional chemical antibiotics that need to be addressed before phage
therapy can be fully accepted in modern clinical practice (Table 1.2). (1) Phages will likely not be
an appropriate therapeutic for all infections. While some antibiotics are capable treating
intracellular bacterial pathogens, phages do not have a reliable mechanism of entry into eukaryotic
cells. (2) Also, there has been decades of research performed on antibiotics and their interactions
with the immune system, whereas abundant analogous research with phages has yet to be
completed

90, 93

. (3) Since phages can be found everywhere, including within the human

microbiome, neutralizing antibodies against certain phages typically associated with humans may
be a general obstacle for phage therapy. (4) Because a phage population can undergo rapid
exponential growth, widespread lysis of target bacteria can potentially release bacterial antigens
that could be dangerous, particularly if the phages are administered internally; thus, endotoxin
removal from preparations of phage lysates intended for therapy, as well as generation of
endotoxins during therapy are valid concerns. (5) Finally, regulatory hurdles represent a significant
barrier to the implementation of phage therapy in modern medicine; unlike the well-established
path to approval of antibiotics, this path is currently being paved for phages and therefore very
little useful precedence exists.
Realistically, therapeutic use of phages may never completely replace administration of
chemical antibiotics and may be inappropriate under some clinical conditions, suggesting that
adjuvant approaches should be closely studied. A mixed therapy of phages and antibiotics could
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be an ideal combination that capitalizes on each treatment’s differing strengths (Table 1.2). Bedi
et al. (2009) observed an additive effect when phages and antibiotics were used to treat a Klebsiella
pneumoniae biofilm48. Knezevic et al. (2013) investigated the potential for phage-antibiotic
synergism and observed synergy between P. aeruginosa phages and subinhibitory concentrations
of ceftriaxone, but not with gentamicin, ciprofloxacin or polymyxin B 94. They proposed that the
mechanism of action of the antibiotic must not interfere with critical processes in phage replication
to see a synergistic effect. While not all phage and antibiotic combinations appear to be synergistic
and the mechanisms behind synergism are still being explored, precision medicine is currently in
vogue, and phage therapy shows promise as a ‘personalized’ approach for at least some infected
individuals. As with any drug, the ideal circumstance is that phage therapy should be developed to
reduce off-target effects and to minimize disruption of helpful microbiome communities to the
extent possible.
Other Considerations for Phage Therapy
One method employed to expand phage host-range and subvert the criticism of narrow spectrum
is to combine multiple phages to create phage cocktails. Traditionally, this has been perceived as
a benefit, allowing the cocktail to be used against different strains or species of bacteria, and
presumably decreasing the likelihood that mutations against all of the phages will simultaneously
occur. Recent case studies show that in principle either a single phage or phage-cocktail approach
might work (see Clinical Cases). However, a conceivable drawback of phage cocktails is their
ability to select for “broad-spectrum” mechanisms of phage resistance, such as the production of
a capsule that surrounds the cell, preventing phage binding. For these reasons, a rational approach
to designing cocktails is warranted, involving consideration of: mechanism(s) whereby phage
resistance can evolve; potential for bacteria to develop cross-resistance to multiple phages; and
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confirmation that the various phages in a cocktail do not compete with one another to reduce the
overall efficacy. At the least, we see relevance for a more dedicated merger between phage-cocktail
formulation and core principles and theories of evolution and ecological competition.
A related subject is the mode of delivery for phages in therapy, and whether this choice
would impact relative ratios of phages to bacteria at the site(s) of infection, and/or ratios among
phages in a cocktail as they are administered versus the times when they actually encounter the
infecting bacteria. The self-amplifying nature and lethality of lytic phages suggest that this therapy
should often avoid the analogous consequence of bacterial evolution of resistance to chemical
antibiotics delivered at too low of concentration. However, the density of phage particles relative
to target bacterial cells may greatly impact timing and quality of the phage therapy outcome, and
mode of delivery necessarily affects these key ratios. Therefore, the route of administration for
phage therapy should consider the most likely method to deliver the highest concentration of phage
particles to the site of infection, and therapeutic approaches might consider low initial doses of
phages that are adjusted over time. Phage studies have not focused very closely on the therapy
benefits versus costs of changes in the multiplicity of infection (ratio of phage particles to target
susceptible bacterial cells) over time, either via administration or by estimating changes within the
treated human or animal model; this seems like a relevant focus for phage therapy research moving
forward.
Summary
Renewed interest in phage therapy in the West, and its continued development in countries such
as Poland, Russia, and Georgia, mark a time for optimism for a viable alternative (or adjunct) to
antibiotic therapy. Phage therapy like any medical treatment has benefits, costs and limitations in
usefulness that merit close scrutiny

95

. Overall, we can identify several intriguing questions and
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topics that should be addressed, especially as greater numbers of clinical trials on phage therapy
are planned and executed. Is it possible to discover or engineer individual phage strains that
broadly infect genotypes of a target pathogen, meriting their approval as standalone ‘drugs’? Or,
would additional experiments on phage cocktails provide convincing evidence that phage mixtures
should be the standard of care? Bioprospecting for phages is likely to continue yielding candidates
with useful biologically properties, such as ability to select for reduced virulence and resensitization of bacteria to antibiotics. But what is the probability that bacteria can evolve
simultaneous resistance to both phages and antibiotics at no cost? How can the process of
bioprospecting for phages be made more efficient? Could developing genomics and bioinformatics
analyses as well as computer algorithms help identify potential phage candidates and predict
phage-binding to cell receptors, strictly through high-throughput sequencing? Would reliable
models such as non-pathogenic E. coli yield sufficiently useful data to predict utility of phage
therapy in pathogens that are much harder to culture in the laboratory or where we lack animal
models for acute and chronic bacterial diseases? How is phage therapy observed or theoretically
predicted to interact with the immune system and human microbiomes 93, 96, 97, to either enhance
or suppress this approach in resolving systemic and biofilm infections? How would these
interactions differ in sites as different as the respiratory and gastrointestinal systems? This nonexhaustive list highlights many hypotheses regarding phage therapy that should be the focus of
future basic research. Fortunately, this is an opportune time for basic researchers, clinicians, and
physicians to work together to address open questions through rigorous experiments in the
laboratory, in vivo models and clinical cases to reward phage therapy with the renewed interest
and greater examination that it deserves.
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Chapter 1 Figures
Figure 1.1 Lytic phage infection cycle

A cycle of lytic phage replication begins when the virus recognizes and irreversibly binds to a receptor (protein or
sugar) on the surface of a bacterial cell. The phage delivers its genomic content into the cytoplasm of the bacterial
cell. Typically, host resources, including proteins and genomes are repurposed to fuel phage replication. Replication,
transcription and translation of the phage genome begins usually through redirecting host metabolism to the production
of new phage particles. Upon assembly of new phage particles, lysis of the bacterial cell allows newly replicated phage
particles to escape the cytoplasm and go on to infect other phage-sensitive bacterial cells.
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Figure 1.2 Examples of bacterial receptors for phage binding

Phage encode binding proteins that recognize and attach to sites on the surface of a bacterial cell. Many phage bind to
protein structures on the bacteria such as pili (depicted in red) 22, flagella (yellow) 60, porins (blue) 19 or efflux pumps
(purple) 64. Phage have also been reported to bind to specific sugar moieties in LPS (green) 22.
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Figure 1.3 Phage selection against virulence or antibiotic resistance

Certain lytic phage may be more effective in phage therapy, because they kill target bacteria while simultaneously
imposing strong selection against bacterial virulence or antibiotic resistance when bacteria mutate to avoid phage
attack. Phage that use antibiotic efflux pumps as receptors (red) can select for phage-resistant bacterial mutants with
impaired efflux pumps; these phage-resistant bacterial mutants are more sensitive to antibiotics 23. Phage that bind to
structural virulence factors such as a capsular antigen (purple) can select for phage-resistant bacterial mutants that
lack the capsule 38; these non-capsulated phage-resistant mutants are less virulent bacteria because they are more easily
engulfed by phagocytic cells 52.
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Table 1.1 Case Reports and Clinical Trials
Clinical Case Reports
Infection

Case 1

Case 2

Case 3

Case 4

Case 5
Clinical

Complicating
Conditions

Pseudomonas DiGeorge syndrome
aeruginosa
and congenital heart
bacteremia
disease with pace
maker
Pseudomonas Intra-abdominal
aeruginosa
resection and
urinary tract
irradiation for
infection (2
adenocarcinoma,
years)
bilateral ureteral stent
placement
Acinetobacter Craniectomy
baumanii
surgical site
infection
Acinetobacter Necrotizing
baumanii
pancreatitis
infected
pseudocyst (3
months)
Pseudomonas Aorto-cutaneous
aeruginosa
fistula
infected aortic
graft (3 years)
Trials

Antibiotic
Courses

MEM, TOB,
MEM, TOB, ATM,
ATM, PMB and PMB, CST
CST
GEN, CAZ, CIP None reported
and MEM

Trial

5

Initial PT for 36
hours (6 doses
total), PT resumed
11 days later
7
2 × 10 PFU directly instilled 10 days (MEM and
into the bladder every 12 hours CST treatment
initiated on day 6)
3.5 × 10 PFU delivered
intravenously every six hours

7

Combination of Intermediate
CST, AZM and sensitivity to CST
RIF
with resistance to all
other tested antibiotics
AZM, CST,
Cephalosporins,
RIF
MEM, GEN, AMK,
SXT, TET, CIP and
CST

8.56 × 10 PFU delivered
intravenously every two hours

CAZ and CIP

1 × 10 PFU delivered
topically on fistula

Treatment
group
Pseudomonas Placebo-controlled,
12 individuals
double blind for safety received phage
Trial 1 aeruginosa
otitis
and efficacy
cocktail
Infection

Antibiotic Resistance
Duration of
Phage Dose and Application
or Allergies
Phage Treatment

CIP

Placebo group

8 days (98 doses
total)

Outcome
Blood cultures negative
after PT but reverted to
positive upon cessation
of PT
Urine samples sterile
following a 30-day
course of MEM

Initial improvements
observed; bacterial load
not measured

9

84 days (336 doses Clinical improvement
total), MIN added and resolution of
on day 2
infection

8

Single dose

5 × 10 PFU delivered
intravenously every six hours

Phage Dose and Application

Cultures negative at four
weeks post treatment

Outcome

9

12 individuals
10 PFU delivered intra aurally Three patients from each group had
received single dose of (single dose)
undetectable levels of P. aeruginosa at the
glycerol-PBS buffer
end of the trial

Details and summaries are provided for each of the case reports and clinical trials discussed in the main text.
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Table 1.1 Continued

Trial 2

Escherichia
coli diarrheal
diseases

Placebo-controlled,
40 individuals
double blind for safety received phage
and efficacy
cocktail M, 39
individuals
received phage
cocktail T

Pseudomonas Placebo-controlled,
12 individuals
aeruginosa
blinded trial for safety received a phage
Trial 3 burn wound
and efficacy
cocktail
infection

41 individuals
received oral
rehydration solution

13 individuals
received standard of
care 1% sulfadiazine
silver

9

1.4 × 10 PFU cocktail M or
8

3.6 × 10 PFU cocktail T
delivered orally in oral
rehydration solution 3 times
per day for 4 days (12 doses
total)
7
2 × 10 PFU (expected) 2002000 PFU (actual) applied
topically 1 time per day for 7
days (7 doses)

No significant difference between PT group
and placebo group

Trial was stopped early due to insufficient
efficacy of PT as compared to the standard of
care (placebo) treatment. This was likely due
to significantly lower applied dose of phage
than expected.

MEM, meropenem; TOB, tobramycin; ATM, aztreonam; PMB, polymyxin B; CST, colistin; GEN, gentamicin; CAZ, ceftazidime; AZM, azithromycin; RIF, rifampin;
AMK, amikacin; MIN, minocycline; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; CIP, ciprofloxacin; PT, phage treatment
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Table 1.2 Comparing and contrasting antibiotics and phage

Antibiotics

Lytic (‘Virulent’) Phage

Activity & Mechanism of Action
Bacteriostatic or bacteriacidal
Typically disrupts ONE bacterial process
Broad-spectrum more common than narrowspectrum
Disruption of microbiome

Bacteriacidal
Disrupts MANY/ALL bacterial processes

Not very effective against biofilms

Penetration and destruction of biofilms

High degree of species or strain specificity
Only disrupts target bacteria

Clinical Use
Minimal identification of bacteria
Short time between diagnosis and treatment
Constant dosing to maintain inhibitory
concentrations
Potential for immune recognition
Widely accepted; used as treatment for
infections
Diffusion through membranes allows for
treatment of intracellular bacteria

Phage tested against target bacteria
Longer time between diagnosis and
treatment
Self-amplifying while target bacteria are
present
Potential for immune recognition
Push back on clinical application; only used
on a compassionate care basis
Unable to penetrate eukaryotic cells

Discovery, production & manufacturing
Slow discovery process

Rapid discovery process
Steps must be taken to ensure removal of
Production methods in place to ensure safety
contaminating bacterial antigens generated
of products
during production
Regulations for production & manufacturing Require new regulations for production &
in place
manufacturing
Resistance
Resistance inevitable
Resistance frequently accompanied by
compensatory mutations

Resistance inevitable but phage can coevolve
to infect resistant bacteria
Resistant mutants may result in lower
fitness via reduced virulence or antibiotic
sensitivity

A rational approach to phage therapy has many potential benefits that cannot be achieved with antibiotics alone.
However, there are also limitations to phage therapy, in comparison to traditional antibiotics. While many of these
differences historically have been considered limitations to using phage therapy, in some circumstances the perceived
drawbacks may instead be leveraged as benefits. Both types of therapies historically have been administered alone;
however, with many identified differences, a combination approach utilizing both therapies may prove to be the most
efficacious in the long run
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Chapter 2: High-throughput discovery of phage receptors using transposon insertion
sequencing of bacteria
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Preface
Chapter 2 has been adapted from an article that is published: Kortright, K. E., Chan, B. K., &
Turner, P. E. (2020). High-throughput discovery of phage receptors using transposon insertion
sequencing of bacteria. Proceedings of the National Academy of Sciences, 117(31), 18670-18679.
The study was designed by Kaitlyn Kortright, Dr. Paul Turner and Dr. Benjamin Chan. Kaitlyn
Kortright preformed all experiments and analyzed data. The manuscript was prepared and edited
by Kaitlyn Kortright, Dr. Paul Turner and Dr. Benjamin Chan.
Raw sequencing is publicly available at NCBI Sequence Read Archive Project #
PRJNA637562

and

supplemental

datasets

have

been

deposited

on

Dryad

(doi:10.5061/dryad.t76hdr7z3). We thank J. Wertz for strains; A. Goodman, B. Kazmierczak, S.
Shames and D. Weinberger for valuable discussions regarding this study; and J. Bull and A.
Hatoum-Aslan for helpful comments on the manuscript.
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Abstract
As the most abundant microbes on earth, novel bacteriophage (phage; bacteria-specific viruses)
are readily isolated from environmental samples. However, it remains challenging to characterize
phage-bacteria interactions, such as the host receptor(s) phage bind to initiate infection. Here, we
tested whether transposon insertion sequencing, INSeq, could be used to identify bacterial genes
involved in phage binding. As proof of concept, results showed that INSeq screens successfully
identified genes encoding known receptors for previously characterized viruses of Escherichia coli
(phage T6, T2, T4 and T7). INSeq screens were then used to identify genes involved during
infection of six newly isolated coliphage. Results showed that candidate receptors could be
successfully identified for the majority (five of six) of the phage; furthermore, genes encoding the
phage receptor(s) were the top hit(s) in the analyses of the successful screens. INSeq screens
provide a generally useful method for high-throughput discovery of phage receptors. We discuss
limitations of our approach when examining uncharacterized phage, as well as usefulness of the
method for exploring the evolution of broad versus narrow use of cellular receptors among phage
in the biosphere.
Chapter Introduction
At an estimated 1031 particles, the number of bacteriophage (phage; bacteria-specific viruses) in
the global biosphere comprises a vast and uninvestigated microbiological diversity 98. This largely
untapped “bioprospecting” resource allows for newly discovered, naturally-occurring phage, to be
developed for numerous applications. In stark contrast to this biodiversity are the relatively few
phages that have been well-characterized (e.g., lambda, ΦX174, T4, T7, Φ6). These well-studied
phages have been valuable for elucidating fundamental aspects of molecular biology and
evolutionary genetics 14-16. However, there is increasing interest in utilizing phage for a myriad of
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purposes, including alleviating current medical challenges posed by antibacterial resistance,
exemplified by recent cases where phages were used to treat antibiotic-resistant bacterial infections
in humans 13, 99. It is therefore crucial to design approaches whereby newly discovered phage are
characterized prior to any intended applications.
Isolating phage strains from environmental sources can be straightforward, though
uncovering detailed characteristics of phage biology can be challenging. Sequencing approaches
and molecular techniques are increasingly affordable, allowing for easier determination of genome
size and nucleic acid content (DNA vs. RNA; single- vs. double-stranded) used to classify newly
discovered phages into known or proposed virus families

100

. Electron microscopy is typically

sufficient to describe basics of phage morphology and capsid structure

101

. Classic laboratory

methods are useful for estimating host range (infectability across bacterial genotypes or species)
and to determine whether a phage has a temperate versus strictly lytic replication cycle

100

.

However, other details of phage-bacteria interactions can be more difficult to ascertain. In
particular, identifying the specific cell-surface receptor(s) that a phage uses in host binding, and
the bacterial genes that are involved in resistance to phage infection are not as readily determined
using the above methods.
To initiate an infection, a phage particle must first recognize and bind one or more receptors
on the surface of a susceptible bacterial cell. Many of the phage specific to Gram-positive bacteria
use carbohydrate moieties of peptidoglycan or techoic acid as their receptors 102. Whereas others,
such as phage g which infects Bacillus anthracis and phage SPP1 that infects Bacillus subtilis, use
protein receptors GamR and YueB, respectively 61, 103. Thus far, receptors used by phage of Gramnegative bacterial hosts appear limited to specific proteins and/or lipopolysaccharide (LPS)
moieties present on the outer-cell membrane 104-111. Overall, these binding targets are often highly-
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conserved structures of bacteria, indicating that phage have been evolutionarily selected to exploit
essential features of their hosts 112. In the simplest cases, a phage may use a single outer-membrane
protein as a receptor, such as phage T6 attachment to the Tsx nucleoside channel of Escherichia
coli 106. Other phage bind to a specific LPS motif, as seen in several members of the Podoviridae
virus family

108

. In further examples, phage use a primary receptor to facilitate attachment but

require a secondary receptor to irreversibly bind to a host cell

110, 111

. Finally, phage such as T2

can use two or more receptors on the surface of a bacteria interchangeably to bind and initiate
infection 104, 107.
Elucidating molecular details of phage binding is fundamental to understanding phage
biology because the receptors confer host-specificity of a virus, by allowing phage to differentiate
between species or strains of bacteria. Nevertheless, it is challenging to determine phage receptors,
especially when host bacteria themselves are not well characterized. Previously, knock-out
libraries such as the Keio collection (single-gene deletion mutants of E. coli K-12) 113 have been
utilized to identify specific bacterial genes involved in phage T7 infection

114

, whereas similar

resources do not exist for other non-model bacteria. Even in the case of E. coli, however, such
methods can be laborious, involving the screening of individual phage samples on very large
numbers of mutant bacterial strains if genes for phage receptors are unknown. Transposon mutant
libraries have been used to identify bacterial mutants that are resistant to phage infection

115-117

.

While this method requires relatively less effort, it is limited by the number of transposon mutants
chosen for follow-up study, making it potentially challenging to identify the receptor(s) used by a
single phage. One other common method to identify possible phage receptors is to characterize
spontaneous phage-resistant mutants of bacteria. However, this approach typically necessitates
comparing whole-genome sequences of phage-resistant mutants to a well-annotated reference
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genome to identify candidate mutations, which are not guaranteed to be in genes encoding phage
receptors.
Advances in high-throughput sequencing have facilitated the development of new
sequencing-based transposon mutant screens, which enable the rapid identification of genes that
contribute to bacterial fitness in a particular selective environment 118, 119. This method makes use
of a modified transposon to create a diverse transposon mutant library, where each bacterial
genome contains a single randomly-incorporated insertion mutation. The sites of transposition in
the mutant population can be easily identified by sequencing, and the relative abundances of
specific insertions can be quantified. Comparison of the relative abundances of transposon mutants
pre- and post- selection can be used to identify genes contributing to fitness (bacterial growth)
under the selective environment of interest.
Here, we describe a novel high-throughput method to identify phage receptors by querying
the entire repertoire of bacterial genes that are critical for survival during selection by lytic phage
(Figure 2.1A). The disruption of a gene involved in phage resistance would result in a fitness
disadvantage under the selective pressure of phage; consequently, these mutants would be
represented at a lower frequency in the output transposon mutant pool (TMP) (Figure 2.1B).
Conversely, disrupting a bacterial gene required for phage infection and replication (e.g. genes
encoding phage receptors), would provide a fitness advantage under the selective pressure of phage
and these mutants should be enriched in the output TMP.
We hypothesized that this approach could successfully identify bacterial genes responsible
for receptor-binding in four well-characterized viruses capable of infecting E. coli K12: phages
T2, T4, T6 and T7. Results of our high-throughput method agreed with the published literature in
all cases. We further verified these conclusions using classic adsorption (phage attachment) assays,
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demonstrating that phages fail to attach to bacterial knockout mutants lacking the gene(s) encoding
phage receptor(s). We then tested our second hypothesis that this method could be used to identify
receptor-binding genes in each of six newly discovered and previously uncharacterized phage,
similarly capable of infecting E. coli K12. Our approach, along with confirmatory adsorption
assays, was successful in discovering the binding targets for five out of six of these viruses,
demonstrating both the general utility of the method as well as the enduring challenge of
developing an infallible technique for discerning phage receptors in bacteria.
Results
INSeq transposon mutant library covers 80% of non-essential genes
The final pooled transposon mutant library contained 17,100 independent transposon insertions in
3,253 bacterial genes. Visual inspection of results (Figure 2.2) showed genome coverage did not
appear to be affected by the inherent GC bias of mariner transposons 120. However, there was an
increased number of transposition events near the E. coli K12 origin of replication (Figure 2.2).
This result likely was attributed to multiple copies of the origin present during DNA replication
120

. While the final library was not completely saturated (i.e., not every non-essential gene was

represented by a transposon mutant), approximately 80% of non-essential E. coli genes had at least
one independent transposon insertion event in the final transposon mutant library. We used
EcoCyc

121

to compile a list of 137 genes expressed at the cell outer membrane (Table 2.1); of

these genes, 31 were not represented in the TMP used for our screens.
The INSeq screen was initiated with a multiplicity of infection (MOI; ratio of phage to
bacteria) roughly equaling 0.01 (see Methods). We noted that a lower MOI could allow for the
occurrence of additional spontaneous (non-transposon-insertion) mutations that could experience
subsequent positive selection in the phage environment. Nevertheless, low MOI was essential to
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allow the TMP to undergo multiple rounds of cell division under phage selection, which was
necessary for transposon mutant enrichment in the designed INSeq screen (Figure 2.1).
Furthermore, we reasoned that the reduced initial selective pressure at low MOI would allow us to
observe transposon-disrupted genes with subtle (i.e., low to moderate) fitness effects 122.
INSeq identifies receptors for phages T6, T2, T4 and T7
As a proof of concept for our method, we tested whether an INSeq screen could accurately identify
the bacterial receptors for four well-characterized phages: T6, T2, T4 and T7. Controls consisted
of INSeq screens using ‘mock infections’ that were performed identically, but in the absence of
test phage. Results (Figure 2.3 A-D) were plotted to depict all insertions in bacterial genes on a
logarithmic scale, as the ratio of input normalized (to counts per million, CPM) reads to output
normalized reads in CPM. As compared to the mock infected control (Supporting Information
Appendix: Figure S2.1 A), each screen in the presence of a test phage resulted in an observed shift
of the TMP with many transposon mutants becoming under-represented in the output population.
This result was consistent with phage imposing strong selection pressure on the TMP. As the entire
TMP shifts towards under-representation in the output population due to declining abundance of
bacteria, it becomes difficult to distinguish truly significant hits that are at a fitness disadvantage
in the presence of phage. However, this does not impair our ability to identify genes encoding
phage receptors, as mutants in these genes should become over-represented in the output
population. Therefore, candidate receptor hits were considered if they were statistically significant,
had a positive log ratio, A, of output (AO) to input (AI) relative abundance (A = log[AO/AI]), and
were genes encoding a membrane protein (Figure 2.3 E).
The screen in the presence of phage T6 (Figure 2.3 A) yielded 144 significant hits (Chapter
2 Appendix: Supplemental Data 1), of which 59 were positively enriched in the presence of phage
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T6. The log ratio of output to input relative abundance (A) of a subset of the TMP, transposon
mutants in genes encoding membrane proteins (Figure 2.3 E), were queried for candidate
receptors. Transposon mutant tsx::Tn (A = 3.09), was the top hit of these screens. This result was
consistent with previous observations of phage T6 using the Tsx nucleoside channel as a primary
receptor 106. Eight other genes encoding membrane proteins were enriched in the output: lamB::Tn
(A = 1.84), btuB::Tn (A = 1.94), ompX::Tn (A = 0.90), rhsD::Tn (A = 0.55), ybgQ::Tn (A =
0.36), ynfB::Tn (A = 0.22), ompW::Tn (A = 1.08), and pgaB::Tn (A = 0.68). However, A-values
of these hits were far lower than that of tsx::Tn, indicating that in future screens, only the hits with
the highest A-values should be considered as candidate receptors. Nonetheless, a subset of these
other eight hits were assayed in further experiments to demonstrate that these genes were not
involved in the binding of phage T6 (see below).
The phage T2 screen (Figure 2.3 B) resulted in 143 significant hits, of which 86 (Chapter
2 Appendix: Supplemental Data 1) were positively enriched in the presence of phage T2.
Candidate receptors fadL::Tn (A = 2.60) and ompF::Tn (A = 2.53) were identified (Figure 2.3 E)
as the top two hits of these screens. This was a key result, as it was unclear if our approach could
successfully identify both receptors used by a phage when the presence of only one was necessary
and sufficient for phage adsorption. Thus, these results were consistent with previous observations
of OmpF and FadL as interchangeable receptors for phage T2

104, 107

. There were two other

enriched hits in genes encoding membrane proteins: rhsD::Tn (A = 1.00) and ynfB::Tn (A =
0.55).These two hits also came up in the screen with phage T6, indicating that they might be
commonly required for phage infection. However, as above, their A-values were far below those
of fadL::Tn and ompF::Tn, and neither were considered for follow-up validation.
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The phage T4 screen (Figure 2.3 C) resulted in 177 significant hits, of which only 20
(Chapter 2 Appendix: Supplemental Data 1) were positively enriched in the presence of phage T4.
The top hit (Figure 2.3 E) was ompC::Tn (A = 2.35); additionally envZ::Tn was significantly
enriched in the output TMP (Figure 2.2 C). EnvZ is part of a two-component regulatory system
that increases the expression of OmpC 123. Two other identified hits (Figure 2.3 E) were yjbF::Tn
(A = 1.04) and yjbH::Tn (A = 0.34). Another gene in the same operon, yjbE::Tn (A=1.36), was
significantly enriched in the output TMP. The Yjb operon is involved in production of extracellular
polysaccharide and biofilm formation

124

. Previous literature suggests that phage T4 is not

spatially inhibited by extracellular matrixes and is instead able to associate with the surface of
biofilms 125. While it is interesting that multiple genes in this operon are significantly enriched in
the output, further investigations of the importance of phage T4 with products of the Yjb operon
is reserved for future studies, as previous results have demonstrated that phage T4 uses both OmpC
and LPS as co-receptors 110. When OmpC is present, phage T4 can infect regardless of the terminal
sugar residue of LPS; however, in the absence of OmpC, phage T4 is able to attach to LPS chains
with an exposed, terminal glucose residue 110. Exposure of this terminal glucose residue in LPS is
conferred by a deletion of waaU, a gene that was not included in the TMP. Validation assays,
therefore, were conducted on the top hit from this screen, OmpC (see below).
The phage T7 screen (Figure 2.3 D) resulted in 188 significant hits, of which 44 (Chapter
2 Appendix: Supplemental Data 1) were enriched in the output TMP. A previous screen of the
Keio collection identified 10 genes important for phage T7 infection; however, none of these
single-gene deletions were sufficient to abolish infection

114

. Phage T7 is predicted to use LPS,

specifically lipid A or a keto-deoxyoctulosonate (KDO) sugar moiety, as a receptor 126; therefore,
it is unlikely that deletion of a single bacterial gene would eliminate phage adsorption as many of
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the genes involved in synthesis of the inner core regions of LPS are essential. Therefore, instead
of querying the 44 significantly output-enriched hits from the INSeq screen for a specific gene,
these hits were subjected to a gene ontology (GO) enrichment analysis 127. The results of GO Term
analysis indicated that the significant, output-enriched transposon mutants from the phage T7
screen were enriched for 22 genes involved in cellular biosynthetic processes (pyrI, yjbH, mutT,
accA, uvrD, mmuP, yaeI, mmuM, hisA, metG, yegS, carB, sufS, opgH, waaF, gmhB, trpS, waaG,
yebK, speB, hldD, and dnaQ). Upon closer inspection, approximately one third of these genes
appeared to be involved in LPS metabolism: yaeI, waaF, gmhB, waaG, hldD, and yegS.
Phosphodiesterase, YaeI, is annotated as a protein involved in lipid A biosynthesis and YegS is an
annotated lipid kinase; while waaF, gmhB, waaG, and hldD are four out of five genes that make
up Functional Gene Cluster 91 which consists of genes involved in synthesis and polymerization
of the core heptose region of LPS. This result was encouraging, as it was unclear if our screen
would be successful in identifying LPS as a receptor due to the complex nature of LPS biosynthesis
and the essentiality of many of the genes involved.
We note that false positives are expected to occur during our screen, especially since
previous studies demonstrate that altering expression of one outer-membrane protein affects the
expression of other outer-membrane proteins 128. While we observed some false positives (e.g.,
see phage T6 results above), identification of phage receptors is still expected to succeed with this
method in combination with confirmatory assays described below. In each of the screens
conducted with phages T2, T4 and T6, the known receptors were all the top hit(s) from the short
list of candidate receptors. The use of LPS as a receptor, as is the case for phage T7, is likely to be
successfully identified using GO Term with the overrepresented hits.
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Efficiency of plating and adsorption assays confirm known receptors for characterized
phages
To verify that the top identified hits in the INSeq analyses were genes important for phage
infection, we conducted efficiency of plating (EOP) assays to measure phage ability to
productively infect bacterial strains lacking expression of the candidate gene

129

relative to

productive growth on WT bacteria for a subset of the top hits. Since EOP does not directly measure
phage attachment, adsorption assays were used to confirm that the putative genes were phage
receptors for a subset of the top hits (Figure 2.4). We concluded that EOP and adsorption assays
were successful in confirming that the top hit(s) from the screens with phage T6, T2, and T4 were
the known receptor(s) (Chapter 2 Appendix: Supplemental Results). In addition, results from GO
Term enrichment for phage T7 were confirmed by reduction in titers upon adsorption with LPS.
INSeq identifies candidate receptors for newly isolated phage
Next, uncharacterized phage were screened for receptors using our validated methods. Six phages
(EC14, EC35, R3, P2, U115 and 8S) were chosen randomly from a large library of environmental
phage isolates, and subjected to an INSeq screen for receptor identification. Prior to the current
study, no traits for these phage strains were determined, other than their ability to infect E. coli
K12. Screens with these six coliphage were performed as described above; hits that were
statistically significant, had a positive log ratio of output to input relative abundance, and were in
genes encoding membrane proteins were considered for further validation.
The phage R3 screen resulted in 161 significant hits (Supplemental Figure S2.3 A), of
which, 67 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage R3.
Only two hits (Figure 2.5) were identified, ompA::Tn (A = 3.44) and rhsD::Tn (A = 0.96). As the
top hit, OmpA was considered the candidate receptor for phage R3.
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The phage U115 screen resulted in 150 significant hits (Supplemental Figure S2.3 B), of
which, 58 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage
U115. The top hit (Figure 2.5) of these screens was tsx::Tn (A = 3.17). There were four other hits:
lamB::Tn (A = 1.41), rhsD::Tn (A = 0.88), ompX::Tn (A = 0.45) and ybgQ::Tn (A = 0.06). The
top two hits from these screens, Tsx and LamB, were considered candidate receptors for phage
U115.
The phage P2 screen resulted in 143 significant hits (Supplemental Figure S2.3 C), of
which, 59 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage P2.
Three hits (Figure 2.5) were slightly enriched: rhsD::Tn (A = 0.92), ynfB::Tn (A = 0.18), and
yjbH::Tn (A = 0.84). However, none of these hits were promising, as receptors for the well
characterized phages T6, T2 and T4 were enriched to a log ratio greater than 1. Furthermore, all
three of these transposon mutants were background hits in other screens. Therefore, it is likely that
either phage P2 uses LPS as a receptor (as in phage T7), or that the receptor for phage P2 is one
of the 31 membrane proteins not included in the TMP.
The phage 8S screen resulted in 164 significant hits (Supplemental Figure S2.3 D), of
which, 49 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage 8S.
The top two hits (Figure 2.5) were ompC::Tn (A = 2.09) and lamB::Tn (A = 1.36). Other hits
included rhsD::Tn (A = 0.64) and ynfB::Tn (A = 0.08). Additionally, OmpC regulators, envZ::Tn
(A = 2.50) and ompR::Tn (A = 2.57), were enriched in the output TMP. The top two hits from this
screen, OmpC and LamB, were considered candidate receptors for phage 8S infection.
The phage EC35 screen resulted in 160 significant hits (Supplemental Figure S2.3 E), of
which, 69 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage
EC35. The top two hits (Figure 2.5) were lamB::Tn (A = 2.47) and ompC::Tn (A = 2.33). Other
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hits included rhsD::Tn (A = 0.50) and loiP::Tn (A = 2.42). Additionally, OmpC regulators,
envZ::Tn (A = 2.38) and ompR::Tn (A = 3.03), as well as LamB regulators, malT::Tn (A = 2.61)
and malK::Tn (A = 0.31), were enriched in the output TMP. The top three hits from this screen
were LamB, OmpC and LoiP; however, loiP::Tn was only enriched in one out of three replicate
screens. Therefore, LamB and OmpC were considered candidates for phage EC35 receptors.
The phage EC14 screen resulted in 177 significant hits (Figure 2.5), of which, 32 (Chapter
2 Appendix: Supplemental Data 1) were enriched in the presence of phage EC14. Similarly to
phage EC35, the top two hits from the screen with phage EC14 were lamB::Tn (A = 2.47) and
ompC::Tn (A = 2.33). The other hit was rhsD::Tn (A = 0.48). Additionally, OmpC regulators
envZ::Tn (A = 2.09) and ompR::Tn (A = 2.77), LamB regulator malT::Tn (A = 2.60), and malK::Tn
(A = 0.003) were enriched in the output TMP. LamB and OmpC were considered candidates for
phage EC14 infection.
Receptors for five uncharacterized phages identified with EOP and adsorption assays
EOP and adsorption assays were used to validate the candidate receptors for uncharacterized phage
which were identified in each INSeq screen.
Outer membrane protein OmpA was the candidate with the highest A-value in the screen
with phage R3 (Figure 2.5), and was selected as the likely receptor for further analysis. In an EOP
assay, phage R3 had an EOP (Figure 2.6 A) below the limit of detection on BW25113DompA.
Plaquing was restored upon plasmid complementation of the ompA gene; however, plaquing was
only restored to 46% of the phage growth on the parental strain. This result was likely due to
differences in expression levels between chromosomally-encoded ompA and exogenous ompA.
Furthermore, phage R3 did not adsorb (Figure 2.6 B) to strain BW25113DompA. Similar to
plaquing, adsorption was restored upon complementation with OmpA. Results of both the EOP
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and adsorption assays strongly indicated that OmpA was the primary receptor for the previously
uncharacterized phage R3.
The screen of phage U115 identified Tsx, a nucleoside transporter, as well as LamB as
potential receptors for phage U115 (Figure 2.5). Phage U115 had an EOP (Figure 2.6 C) below
the limit of detection on BW25113Dtsx and plaquing was restored to wild-type levels upon
complementation with Tsx. Deletion of lamB had no significant effect on the EOP of phage U115.
Phage U115 did not adsorb (Figure 2.6 D) to BW25113Dtsx or to the empty vector control,
BW25113Dtsx. However, complementation with Tsx not only restored phage U115 adsorption,
but allowed U115 to adsorb better than wild-type; 90% of phage U115 has adsorbed to
BW25113Dtsx::pSF-tsx by 15 minutes while only 46.4% of phage U115 had adsorbed to WT by
20 minutes. This result was likely due to the overexpression of exogenous tsx resulting in more
Tsx on the outer membrane, relative to basal expression in WT bacteria. Phage U115 adsorbed to
BW25113DlamB at levels comparable to wild-type. Results of both the EOP and adsorption assays
indicated that phage U115 did not require LamB as a receptor to adsorb or infect E. coli, and that
Tsx was the primary receptor for phage U115.
The INSeq screen of phage 8S identified OmpC, an outer membrane porin, and LamB as
potential receptors for the virus (Figure 2.5). EOP assays (Figure 2.6 E) revealed a 2.3-fold
decrease in EOP of phage 8S on BW25113DompC and a 1455-fold decrease in EOP on
BW25113DlamB. Phage 8S was unable to infect the double knockout, BW25113DompCDlamB,
and infection was restored upon complementation with either ompC or lamB. Phage 8S appeared
to adsorb (Figure 2.6 F) to BW25113DompC at levels similar to wild-type. However, phage 8S did
not significantly adsorb to BW25113DlamB or to BW25113DompCDlamB. Adsorption was
restored upon complementation of BW25113DompCDlamB with lamB but not ompC. This result
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indicated that LamB was necessary for adsorption of phage 8S. However, since phage 8S was able
to infect BW25113DlamB but unable to infect BW25113DompCDlamB, it likely used OmpC as a
secondary receptor. Adsorption assays indicated that LamB was the primary receptor for phage 8S
as it adsorbed well to BW25113DompCDlamB:pSF-lamB but did not adsorb appreciably to
BW25113DompCDlamB complemented with ompC over the course of the assay.
Similar to the screen for phage 8S, the screen for phage EC35 identified OmpC and LamB
(Figure 2.5). There was a 1.7-fold decrease and a 6-fold decrease in EOP (Figure 2.6 G) of phage
EC35 on BW25113DompC and BW25113DlamB, respectively. Phage EC35 was unable to infect
BW25113DompCDlamB and infection was restored upon complementation with either ompC or
lamB. Phage EC35 was unable to adsorb (Figure 2.6 H) to BW25113DlamB or
BW25113DompCDlamB, but was able to adsorb to BW25113DompC and BW25113DompCDlamB
upon complementation with lamB, and not with ompC. Again, these data indicated that phage
EC35 used LamB as a primary receptor but likely required OmpC as a secondary receptor, as only
deletion of both ompC and lamB abolished infection in an EOP assay.
INSeq screens for a third phage, EC14, also identified OmpC and LamB as potential
receptors (Figure 2.5). There was a 1.2-fold decrease and a 2.6-fold decrease in EOP (Figure 2.6
I) of phage EC14 on BW25113DompC and BW25113DlamB, respectively. Phage EC35 was
unable to infect BW25113DompCDlamB. Complementation with either ompC or lamB was
sufficient to restore infection. Phage EC14 was unable to adsorb (Figure 2.6 J) to BW25113DlamB
and

BW25113DompCDlamB

but

was

able

to

adsorb

to

BW25113DompC

and

BW25113DompCDlamB upon complementation with lamB or ompC. This result indicated that,
unlike phage 8S or EC35, EC14 was able to use either LamB or OmpC as a receptor.
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Unlike the screens above, the screen with phage P2 resulted in no statistically significant
hits (Figure 2.5) with a log ratio of output CPM to input CPM above 1.0 in genes expressed at the
outer membrane; the top two hits were rhsD (A = 0.92) and yjbH (A = 0.84). Transposon mutant
rhsD::Tn is likely background noise as it came up in every screen and follow up assays were not
done. EOP and adsorption assays were performed with BW25113DyjbH. There is no decrease in
EOP of phage P2 on BW25113DyjbH (Supplemental Figure S2.4 A). Phage P2 is able to adsorb
to BW25113DyjbH (Supplemental Figure S2.4 B). It is possible that similar to phage T7, phage
P2 uses LPS as a receptor. However, incubation with purified LPS did not result in a significant
drop in titer (Supplemental Figure S4 C). Furthermore, GO term analysis did not uncover any
significant enrichment for any biological processes. Another possibility is that similar to phage
T2, phage P2 has multiple receptors. However, successful identification of both receptors of phage
T2 indicates that our method should allow for the identification of multiple receptors. Therefore,
it is likely that the receptor for phage P2 is one of the 31 outer membrane genes that was not
represented in the original TMP; it is possible that a transposon mutant library with higher
saturation would allow for the identification of the phage P2 receptor. However, it is also possible
that an essential gene encodes the receptor for phage P2 which would not be included in a
transposon mutant library.
In all screens performed, whether well-characterized phage or newly-isolated ones, lon::Tn
was consistently the top hit (Figure 2.3 and Supplemental Figure S2.3). As lon encodes the Lon
protease which functions in the cytoplasm, it was not considered a candidate receptor hit and no
follow up was conducted. However, mutations in lon that disrupt the proteolytic function result in
accumulation of rcsA, an activator of capsular polysaccharide biosynthesis

130

. Therefore, it is

likely that deletion of lon generally results in phage resistance due to overexpression of capsule.
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Based on these screens, it is possible that mutations in lon result in a smaller fitness cost than
mutations in genes that code for phage receptors. This result will be explored further in future
studies.
Discussion
INSeq screens were successful in identifying candidate phage receptors for five out of six
previously uncharacterized phage and further analysis of specific hits confirmed that the top hit(s)
identified in the screens were the phage receptor(s). We note that our approach is designed to
identify the receptor(s) used by a phage when interacting with the single bacterial strain. However,
this method could be employed in multiple different strains of bacteria in order to identify receptors
for different hosts a for phage that encode multiple tailspikes that permit infection across multiple
bacterial hosts 131.
Interestingly, each of the phage receptors identified in this study have been identified as
receptors for other phage 132. With 137 annotated membrane proteins and a branching LPS chain
consisting of 10 sugar monomers with various phosphate groups in E. coli BW25113, it is
surprising that previous reviews on phage receptors reported that only ~10 membrane proteins and
various sugar linkages were exploited as phage receptors

132, 133

. Furthermore, three out of five

phages chosen randomly from our coliphage library used OmpC as a receptor in some capacity.
These observations are interesting because the vast biodiversity of lytic phage suggests that these
viruses may have evolved to exploit most, if not all, possible receptors on the surface of bacteria,
implicating selection by these ‘predatory’ phage as a possible key driver of genomic diversity in
bacteria 134. However, this expectation assumes that all cell-surface structures are equally suitable
to serve as phage receptors in the eyes of natural selection. Rather, selection for phage to use a
particular structure on the surface of a bacterium is likely influenced by the abundance of that
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molecule on the surface and whether the protein is well-conserved among bacterial genotypes.
Both OmpA and OmpC are reported to be among the top 20 most highly expressed proteins in E.
coli, with 207,618 and 163,538 molecules per cell respectively

135

. On one hand, with so many

potential binding sites on the surface (~1 OmpA or OmpC molecule per 30 nm2), a bacterium is
extremely vulnerable to attack by phage that bind to either OmpA or OmpC, suggesting that phage
should be strongly selected to target these structures 136. However, on the other hand this creates
the possibility for intense competition among phage that use common binding sites such as OmpA
or OmpC, which likely results in selection for phages to exploit a less common receptor to reduce
competition for hosts. Previously, phage receptors have been vastly understudied, likely because
of the large effort required to screen phage on individual bacterial mutants. Thus, the higherthroughput INSeq screen presented here demonstrates a method to rapidly identify phage
receptors, fostering a broader possibility to efficiently explore the evolution of phage binding sites
and inter-phage competition to use these receptors. This could be a key first approach in the
ultimate study of whether virus evolution has resulted in some binding targets to be over- versus
under-exploited in the phage world.
Around the time of submission, both a paper came out and a preprint was posted describing
similar methods for identifying genes involved in phage infection in Enterococcus faecalis and E.
coli respectively

137, 138

. However, there were some differences in outcomes among these studies

which may reflect differences in the efficacies of the approaches. It would be interesting to
compare these various methods in future work.
Conclusion
Transposon insertion sequencing is a powerful technique that allows for identification of bacterial
genes that contribute to fitness in particular selective conditions. Here, we used INSeq screens to
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identify phage receptors for multiple E. coli phage. Proof of concept experiments validated this
approach by confirming known phage receptors. In particular, this method was successful in
confirming receptors for previously well-characterized phage that use a single protein receptor,
dual-protein receptors, a primary LPS receptor and secondary protein receptor, and LPS as
receptor. This method was then extended to identify receptors for five out of six previously
uncharacterized randomly-chosen phage. We expect that a more saturated transposon mutant
library would allow for identification of the receptor for newly-discovered phage P2. Our approach
was particularly promising, because for each screen that resulted in the successful protein receptor
identification, the genes encoding the receptors were among the top hits for each phage.
In addition to identifying phage receptors, our screens could provide information about the
fitness of other bacterial genes in the presence of phage, such as bacterial genes that were involved
in phage replication or resistance to phage. Thus, our approach might allow for identification of a
subset of bacterial genes that are universally important during phage infection or resistance.
While this study focused on phage receptors for viruses that infect E. coli, transposoninsertion sequencing provides information for any transposon mutant in the TMP, and has been
employed in many different species of bacteria 129, 139-142. Our new method for the high-throughput
identification of phage receptors should allow for rapid characterization of newly isolated phage
that target various different species of bacteria. If enough phage receptors are identified for
sequenced phage, bioinformatic approaches might be extended to allow for receptor identification
based on the genomes of phage alone. Furthermore, in addition to using INSeq screens to identify
phage receptors, our screens provide information about the fitness of other bacterial genes in the
presence of phage, potentially allowing for the identification of a subset of bacterial genes that are
universally important during phage infection. Therefore, in addition to allowing for a high-
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throughput identification of phage receptors, INSeq screens may provide insight into generalized
mechanisms of phage resistance.
Materials and Methods
Bacterial strains, plasmids and phage
Bacteria used in this study were obtained from the Coli Genetic Stock Center at Yale University,
and phages T2, T4, T6 and T7 were kindly provided by J. Wertz (Yale U). The six uncharacterized
phages in the study were isolated from sewage or environmental water samples. All bacteria,
plasmid and phage strains are listed in Supplemental Table S2.1 of the Chapter 2 Appendix.
Bacteria were cultured at 37oC with shaking (200 rpm) in Luria Broth (LB) and on LB agar (15%)
plates, where dilutions in LB followed by plating were used to estimate bacterial densities as
colony-forming units (CFU) per mL. Carbenicillin (Cb; 100µg/mL), gentamicin (Gm; 10 µg/mL),
kanamycin (Km; 50 µg/mL), arabinose (0.1%) and isopropyl b-D-1-thiogalactopyranoside (IPTG;
1mM) were added when appropriate. Phage strains were amplified in shaking liquid culture
overnight on the amplification host, BW25113DicdC (hereafter referred to as wild-type, WT), and
filter sterilized with a 0.22µm filter to obtain a cell-free lysate. Titers were estimated as plaqueforming units (PFU) per mL, and determined by plaques formed via dilution plating in ‘soft’ agar
(7.5%) overlays on lawns of WT grown on agar plates, unless otherwise noted.
INSeq transposon mutant library preparation
The insertion-sequence (INSeq) transposon mutant library was made via conjugation. Donor
bacterial strain S17 l pir 118 containing plasmid pSAM_PA 142 was conjugated with recipient strain
WT on plates containing arabinose, at a ratio of 1:1 donor to recipient. After 3 hours incubation at
37oC, conjugation mixtures were plated for single colonies on plates with Gm and Km to isolate
transconjugants that were resistant to both markers (Gmr, Kmr). Following 24 hours incubation at
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37oC, colonies were scraped into LB medium using a sterile spatula and stored in 20% glycerol at
-80°C.
INSeq screen
Aliquots of the library were thawed on ice, washed once in LB and resuspended to a concentration
of approximately 107 CFU/mL in LB and incubated at 37oC for 1 hour, with shaking. A sample of
test phage was added, in triplicate, to a final concentration of approximately 105 PFU/mL, for
MOI» 0.01. Following overnight incubation, cultures were harvested and genomic DNA was
extracted and prepared for sequencing 141. DNA libraries were pooled and sequenced at the Yale
Center for Genome Analysis via the Illumina HiSeq2500 system. Sequences were analyzed using
scripts modified from Goodman et al (2009). Briefly, using Python scripts adapted from analysis
packages previously described

141

, sequencing reads were indexed by barcode, and transposon

sequence was trimmed leaving 16 base pairs of adjacent genomic DNA. These 16 base pair
sequences were aligned to the reference genome (Genbank accession # CP009273.1) using
Bowtie2, by counting the number of reads for each insertion site, normalizing to counts per million
reads and binning by gene143. Transposon insertions mapping to the distal 5% ends of any coding
region as well as transposon insertions mapping to intergenic regions were filtered out during
analysis. A Z-test was performed using the log ratio of normalized output count to normalized
input count, and Q-values from false discovery rate (FDR) correction of < 0.05 were considered
significant for further analysis.
Efficiency of plating, and adsorption assays
Efficiency of plating (EOP) was measured as the ratio of the test phage titer on the experimental
strain to its titer on the WT strain. Phage binding to cells (adsorption) was measured over a 20
minute adsorption assay

144

, which estimates the rate of ‘disappearance’ of phage particles (i.e.,
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reduction in titer) in liquid LB medium over time when viruses are challenged to attach to bacterial
cells.
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Chapter 2 Figures & Tables

Figure 2.1 Design of INSeq screen

Design of INSeq screen. A Experimental setup for selection of pooled transposon mutant library (TMP) with phage
indicating enrichment for phage-resistant mutants B Mutants in genes involved in resistance to phage will become
underrepresented in
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Figure 2.2 Genome plot of E. coli strain BW25113

Genome plot of E. coli strain BW25113. Track 1 (inside) is a heat map of GC content, where red represents high GC
content and blue represents low GC content. Track 2 plots the abundance of transposon insertions in a coding region
(green) or intergenic region (blue). Track 3 shows intergenic regions (red) and Track 4 shows coding regions (multicolor).
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Figure 2.3 Results of INSeq screen with well-characterized phage.

Results of INSeq screen with well-characterized phage. Each point represents the normalized relative abundance of
all transposon mutants in a specific gene. All statistically significant transposon mutants are grey (P < 0.05). Certain
hits are colored; other mutants in regulatory genes are unfilled circles in the same color as the gene. A Results of a
screen with phage T6. Significantly over-represented hits tsx::Tn, btuB::Tn, lamB::Tn, and ompX::Tn are in blue,
orange, red and yellow respectively. B Results of a screen with phage T2. Significantly over-represented hits ompF::Tn
and fadL::Tn in green and blue respectively. C Results of a screen with phage T4. Significantly over-represented hit
ompC::Tn is in purple. D Results of screen with phage T7. E Log ratio (A) of relative abundance of 106 transposon
mutants in genes encoding membrane proteins for each screen. The outlier in the control screen is lamB::Tn.
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Figure 2.4 Assays validating phage receptors of well-characterized phage

Assays validating phage receptors of well-characterized phage. A Efficiency of plating (EOP) assays for phage T6 on
various E. coli strains. EOP was calculated as a ratio of titer on test strain to the titer on WT (BW25113 DicdC). EOPs
are plotted as mean and standard deviation of three independent experiments. Significance was calculated using T-test
as significantly different from 1. “<200” indicates that the titer on the test strain was below the limit of detection for
this assay which was 200 PFU/mL. B Adsorption assays of phage T6 on various E. coli strains plotted as a log of the
percent of free phage. Dashed lines indicate stains with an empty vector (pSF) or a complement vector (pSF-tsx)
grown in the presence of 100 mg/L carbenicillin with induction by 1mM IPTG. Percent free phage was determined as
a ratio of free phage at the time point divided by total phage added at the beginning of the assay and is plotted as a
mean and standard deviation of three independent experiments. Linear regression was performed for each strain.
Regression lines with a significantly non-zero slope indicate that the particular strain is able to support phage T2
adsorption. C EOP assays for phage T2 on various E. coli strains. D Adsorption assays of phage T2 on various E. coli
strains. E EOP assays for phage T4 on various E. coli strains. F Adsorption assays of phage T4 on various E. coli
strains. G LPS phage inactivation assays for phage T2, T4 and T7. Titers for each phage was determined after a 20
minute incubation with either 80 ng/mL LPS or water 61. Titers are plotted as means with standard deviation from
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three independent experiments. A T-test was used to determine significant differences between the mock condition or
the LPS condition. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001)

61

Figure 2.5 Results of INSeq screen with uncharacterized phage.

Results of INSeq screen with uncharacterized phage. Log ratio (A) of relative abundance of 106 transposon mutants
in genes encoding membrane proteins for each screen with uncharacterized phage. Grey represents statistically
significant hits, other top hits ompA::Tn, tsx::Tn, ompC::Tn, and lamB::Tn are in green, blue, purple and red
respectively. The outlier in the control screen is lamB::Tn. (P < 0.05).
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Figure 2.6 Assays validating phage receptors of newly isolated phage

Assays validating phage receptors of newly isolated phage. A Efficiency of plating (EOP) assays for phage R3 on
various E. coli strains. B Adsorption assays of phage R3 on various E. coli strains plotted as a log of the percent of
free phage. C EOP assays for phage U115 on various E. coli strains. D Adsorption assays of phage U115 on various
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E. coli strains. E Efficiency of plating (EOP) assays for phage 8S on various E. coli strains. F Adsorption assays of
phage 8S on various E. coli strains plotted as a log of the percent of free phage. G EOP assays for phage EC35 on
various E. coli strains. H Adsorption assays of phage EC35 on various E. coli strains. I EOP assays for phage EC145
on various E. coli strains. J Adsorption assays of phage EC14 on various E. coli strains. (* indicates p < 0.05, **
indicates p < 0.01, *** indicates p < 0.001).
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Table 2.1 List of genes encoding membrane proteins
acrZ
amiD
appX
bamA*
bamB
bamC
bamD*
bamE

envY
fadL
fecA
fepA
fhuA
fhuE
fimD
fiu

mdtQ
mepS
mipA
mlaA
mliC
mltA
mltB
mltC

pgaA
pgaB
pgpB
phoE
pldA
ppk
pqiC
qseG

yaiW
ybgQ
ybhC
yceK
ychO
yddB
yddL*
ydeT

bcsC
bglH
bhsA
blc
borD
btuB
chiP
cirA
csgB
csgE
csgF
csgG
cusC
ecnA
ecnB
ecpC
elfC
emtA

flgG
flgH
flu
gfcD
gfcE
gspD
hofQ
htrE
lamB
loiP
lolB
lpoA
lpp
mdtP
lpoB
lptA*
lptD*
lptE*

mltD
mltF
nanC
nfrA
nlpD
nlpE
nlpI
ompA
ompC
ompF
ompL
ompG
ompN
ompT
ompW
ompX
pagP
pal

rcsF
rhsB
rhsD
rlpA
rsxG
rzoD
rzoR
sfmD
skp
slp
slyB
tamA
tamB
tolC
tsx
uidC
wza
yaiO

ydiY
yehB
yfaL
yfaZ
yfcU
yfeN
yfgH
yfiB
yghG
ygiB
yhcD
yiaD*
yiaT
yjbF
yjbH
yjgL
yliI
yncD

ynfB
ypjA
ypjB
yqhH
yraJ
yraP
yzcX

List of genes encoding membrane proteins. Bolded genes are not included in the TMP. A * indicates essential genes
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Chapter 2 Appendix
Supplemental Results
Efficiency of plating and adsorption assays confirm known receptors for characterized
phages
Plaques of phage T6 were below the limit of detection (200 PFU/mL) on bacterial strain
BW25113Dtsx and complementation with plasmid pSF-tsx restored plaquing to similar levels as
on WT (Figure 2.4 A). Phage T6 did not adsorb to BW25113Dtsx, however adsorption was restored
upon complementation (Figure 2.4 B). While these results, along with previous literature,
demonstrate the ability of phage T6 to use Tsx as a receptor, EOP and adsorption assays were run
on the other enriched membrane genes from the screen. As expected, phage T6 had an EOP similar
to WT and adsorbed to BW25113DompX, BW25113DlamB and TA563btuB::Tn (Figure S2.2
A,B), indicating that these genes were not involved in phage binding.
Both BW25113DompF and BW25113DfadL were able to support phage T2 infection and
replication at a similar level as WT (Figure 2.4 C). However, on a double knockout
(BW25113DompFDfadL), phage T2 plaques were below the limit of detection, indicating that host
bacteria lacking both ompF and fadL genes were unable to support phage infection and replication.
Infection of phage T2 was restored through complementation of either OmpF or FadL in
BW25113DompFDfadL (Figure 2.4 C). Phage T2 did not adsorb to BW25113DompFDfadL
(Figure 2.3 D) in the time allowed in the assay. In contrast, adsorption was restored upon
complementation with either OmpF or FadL (Figure 2.4 D). These results, combined with the
aforementioned inability to detect phage T2 plaques on strain BW25113DompFDfadL, strongly
suggested that phage T2 could use either OmpF or FadL as a receptor to initiate productive lytic
infection.
66

We similarly analyzed whether our approach accurately identified known binding
mechanisms for phage T4. Results for phage T4 (Figure 2.4 E) showed virus infection of
BW25113DompC was below an EOP of 1.0, but was not significantly different from the
complemented strain or the complemented control. Adsorption of phage T4 (Figure 2.4 F) to strain
BW25113DompC was diminished and could be rescued upon exogenous expression of OmpC.
However, phage T4 could use LPS as a co-receptor and therefore could still infect
BW25113DompC as seen in the EOP assay. The results of the EOP and adsorption assays
corresponded with previous observations in the literature that phage T4 uses OmpC to reversibly
bind cells and increase efficiency of adsorption while irreversibly binding LPS a co-receptors110,
130

.
Last, we conducted experiments to verify that our method produced results consistent with

known receptor usage of phage T7. Instead of traditional EOP or adsorption assays with isogenic
strains of E. coli, purified LPS was used to determine if LPS was a receptor for phage T7.
Incubation of phage T7 with 80 ng/mL of LPS resulted in observed reduction in phage titer (Figure
2.4 G) as compared to incubation of phage with no LPS, which indicated that phage T7 could use
LPS alone as a receptor. Interestingly, there was no observed drop in titer when phage T4 was
incubated with LPS even though phage T4 could infect cells in the absence of OmpC (Figure 2.4
G). The results of the adsorption assay indicated that phage T4 did not appreciably adsorb to
BW25113DompC over a 20 minute period. Therefore, perhaps longer incubation of phage T4 with
LPS would result in a reduction of titer.
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Supplemental Datasets
Supplemental Data 1 can be found on Dryad (doi:10.5061/dryad.t76hdr7z3). Statistically
significant hits for each phage screen with the Q- value, log ratio of output to input counts (A),
Gene ID, and gene name. X indicates that the hit was either enriched in the output or in a gene
that encodes a membrane protein, respectively.

68

Supplemental Figure S2.1 Results of a control INSeq screen

Results of a control INSeq screen. Each point represents the normalized relative abundance of all transposon mutants
in a specific gene. All statically significant transposon mutants are grey.

69

Supplemental Figure S2.2 Additional assays validating phage T6 receptor

Additional assays validating phage T6 receptor A Efficiency of plating (EOP) assays for phage T6 on various E. coli
strains. B Adsorption assays of phage T6 on various E. coli strains plotted as a log of the percent of free phage. (*
indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001)
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Supplemental Figure S2.3 Results of INSeq screen uncharacterized phage

Results of INSeq screen uncharacterized phage. Each point represents the normalized relative abundance of all
transposon mutants in a specific gene. All statically significant transposon mutants are grey (P < 0.05). Certain hits
are colored; other mutants in regulatory genes are triangles in the same color as the gene they regulate. A Results of a
screen with phage R3. Significantly over-represented hit ompA::Tn is in green. B Results of a screen with phage U115.
Significantly over-represented hits tsx::Tn and lamB::Tn in blue and red respectively. C Results of a screen with phage
P2. D Results of screen with phage 8S. Significantly over-represented hits ompC::Tn and lamB::Tn in blue and red
respectively. E Results of screen with phage EC35. Significantly over-represented hits ompC::Tn and lamB::Tn in
blue and red respectively. F Results of screen with phage EC14. Significantly over-represented hits ompC::Tn and
lamB::Tn in blue and red respectively.
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Supplemental Figure S2.4 Assays examining phage receptors of newly isolated phage

Assays examining phage receptors of newly isolated phage. A Efficiency of plating (EOP) assays for phage P2 on
various E. coli strains. B Adsorption assays of phage P2 on various E. coli strains plotted as a log of the percent of
free phage. C LPS phage inactivation assays for phage R3, U115, P2, 8S, EC35 and EC14. Titers are plotted as means
with standard deviation from three independent experiments. A T-test was used to determine significant differences
between the mock. (*** indicates p < 0.001)

72

Supplemental Table S2.1 Bacterial strains, plasmids and phage used in this chapter
Strians
S17lpir
S17lpir::pSAM_PA
BW25113
BW25113DicdC
TMP
BW25113DompA
BW25113DompA::pSF_empty
BW25113DompA::pSF_ompA
BW25113DompF
BW25113∆fadL
BW25113DompF∆fadL
BW25113DompF∆fadL ::pSF_empty
BW25113DompF∆fadL ::pSF_ompF
BW25113DompF∆fadL ::pSF_fadL
BW25113DompC
BW25113DompC ::pSF_empty
BW25113DompC ::pSF_ompC
BW25113DlamB
BW25113DlamB::pSF_empty
BW25113DlamB::pSF_lamB
BW25113DompC ∆lamB
BW25113∆ompC ∆lamB::pSF_empty
BW25113∆ompC ∆lamB::pSF_ompC
BW25113∆ompC ∆lamB::pSF_lamB
BW25113Dtsx
BW25113Dtsx::pSF_empty
BW25113Dtsx::pSF_tsx
BW25113DompX
TA563(btuB::Tn)

Antibiotic Resistance
-GmR
-KmR
GmR, KmR
KmR
KmR, CbR
KmR, CbR
KmR
KmR
KmR
KmR, CbR
KmR, CbR
KmR, CbR
KmR
KmR, CbR
KmR, CbR
KmR
KmR, CbR
KmR, CbR
KmR
KmR, CbR
KmR, CbR
KmR, CbR
KmR
KmR, CbR
KmR, CbR
KmR
TetR

Source
116
140
CGSC
CGSC
This study
CGSC
This study
This study
CGSC
CGSC
This study
This study
This study
This study
CGSC
This study
This study
CGSC
This study
This study
This study
This study
This study
This study
CGSC
This study
This study
CGSC
CGSC

Plasmid
pSF_empty
pSF_ompA
pSF_ompC
pSF_ompF
pSF_fadL
pSF_lamB
pSF_tsx

Antibiotic Resistance
AmpR
AmpR
AmpR
AmpR
AmpR
AmpR
AmpR

Source
Oxford Genetics (OGS634)
This study
This study
This study
This study
This study
This study

Phage
T2
T4
T6
T7
R3
U115
EC14
EC35
P2
8S

Source
J. Wertz (Yale U)
J. Wertz (Yale U)
J. Wertz (Yale U)
J. Wertz (Yale U)
This study
This study
This study
This study
This study
This study

GmR, gentamicin resistant; KmR, kanamycin resistant; CbR, carbenicillin resistant; TetR, tetracycline
resistant; AmpR, ampicillin resistant
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Chapter 3: Phenotypic variation among Pseudomonas aeruginosa populations when
coevolving with phage OMKO1
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Preface
Chapter 3 has been adapted from a manuscript that is intended for submission to Journal of
Evolutionary Biology in Summer, 2021.
This study was designed by Kaitlyn Kortright and Dr. Benjamin Chan. Kaitlyn Kortright
and Dr. Benjamin Chan preformed experiments. Kaitlyn Kortright analyzed data. The manuscript
was prepared and edited by Kaitlyn Kortright, Dr. Benjamin Chan and Dr. Paul Turner. Raw
sequencing will be publicly available at NCBI Sequence Read Archive Project # PRJNA713810.
This project was supported by an award from Cystic Fibrosis Foundation, and a portion of the
resources to conduct genome-sequencing came from an award to Felix Biotechnology.
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Abstract
Experimental evolution studies have long been used to examine coevolutionary dynamics between
phages and bacteria; however, here we extend traditional coevolution studies to examine
both coevolutionary dynamics of phage OMKO1 and Pseudomonas aeruginosa and the evolution
of an anticipated trade-off between phage resistance and antibiotic resistance in the bacteria. We
observed that lytic phage OMKO1 and P. aeruginosa are able to coexist over a 10-passage
evolution experiment, and ‘time-shift’ assays revealed that coevolutionary dynamics of the two
microbes followed an arms-race pattern of coevolution with slight differences in dynamics across
all three experimental populations. Measurements of antibiotic resistance at both clonal and
population levels demonstrated that one experimental population evolved phage resistance at the
expense of decreased resistance to tetracycline and erythromycin antibiotics (evolutionary tradeoff), whereas the other two P. aeruginosa treatment populations did not suffer the predicted tradeoff. Whole genome sequencing of bacterial populations revealed that treatment populations
accrued greater mutational differences relative to the wild-type ancestor, compared to a control
where bacteria evolved in absence of phage selection. In each treatment population, mutations
were found in genes involved in biosynthesis of flagella, type-IV pilus and lipopolysaccharide; no
mutations in these genes were observed in the control. In the bacterial population that showed a
trade-off, results indicated three mutations in fleQ, wzz1 and wzz2, that swept to fixation at the
same passage when the phage-resistance/antibiotic-resistance trade-off was observed. Results of
this coevolution experiment remind that predicted evolutionary trade-offs may not always occur,
and that in-vitro experimental studies of phage-bacteria interactions are valuable for elucidating
possible adaptive trajectories.
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Chapter Introduction
It is estimated that Earth contains a staggering 1030 bacterial cells, and these are even outnumbered
roughly tenfold by bacteriophages (phages; viruses of bacteria) that specifically infect them
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.

Although these ubiquitous microbes form the bases of ecosystems, details of their coexistence and
antagonistic coevolutionary interactions remain understudied. Nevertheless, the limited studies
demonstrate that phage-bacteria associations have significant and widespread implications,
including biogeochemical cycling of carbon, nitrogen, and phosphorus in oceans; regulating
primary production in ecosystems; dictating flamingo population crashes
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; and developing

antibacterial therapies. Phage therapy, the therapeutic use of phages to treat bacterial infections, is
increasingly being considered as an adjunctive approach to treat multi-drug resistant bacterial
infections. However, without rigorous studies of the coevolutionary details of phage-bacteria
interactions, such treatments may yield unanticipated outcomes. Experimental evolution studies
could benefit the re-emerging field of phage therapy, by describing the evolutionary dynamics that
occur when bacteria are subjected to phage selection pressures. Additionally, experimental
evolution studies might inform both the repeatability and predictability of the outcomes of these
treatments. If phage therapy is to be used successfully, it is crucial to better understand the
dynamics of phage-bacteria coevolution.
Lytic phages exert selection pressure on bacteria to evolve resistance; in response, resistant
bacteria select for phages to evolve improved infectivity. This reciprocal selection can produce
two types of antagonistic coevolution: arms race dynamics (ARD) versus fluctuating selection
dynamics (FSD). ARD follows a classic ‘gene-for-gene’ model where one bacterial genotype has
a broad resistance (and one phage genotype has very broad infectivity), meaning that the bacteria
evolves to resist all phage genotypes (and the phages coevolve to infect all bacterial genotypes) in
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the phage-bacteria relationship
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. In contrast, coevolution via cyclical fluctuations in allele

frequencies is the basis of FSD, which follow matching-allele models of coevolution 148, 149. Here,
phage infectivity (or bacterial resistance) requires a specific match between the bacterial and phage
genotypes, and polymorphism is maintained by negative frequency-dependent selection. Theory
predicts that environments with weaker costs of resistance/infectivity should produce ARD,
whereas those with stronger costs should foster FSD; ARD are seen in many phage-bacteria
coevolution studies 150-153 with fewer showing FSD 154, 155 suggesting that the cost of evolution of
phage resistance tends to be weak under laboratory conditions. However, if a trade-off exists
between phage resistance and another phenotypic trait, there might be a greater cost to phage
resistance than previously observed.
Phage OMKO1 is a ‘jumbo phage’ of Pseudomonas aeruginosa that selects for phage
resistant bacteria with increased sensitivity to traditional antibiotics

64

. This observed trade-off

between phage resistance and antibiotic resistance may be explained by the binding of phage
OMKO1 to the surface exposed outer membrane component, OprM, of one of the multi drug efflux
pump systems (MexAB-OprM) in P. aeruginosa. However, recent evidence suggests that OMKO1
is either plastic or highly evolvable in its binding, perhaps using the type-IV pilus or flagellum as
a receptor instead of OprM (unpublished data). Here, we conducted a short-term (10 passage)
laboratory coevolution experiment with replicate communities of phage OMKO1 and P.
aeruginosa strain PA01, to determine (1) if phage OMKO1 and the host bacteria can coexist over
approximately 100 bacterial generations, (2) whether ARD or FSD govern the coevolutionary
trajectories, (3) if a trade-off between phage resistance and antibiotic resistance occurs, and (4)
which loci in the bacterial genome undergo changes relative to the wild-type sequence.
Results
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Bacteria and lytic phages coexist for the duration of a short-term coevolution experiment
A short-term (10-passage) serial-transfer experiment (as described in the Methods) was conducted
with P. aeruginosa strain PA01 and lytic phage OMKO1, to test whether the microbes could
coexist and to look for evidence that coevolution occurred (Figure 3.1). All three treatment
communities (bacteria plus phages) presented generally lower bacterial densities in the first half
of the study (days 1 to 5), compared with maximum densities achieved by bacteria in the one
control containing bacteria alone, which was numerically stable throughout (Figure 3.2A).
Furthermore, all of the treatments experienced decreases in bacterial density that were not evident
in the control; the bacteria fell to a low density in all treatments at passage 2; in treatments 1 and
2 at passage 5; and in treatment 3 at passage 6. Interestingly, the lower bacterial densities in
treatment 1 at passages 2 and 5 correlate with higher phage titers at these same time points (Figure
3.2B), with phage titer becoming stable around 109 PFU/mL for the remainder of the study. The
phage titers of the other two treatments tracked with each other; after a large increase in titer at
passage 1, phage titers in treatments 2 and 3 steadily decreased until passage 9, such that all three
treatments ended with 109 PFU/mL (Figure 3.2B). We concluded that PA01 bacteria and phage
OMKO1 were capable of coexisting throughout the 10-passage study, indicating that reciprocal
coevolution was at least possible during the short-term experiment.
Coevolutionary timeline of PA01 and OMKO1 occurs differently in three populations
To determine if bacteria in experimental treatments were evolving to resist phages, the fitness
(fitness = OD600challenge / OD600LB) of 96 randomly-sampled bacterial clones was assayed as
described in the Methods. As expected, bacterial clones from the control showed lower fitness in
the phage challenge than bacterial clones from the treatments, which were subjected to phage
selection (Figure 3.3 and Supplemental Figure S3.1). Furthermore, bacterial clones from earlier
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passages of each treatment population were less-fit in the phage challenge, than bacterial clones
from the same treatment isolated during later passages (Figure 3.3A-C). Fitness of bacterial clones
from treatment 1 and 2 increased markedly from passages 2 to 3 (Figure 3.3A,B). While the fitness
of bacterial clones from treatment 1 remained stable for the rest of the experiment, the fitness of
bacterial clones from treatment 2 seemed to decrease slightly in the later passages (Figure 3.3A,B).
The fitness of bacterial clones from treatment 3 increased gradually over the 10 passages, without
the dramatic ‘jump’ upwards in fitness observed in treatments 1 and 2 (Figure 3.3C). We concluded
that fitness of treatment bacteria in a phage challenge increased over time, indicating evolution of
phage resistance in P. aeruginosa tended to occur in the presence of phage OMKO1 selection.
To examine whether phages in the treatments changed in terms of their host range, phages
at each passage were assayed for their ability to infect the ancestral PA01 used to initiate the
experiment. Impact of phages on the growth curves measured for test bacteria were used to
examine whether viruses changed in their killing efficiency. Results showed that phages in the
earlier passages were better able to suppress (negatively-impact) bacterial growth, compared to
those isolated in later passages (Figure3.4A-C). The maximum OD600 value of the test bacteria
was extracted from each growth-curve dataset, to better-visualize the reduced fitness of passaged
phages when allowed to infect the ancestral bacteria. Phages from passage 1 of treatment 1
suppressed bacterial growth (OD600 of ~0.5), while later-passage phages allowed the ancestral
bacteria to achieve OD600 of approximately 0.9 (Figure 3.4D). Phages from treatments 2 and 3
caused less-dramatic fitness reductions on ancestral bacteria, with earlier passages (1 through 4)
suppressing bacterial growth at OD600 of approximately 0.35, and later passages (5 through 10)
allowing bacteria to reach maximum OD600 of 0.45 (Figure 3.4D). We concluded that phage
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fitness, as measured by the ability to infect ancestral PA01, decreased over time in all treatments,
indicating that phage evolution had occurred.
Coevolutionary dynamics were investigated using time shift assays, where the bacteria
obtained at each passage were cross-streaked against the phages from each passage to ascertain
bacterial resistance and phage infectivity. In general, bacteria from each treatment were more
resistant to phages of the past, and more sensitive to phages from future passages (Figure 3.5A).
Correspondingly, phages were more infective on bacteria of the past, and less infective on bacteria
of the future (Figure 3.5B). Some bacteria from treatments 2 and 3 were sensitive to phages from
the past, specifically 6, 7 or 8 passages prior to the contemporary phages; whereas, in treatment 1
some bacteria were resistant to phages of the future (Figure 3.5A). Time-shift assays for each of
the treatments were consistent with expectations of ARD coevolution.
Trade-off between phage resistance and antibiotic resistance occurs in one population
To determine if the evolution of phage resistance resulted in a trade-off with resistance to
antibiotics, the 96 bacterial clones from each passage that were assayed for fitness in the presence
of contemporary phages (Figure 3.3) were similarly assayed for fitness in 3mg/L of tetracycline.
Over the course of ten passages, fitness in tetracycline of treatment 2, treatment 3 and the control
either didn’t change or increased slightly as seen by a positive slope of the regression line (Figure
3.6B-D). However, fitness of treatment 1 in the presence of tetracycline appeared to decrease over
the ten passages; more specifically, bacterial clones taken from passages 8, 9 and 10 have a lower
fitness than clones taken from earlier passages (Figure 3.6A). These results were confirmed using
both Etest strips and two-fold dilutions to measure the minimum inhibitory concentrations (MIC’s)
of various antibiotics for bacteria taken from each passage. MIC measurements made using Etest
strips show that later passages (days 7-9) of the bacteria taken from treatment 1 have a slightly
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lower MIC to tetracycline and erythromycin (Supplemental Figure S3.2A,B) but remain resistant
to ampicillin (Supplemental Figure S3.2C). Additionally, to determine the MIC needed to kill 90%
of bacteria (MIC90), bacterial from each treatment were plated on a range of two-fold dilutions of
tetracycline (4 and 8 mg/L), erythromycin (64, 128 and 256 mg/L), meropenem (0.25 and 0.5
mg/L) and gentamicin (0.5, 1 and 2 mg/L). MIC90 of gentamicin and meropenem (Supplemental
Table S3.1) remain unchanged over the 10 days of passages, however, MIC90 of tetracycline and
erythromycin (Supplemental Table S3.1) trend down for treatment 1 at the latter passages (days 710) as compared to the control. Taken together, these results show preliminary evidence that a
trade-off between phage resistance and antibiotic resistance may have occurred for treatment 1 but
not for treatment 2 or 3.
Genomics reveals likely loci undergoing change
Deep sequencing (DS) of bacterial populations from each passage was used to examine the
genetics underlying the observed ARD coevolution. Frequencies of high-quality variants in coding
regions that differed from the common ancestor’s genome were plotted as heat maps for each of
the treatments and control (Supplemental Figure S3.3). Treatment 1 showed the greatest number
of alleles that differed from the ancestor (n=288); furthermore, the number of mutations was
elevated at passages 1 and 2 (n=84 and 87, respectively), while the number of such mutations
decreased in future passages (Supplemental Figure S3.3A). Treatments 2 and 3 had fewer sites that
changed (n=125 and n=163 respectively) and the number of mutations did not deviate throughout
the experiment (Supplemental Figure S3.3B,C). As expected, the control had the fewest number
of allele changes (n=115) and the number of mutations did not vary across passages (Supplemental
Figure S3.3D). The majority of the mutations observed in each treatment and the control were
polymorphic non-synonymous (Pn) or polymorphic synonymous (Ps) (Table 3.1). Treatments 1
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and 2 did not have any fixed synonymous mutations (Ds) while treatment 3 and the control had 2
Ds mutations each (Table 3.1). Treatment 1 and 3 had 9 mutations each that were fixed and nonsynonymous (Dn) while treatment 2 and the control had 7 Dn mutations each (Table 3.1).
Additionally, DS and analysis was used to identify a subset of the genetic variations,
specifically variants in genes common to the treatments but not observed in the control. Treatments
1 and 2 had mutations in genes involved in type-IV pilus biogenesis; these bacterial populations
shared 4 point mutations (three of which were non-synonymous) in pilB that were low frequency
variants at passages 1 and 2 (Figure 3.7A,B and Supplemental Table S3.2). Treatment 2 had an
additional two non-synonymous point mutations in fimU that fixed at passage 3 and 4, but were
subsequently lost from the population (Figure 3.7B and Supplemental Table S3.2). No mutations
in type-IV pilus biogenesis genes were observed in treatment 3 or control bacteria (Figure 3.7C
and Supplemental Table S3.3).
All three treatments showed bacteria with mutations in flagellar biosynthesis genes.
Treatment 1 had two non-synonymous mutations in fleQ, three indels in fleS, and two point
mutations in fliI (Figure 3.7A and Supplemental Table S3.2). Treatment 2 bacteria had a single
point mutation in fleQ that fixed at passage 3 and remained at high frequency until passage 8
(Figure 3.7B and Supplemental Table S3.2). Bacteria from treatment 3 had two mutations in fleQ
and an insertion in fleR, all three of which rose independently to high frequency for a single passage
(Figure 3.7C and Supplemental Table S3.2). No mutations in flagella biosynthesis genes were
observed in the control.
Finally, each treatment population showed mutations in multiple genes involved in both
A-band and B-band lipopolysaccharide (LPS) biosynthesis. Treatment 1 bacteria had a high
frequency mutation in wzy at passage 2, a high frequency deletion in wbpL for passages 3 and 4
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and low frequency mutations in wbpX and wbpZ towards the end of the experimental evolution
(Figure 3.7A and Supplemental Table S3.2). Treatment 2 had mutations in wbpX and gmd that
were observed during passages 6 and 7-8 respectively (Figure 3.7B and Supplemental Table S3.2).
Treatment 3 bacteria had mutations in wbpY (passage 6) and wzt (passage 9-10) (Figure 3.7C and
Supplemental Table S3.2). All three treatments had bacteria with multiple non-synonymous wzz1
and wzz2 mutations that occurred over the course of the experiment. No mutations were observed
in any genes involved in LPS synthesis in the control (Supplemental Dataset S1). A complete list
of mutational variants observed in each population can be found in Supplemental Dataset S1.
Discussion
Bacterial densities and phage titers (Figure 3.2) showed that it was possible for lytic phage
OMKO1 and P. aeruginosa host bacteria to coexist for the entirety of a short-term experiment.
Fitness challenges in the presence of phages (Figure 3.3) showed that bacteria from treatment
populations were able to evolve resistance (achieve high fitness) to contemporary phages, while
bacteria from the control remained highly susceptible (low fitness) to phage infection.
Furthermore, decreases in phage titers (Figure 3.2B) for each treatment population seemed to
correlate temporally with the evolution of phage resistance in each bacterial population (Figure
3.3). These population dynamics are most clearly seen in treatment 1; phages from treatment 1
monotonically decreased from passages 1 to 4 (Figure 3.2B, blue) while bacteria from treatment 1
shift from phage-susceptible at passages 1 and 2 to phage-resistant at passages 3 and 4 (Figure
3.3A). However, the titer of treatment 1 phages rebounded after passage 4, likely indicating that
the phage population had evolved to infect the phage-resistant bacteria. Taken together, these
results indicated that bacteria from the treatments containing phages evolved resistance to phages.
Since phages were observed in the final passage in each of the treatments, this indicated that either

84

phages were evolving in response to bacterial evolution, or that bacteria had not evolved complete
phage resistance. Results (Figure 3.4) seemed to indicate that phages had evolved decreased
infectivity on ancestral PA01 bacteria. This was likely due to phage evolution of increased
infectivity on coevolving bacterial populations (phages were evolving to infect bacteria that were
evolving to resist phages). Time shift assays (Figure 3.5) helped illuminate the dynamics of the
coevolution that appears to have occurred in the experimental treatments; bacteria were more
resistant to phages of the past and more sensitive to future phages (Figure 3.5A); and phages were
more infective to past bacteria and less infective to those of the future (Figure 3.5B). These results
were consistent with predictions of ARD. However, there were some instances in treatment 1
where bacteria were resistant to future phages, and in treatments 2 and 3 there were phages that
could successfully infect future bacteria. While the coevolutionary dynamics seemed to follow
patterns generally indicative of ARD, during some passages, FSD may have occurred instead.
All three treatments contained bacterial populations that became resistance to phages;
however, the previously observed trade-off between phage-resistance and antibiotic-resistance was
only observed in treatment 1 (Figure 3.6, Supplemental Figure S3.2 and Supplemental Table S3.1).
This result is curious as each population originated from the same ancestral bacterial clone,
experienced the same selection pressures, and evolved phage-resistant bacteria over time.
Previously, reduced MIC was observed for individual clones of bacteria that evolved resistance to
phage OMKO1, originating both from phage selection on standing genetic variation in the bacteria
and when P. aeruginosa was subjected to short-term experimental evolution 64, 156. This offers two
possible explanations for the non-observed trade-off in treatments 2 and 3. In this study, instead
of measuring MIC using individual clones, MIC was measured at the population level. It is possible
that minority variants present in treatments 2 and 3 did exhibit a trade-off that was missed when
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making measurements at the population level. Additionally, during the short-term coevolution
study, individual bacterial clones in each experimental population experienced selection by coevolving phages, but also contended with other bacterial competitors in the population. Different
bacterial genotypes present in the population likely had differing relative finesses to each other.
Perhaps the trade-off is less likely to occur when bacteria are forced to contend with multiple
selection pressures, due to differences in relative fitness of individual bacterial clones.
Genomics may also help explain why the trade-off was only observed in one bacterial
population. Results showed that there was more genetic variance in the treatment populations than
in the control. Furthermore, bacteria in treatment 1, the only population where the trade-off was
observed, had the most variants, particularly at passages 1 and 2 prior to the evolution of phage
resistance in that treatment (Figure 3.3A). This greater genetic variation likely contributed to a
higher likelihood of mutations present that increased individual fitness in the local environment;
it is possible that this greater genetic variation, early in the experiment for treatment 1, contributed
to the evolution of the observed trade-off between phage resistance and antibiotic resistance.
The observed changes in allele frequency over the course of the experiment demonstrated
that all three treatment populations, as well as the control, underwent microevolution. A higher
ratio of Dn/Ds than Pn/Ps for each treatment as well as the control indicated that these populations
were likely undergoing positive selection 157. During positive selection, also known as Darwinian
selection, certain genotypes are beneficially advantaged and can sweep to fixation, as opposed to
negatively selected (i.e., purifying selection) where deleterious genotypes removed from the
population. In the context of coevolution, positive selection is indicative of ARD while negative
section is indicative of FSD. This supports the conclusions made from the time-shift assays (Figure
3.5); ARD seems to dominate the coevolutionary dynamics of this experiment.
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Additionally, bacterial genomics revealed the loci that changed and likely contributed to
phage resistance and to the trade-off observed in treatment 1. The treatment populations showed
variants in genes involved in the biosynthesis of type-IV pilus, flagella and LPS, while the control
presented no variants in these genes (Figure 3.7, Supplemental Table S3.2 and Supplemental
Dataset S1). The treatment populations did not have any high frequency variants in multi-drug
efflux genes such as oprM, the predicted receptor for phage OMKO1. Unpublished data suggests
that unselected variants of phage OMKO1 use the type-IV pilus or the flagella of PA01 as
receptors. This is interesting considering the convergence of variants with type IV pilus and
flagella changes observed multiple times in the treatments. Transcriptional activator FleQ
regulates FleRS a two-component regulatory system that controls flagellar biosynthesis; each
population has a mutation in at least one of these genes that is fixed for one or more passages at
some point over the course of the experiment 158-160. Treatments 1 and 2 had low frequency variants
in pilB, mutants of which are defective in pili biogenesis, at early passages 161. Treatment 2 had an
additional mutation in fimU, part of the prepilin operon, which was fixed at passage 3 and 4
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Together, these mutations indicate that perhaps more variants in the phage population were using
pili or flagella as receptors instead of the expected receptor, OprM. Further sequencing and
analysis of phage genomes could uncover tail-fiber mutations that confirm this hypothesis. All
three treatment populations had many mutations in various genes involved in LPS biosynthesis,
particularly in genes involved in both A-band and B-band O-antigen synthesis and chain length
regulation (wzz1, wzz2, wzy, wbpX, wbpY, wbpL and wbpZ)

163-167

. While phage OMKO1 is not

expected to use LPS as a receptor, defects in LPS have been shown to result in a loss of both
flagellar- and pili-based motility in P. aeruginosa 168.
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Many of the mutations discussed above were observed transiently in treatments 2 and 3.
However, treatment 1 had three mutations (A1188191G, G3546149A, and C1028191CG in fleQ,
wzz1, and wzz2 respectively) that rose to high frequency or fixed in passages 7 through 10 (Figure
3.7A), making it possible that these mutations are linked together on a single genotype that is at
high frequency in the population. Furthermore, the timing of these mutations corresponds with the
observation of the trade-off between phage resistance and resistance to tetracycline and
erythromycin (Figure 3.5A), indicating that these mutations might be responsible for the trade-off
in treatment 1. Loss of the O-antigen has been previously implicated in alteration of membrane
permeability, due to the hydrophilic nature of the O-antigen 168. Therefore, it is possible that the
mutations in wzz1 and wzz2 are contributing to the trade-off observed between phage resistance and
sensitivity to erythromycin, a hydrophobic antibiotic. This is in contrast to gentamicin where loss
of the O-antigen has been shown to increase resistance to gentamicin; however, no change in
resistance to gentamicin was observed in this study
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. It is not surprising that the trade-off was

not observed for ampicillin, as resistance is usually driven by beta-lactamases present in the
cytoplasm of the bacteria 170 and we did not expect phage selection to affect the expression of these
enzymes. Resistance to meropenem and tetracycline is usually conveyed by the upregulation of
multi-drug efflux pumps

170

; as no efflux mutations were observed in treatment 1 at passages 7

through 10, it is unsurprising we see no trade-off between phage resistance and meropenem
resistance. However, resistance to tetracycline has also been reported to change with alterations in
membrane permeability; therefore, it is possible that the same high-frequency mutations in wzz1
and wzz2 are contributing both to the trade-off between phage resistance and erythromycin
resistance, as well as the trade-off observed between phage resistance and tetracycline

168, 171

.
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Further experiments, using genotyped clones from later passages of treatment 1, could confirm
this observation and will be the goal of future studies.
While the experimental evolution study presented here demonstrates that bacteria and lytic
phages can both coexist and coevolve over a short time period, it also shows that there is more
work to be done if we are to predict the outcomes of such interactions. Each treatment was initiated
using identical starting material: media was taken from the same bottle, bacteria were taken from
the same culture, and phages were taken from the same stock. We see the bacterial evolution of
phage resistance, and convergence on a similar set of variants at the population level in the
treatment populations. However, the bacterial phenotypes at the end of the 10-day passaging are
not the same for each treatment population. Based on prior knowledge of phage OMKO1 selection
resulting in a trade-off between phage resistance and antibiotic resistance, we expected to see this
trade-off evolve in each treatment population 64. Instead, we observe this trade-off occurring only
in bacteria from treatment 1. Although it is possible that the trade-off would have occurred in each
treatment population if we had let the coevolution experiment play out for longer, the evolutionary
dynamics occurring in treatments 2 and 3 seem to be occurring at a different pace than in treatment
1, demonstrating that experimental evolution may not be as repeatable as previously thought 172.
The population level approach combined with the high temporal and genomic resolution used in
this study likely contributed to the observations that highlighted the irreproducibility of evolution
seen between the three experimental populations

172, 173

. This underscores the complexities

involved in predicting evolutionary outcomes; even though the evolution that occurred in this study
was repeatable to some extent, the predicted outcome of the evolution of phage resistance, namely
the trade-off between phage resistance and antibiotic resistance, did not always occur. Clearly there
is more to investigate before we will be able to accurately predict evolutionary outcomes.
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Materials and Methods
Strains and Culture Conditions
P. aeruginosa strain PA01 and phage OMKO1 were the only microbes used in this study. All
bacteria and phages were grown in Lysogeny Broth (LB) medium (10g tryptone, 5g yeast extract,
10g NaCl per L). Bacteria were grown on 1.5% LB agar plates and phages were grown with
bacterial lawns in 0.75% LB top agar.
Experimental Evolution Design
Three treatments (PA01 bacteria plus phage OMKO1) were established. At the start of the
experiment, phages and bacteria were mixed together in a sterile flask at multiplicity of infection
(MOI; ratio of phage particles to bacterial cells) of ~0.0001 initial concentration (i.e., 104 plaqueforming units [PFU] of phage OMKO1 and 108 colony forming units [CFU] of PA01 bacteria per
mL), in a final volume of 10 mL LB medium. One control (bacteria alone) was similarly
established, without input phages. After overnight incubation at 37°C with 200 rpm shaking, each
treatment and control was passaged 1:100 into a new sterile flask with 9.9mL fresh LB medium.
This process of 1:100 serial transfer was repeated for a total of 10 experimental passages.
Bacterial Phenotypic-Challenge Assays
At each passage of the experimental evolution study, a sample from each overnight treatment and
control was diluted and plated on LB agar; after overnight incubation at 37°C visible colonies
formed. At random, 96 individual colonies were picked from each plate and resuspended in 200µL
LB medium. The goal was to compare how 96 randomly-isolated colonies (clones) from each
treatment and control grew across three different challenge environments, throughout the
experiment; 3840 clones total were examined (96 clones from 4 treatments/control over 10
passages). To do so, an equal volume of each resuspended colony was used to inoculate a single
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well in each of three 96-well plates, which contained either LB medium, LB plus phage OMKO1
at MOI greater than 10, or LB with 3mg/L tetracycline. The 96-well plates were then placed in a
static 37°C incubator. After 18 hours, plates were removed from incubation and optical density at
wavelength 600 nm (OD600) was measured for the bacteria in each well, using a spectrophotometer
(Tecan Infinite F500 microplate reader). Fitness of a bacterial clone in the challenge environment
(phage OMKO1; tetracycline) was defined as the observed OD600 in that environment divided by
observed OD600 in the control environment (LB medium). Ratio estimates greater, equivalent and
less than 1.0 indicated that the clone was more fit, equally fit or less fit in the challenge
environment, respectively.
Antibiotic Resistance Measurements
The minimum inhibitory concentrations (MIC) of tetracycline, erythromycin and ampicillin
antibiotics that were effective in impacting growth of a bacterial strain/population were determined
using Etest strips (Biomerieux). Briefly, an overnight culture of bacteria was diluted to a
McFarland standard of 0.5 and spread on Mueller-Hinton agar plates Agar (2g beef extract, 17.5g
casein hydrolysate, 1.5g starch, 17.0g agar per L). The bacterial lawn was allowed to dry and an
Etest strip containing was placed on top of the lawn. After overnight incubation at 37°C the plate
was scored by recording the lowest concentration of antibiotic that inhibited growth (zone of
clearing) of the bacterial lawn.
The MIC necessary to inhibit the growth of 90% of a bacterial population (MIC90) was
determined for tetracycline, erythromycin, gentamicin and meropenem using a direct plating
method. Briefly, serial dilutions of a test bacterial culture were plated on LB plates and on LB
plates containing a range of two-fold dilutions of each antibiotic (tetracycline: 4 and 8 mg/L;
erythromycin: 64, 128 and 256 mg/L; gentamicin: 0.5, 1 and 2 mg/L; and meropenem: 0.25 and
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0.5 mg/L). After overnight incubation at 37°C, CFU were counted for each plate and MIC90 was
recorded as the antibiotic concentration that reduced the number of CFUs to 10% or less of the
CFU observed on LB without antibiotics.
Sequencing and Variant Calling
Bacterial genomes were extracted using a previously described protocol

141

and sequencing

libraries were made using Nextera XT library preparation kits (FC-131-1096, Illumina). Pairedend 150 base pair reads were generated on an Illumina HiSeq 2500 rapid run. High-quality reads
were aligned to the PA01 reference genome (Genbank Accession # AE004091.2) using Bowtie2
143

. Variants were called using GATK 174. Only high-quality variants (GATK quality score > 200)

that were not in intergenic or prophage regions were considered for further analysis in this study.
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Chapter 3 Figures & Tables
Figure 3.1 Experimental setup of short-term coevolution experiment

Experimental setup of short-term coevolution experiment. All populations were started from a clonal PA01 culture.
Three treatment populations of phages and bacteria (blue, purple and green) were initiated at an MOI of ~0.0001. One
control of bacteria only (grey) was started at the same time. All populations were passaged 1:100 every 24 hours into
fresh media.
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Figure 3.2 Bacterial density and phage titer

Bacterial density and phage titer A Bacterial density measured as OD600 at the time of each passage for 10 days for
treatment 1 (blue), treatment 2 (purple), treatment 3 (green) and the control (grey). B Phage titers of OMKO1 from
treatment 1 (blue), treatment 2 (purple) and treatment 3 (green) were measured on the contemporary control.
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Figure 3.3 Bacterial fitness in the presence of contemporary phages

Bacterial fitness in the presence of contemporary phages for approximately 96 randomly selected bacterial clones from
A treatment 1, B treatment 2 and C treatment 3. Bacterial clones from D the control were challenged to grow in the
presence of contemporary phages from treatment 1. Here fitness is defined as the ratio of bacterial density in the phage
challenge to the bacterial density in media. For each population, a linear regression was preformed to determine the
change in fitness overtime.
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Figure 3.4 Impact of phage populations on ancestral bacteria

Impact of phage populations on ancestral bacteria. A-C Bacterial growth curve of ancestral PA01 alone (grey dotted
line) or in the presence of phage populations at each passage from treatment 1, treatment 2, and treatment 3
respectively. Each growth line represents the average of three technical replicates. D The first maximum OD600
measurement for ancestral PA01 grown in the presence of phage populations at each passage from treatment 1 (blue),
treatment 2 (purple) and treatment 3 (green). Error bars represent standard deviation of three technical replicates.
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Figure 3.5 Coevolutionary dynamics

Coevolutionary dynamics A Time shift assays to determine the proportion of phage resistant bacterial populations.
The dashed line at 0 are assays of bacterial populations with contemporary phage populations. Negative numbers
along the x-axis represent assays of bacterial populations with past phage populations. Positive numbers along the xaxis represent assays of bacterial populations with future phage populations. B Time shift assays to determine the
proportion of infective phage populations to time shifted bacterial populations.
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Figure 3.6 Bacterial fitness in the presence of 3mg/L of tetracycline

Bacterial fitness in the presence of 3mg/L of tetracycline for approximately 96 randomly selected bacterial clones
from A treatment 1, B treatment 2, C treatment 3 and D the control. Here fitness is defined as the ratio of bacterial
density in the tetracycline challenge to the bacterial density in media. For each population, a linear regression was
preformed to determine the change in fitness overtime.
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Figure 3.7 Frequencies of new alleles

Frequencies of new alleles of genes involved in type IV pilus biogenesis

104

, flagellar synthesis (grey), and LPS

biosynthesis (B-band genes in solid line and A-band genes in dotted line) of A treatment 1 (blue), B treatment 2
(purple), and C treatment 3 (green).
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Table 3.1 Types of mutations

Ds
Dn
Ps
Pn
Total

1
0
9
82
191
282

Treatment
2
3
0
2
7
9
28
43
89
109
124
163

Control
2
7
39
67
115

The total number of synonymous & fixed (Ds), non-synonymous & fixed (Dn), synonymous & polymorphic (Ps) and
non-synonymous & polymorphic (Pn) mutations in coding regions for treatments 1, 2 and 3 and the control.
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Chapter 3 Appendix
Supplemental Figure S3.1 Fitness in the presence of contemporary phages

Fitness in the presence of contemporary phages for approximately 96 randomly selected bacterial clones from the
control challenged to grow in the presence of contemporary phages from A treatment 2 or B treatment 3. Here fitness
is defined as the ratio of bacterial density in the phage challenge to the bacterial density in media. A linear regression
was preformed to determine the change in fitness overtime.
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Supplemental Figure S3.2 Minimum inhibitory concentrations of each population

Minimum inhibitory concentration for each passage of treatment 1 (blue), treatment 2 (purple), treatment 3 (green)
and the control (grey) of A tetracycline, B erythromycin, and C ampicillin. Measurements were made at the population
level using Etest strips.
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Supplemental Figure S3.3 Heat maps of new allele frequencies

Heat maps of new allele frequencies at each passage for A treatment 1, B treatment 2, C treatment 3 and D the
control.
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Supplemental Table S3.1 MIC90 of tetracycline, erythromycin, meropenem and gentamicin
Tetracycline
Treatment 1

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Day 8

Day 9

Day 10

>8

≤4

>8

≤4

8

>8

≤4

≤4

≤4

≤4

>8

>8

8

8

>8

>8

≤4

≤4

≤4

≤4

>8

8

8

8

>8

8

8

8

8

>8

8

>8

>8

>8

>8

>8

>8

>8

>8

>8

>8
>8

8
>8

8
>8

8
>8

>8
>8

8
>8

≤4
>8

≤4
≤4

≤4
8

8
8

8

8

8

>8

>8

>8

>8

>8

>8

>8

≤4

>8

>8

>8

>8

>8

>8

>8

>8

>8

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Day 8

Day 9

Day 10

>256

128

> 256

≤ 64

256

256

≤ 64

≤ 64

≤ 64

≤ 64

256

256

256

≤ 64

128

> 256

128

128

128

128

> 256

256

256

256

256

256

256

256

256

> 256

> 256

256

256

> 256

256

> 256

256

> 256

> 256

> 256

256

256

256

256

> 256

256

128

128

256

128

> 256
256

256
256

256
256

> 256
256

256
>256

> 256
>256

256
256

128
>256

128
>256

128
256

≤ 64

256

256

256

> 256

256

256

256

> 256

> 256

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Day 8

Day 9

Day 10

> 0.5
> 0.5

> 0.5
> 0.5

> 0.5
> 0.5

≤ 0.25
0.5

> 0.5
> 0.5

> 0.5
> 0.5

0.5
> 0.5

0.5
> 0.5

0.5
> 0.5

0.5
> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

0.5

0.5

0.5

0.5

0.5

0.5

0.5

0.5

0.5

0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

> 0.5

Control

> 0.5
≤ 0.25

> 0.5
> 0.5

> 0.5
> 0.5

> 0.5
> 0.5

> 0.5
> 0.5

> 0.5
> 0.5

> 0.5
> 0.5

> 0.5
< 0.25

> 0.5
> 0.5

> 0.5
> 0.5

Gentamicin

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Day 8

Day 9

Day 10

>2

>2

>2

1

>2

>2

>2

>2

>2

>2

>2
>2

>2
>2

>2
>2

≤ 0.5
>2

≤ 0.5
>2

>2
>2

>2
>2

>2
>2

>2
>2

>2
>2

>2

>2

>2

>2

2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

>2

≤ 0.5

>2

>2

>2

>2

>2

Treatment 2
Treatment 3
Control

Erythromicin
Treatment 1
Treatment 2
Treatment 3
Control

Meropenem
Treatment 1
Treatment 2
Treatment 3

Treatment 1
Treatment 2
Treatment 3
Control

Minimum inhibitory concentration to kill 90% of bacteria (MIC90) of tetracycline, erythromycin, meropenem and
gentamicin made in duplicate for each passage of treatment 1, treatment 2 treatment 3, and the control. (> indicates
the MIC90 was higher than the range of concentrations examined and ≤ indicates the lowest concentration examined
was sufficient to kill 90% of the colony forming units, but the actual MIC90 could be lower)
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Supplemental Table S3.2 Location, mutation and frequencies of new alleles
Treatment 1
Location Gene

Mutation type

5070994
5071004
5071005
5071011
1188191
1188291
1190231
1190236
1190324
1196848
1196853
3546149
3546461
1028191
3537986
6139402
6136624
3529218

non-synonymous
synonymous
non-synonymous
non-synonymous
non-synonymous
12 bp deletion
3 bpdeletion
1 bp insertion
1 bp deletion
synonymous
non-synonymous
non-synonymous
non-synonymous
1 bp insertion
non-synonymous
24 bp deletion
non-synonymous
1 bp deletion

pilB
pilB
pilB
pilB
fleQ
fleQ
fleS
fleS
fleS
fliI
fliI
wzz1
wzz1
wzz2
wzy
wbpX
wbpZ
wbpL

Q411L
H414H
M415L
M417L
N202S

E276E
A278G
A260V
P156L
N381S
T164P

Passage
3

Ancester

Passage
2

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0.1935
0.1935
0.1818
0.1935
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.625
1
0.25
0
0
0.25
0
0
0.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.88235
0
0
0
0
0
0
0
0
0
0.91667 0.88235

Ancester

Passage
1

Passage
2

Passage
3

0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0

0.2222
0.2222
0.2222
0.1667
0
0
0.6364
0.3571
0
0
0

0
0
0
0
1
0
1
0.4074
0
0
0

Treatment 2
Location Gene

Mutation type

5070994
5071004
5071005
5071011
5098645
5098648
1188304
1028719
1029022
6139316
6143588

non-synonymous
synonymous
non-synonymous
non-synonymous
non-synonymous
non-synonymous
non-synonymous
non-synonymous
non-synonymous
5 bp deletion
non-synonymous

pilB
pilB
pilB
pilB
fimU
fimU
fleQ
wzz2
wzz2
wbpX
gmd

Q411L
H414H
M415L
M417L
R145L
V146L
G240C
A183V
V284E
R164S

Frequency of Alternate Allele
Passage Passage Passage
4
5
6

Passage
1

Passage
7

Passage
8

0
0
0
0
1
0
0
0
0
0
0
0.9863
0
1
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0.9348
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.16
0
0
0.1538
0.9912 0.9394
1
0
0
0
0.9623
1
0.9
0
0
0
0
0.31818 0.22581
0.35417
0
0.33333
0
0
0

Frequency of Alternate Allele
Passage Passage Passage
4
5
6

Passage
7

Passage
8

Passage
9

Passage
10

0
0
0
0
1
1
1
0
0.9565
0
0

0
0
0
0
0
0
1
0
1
0
0.6364

0
0
0
0
0
0
1
0
0
0
0.875

0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0.5676
0.575
0.5172
0
0
0
0

0
0
0
0
0
0
0.9167
0
0.875
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
1
0
0.95
0.3103
0

Passage
9

Passage
10
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Supplemental Table S3.3 cont. Location, mutation and frequencies of new alleles
Treatment 3
Location

Gene

Mutation type

1188203
1188291
1191793
3546149
3546176
3546471
3546595
1028365
1028961
1029022
6137773
6139973

fleQ
fleQ
fleR
wzz1
wzz1
wzz1
wzz1
wzz2
wzz2
wzz2
wbpY
wzt

non-synonymous
12 bp deletion
1 bp insertion
non-synonymous
non-synonymous
non-synonymous
1 bp deletion
non-synonymous
non-synonymous
non-synonymous
21 bp deletion
6 bp deletion

Ancester

Passage
1

Passage
2

Passage
3

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0.6667
0
0
0
0

0
0
0
0
0
0
0.2222
0.5714
0
0
0
0

I206S

A260V
Y251C
Q153Stop
A65V
T264P
V284E

Frequency of Alternate Allele
Passage Passage Passage
4
5
6
0.9286
0
0
0
0.7143
0
0
0.8462
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
1
0
0
0
1
0
0
1
0
0.4167
0

Passage
7

Passage
8

Passage
9

Passage
10

0
0
1
0
0
0
0
0
0
0.5455
0
0

0
0
0
0
0
0.9167
0
0
0
0
0
0

0
0
0
0.8462
0
0.4
0
0
0
1
0
0.4444

0
0
0
0.7778
0
0
0
0
0
0
0
0.7

Location, gene, mutation type and frequencies of new alleles found in treatment 1, treatment 2 and treatment 3 plotted in Figure 3.7.
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Supplemental Datasets
Supplemental Dataset 1 can be found on Dryad (doi: 10.5061/dryad.1g1jwstvp). This is a table of
the location, mutation, and frequencies of all high quality (Q>200) found in treatment 1, treatment
2, treatment 3 and the control.
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Chapter 4: Selection for phage resistance reduces virulence of Shigella flexneri
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Preface
Chapter 4 has been adapted from a manuscript that is intended for submission to PLOS Pathogens
in Spring, 2021.
This study was designed by Kaitlyn Kortright and Dr. Benjamin Chan. Kaitlyn Kortright
and Rachel Done preformed experiments. Kaitlyn Kortright analyzed data. The manuscript was
prepared and edited by Kaitlyn Kortright, Dr. Benjamin Chan and Dr. Paul Turner. Raw
sequencing will be publicly available at NCBI Sequence Read Archive Project # PRJNA713796.
We thank Kristen Parent and John Wertz for kindly providing strains used in this study.
Additionally, we would like to thank Valeria Souza for water samples and Dylan Sloan and Akshay
Mody for technical support and assistance with experiments conducted in the early stages of this
study. This project was supported by an award from Project High Hopes Foundation, and a portion
of the resources to conduct genome-sequencing came from an award to Felix Biotechnology.
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Abstract
There has recently been an increasing interest in phage therapy as an alternative option for
infection management, especially when phages have been shown to cause an evolutionary tradeoff between phage resistance and bacterial fitness traits such as virulence. A vast repertoire of
virulence factors allows Shigella flexneri to invade gut epithelial cells, replicate intracellularly,
and evade the immune system through intercellular spread. In particular, the intercellular spread
stage of S. flexneri infection causes tissue damage, contributing to mortality. It has previously been
shown that the porin OmpA is necessary for the polar localization of virulence factor IcsA, which
polymerizes host actin and allows the bacterium to be motile inside host cells. We hypothesize that
a phage which uses OmpA as a receptor to recognize, bind and infect S. flexneri, will select for
phage-resistant bacteria that are attenuated for intercellular spread. Here we show that a naturally
isolated Myoviridae phage, A1-1, requires OmpA as a receptor. Using phenotypic traits observed
from efficiency of plaquing assays, membrane integrity assays, total LPS measurements, MIC
measurements as well as phage cross resistance profiles, five A1-1 resistant S. flexneri mutants
can be placed into two phenotypic groups. R1 and R2 phenotypically resemble ompA knockouts
and R3, R4 and R5 phenotypically resemble LPS-deficient strains. Whole genome sequencing
confirms that R1 and R2 have mutations in ompA, while R3, R4 and R5 have a mutation in gmhA,
a mutation in gmhC and a 30,000 base pair deletion spanning gmhA, respectively. Bacterial plaque
assays confirm that all five phage-resistant mutants are unable to spread intercellularly. Thus,
selection for phage A1-1 resistance results in a trade-off between phage resistance and bacterial
virulence.
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Chapter Introduction
As a facultative, intracellular pathogen and a causative agent of bacillary dysentery, Shigella
flexneri is a Gram-negative bacterium of medical importance. Fecal-oral transmission of these
bacteria is common and usually occurs via contaminated drinking water

175

. Bacteria rapidly

traverse the gastrointestinal tract to invade colonic epithelial cells. Upon invasion, both
chromosomally-encoded and plasmid-encoded virulence factors enable S. flexneri to overcome
host immune responses, replicate intracellularly, and spread to neighboring epithelial cells 176. In
particular, intercellular spread of S. flexneri is a virulence trait that damages colonic epithelial
cells, destroying barrier function and resulting in severe shigellosis and dysentery.
Shigellosis is a major public health problem in low-income countries that lack dependable
water sanitation, and this disease contributes to approximately 1.3 million deaths annually

177

.

Children under the age of five account for almost 70% of the total mortality, primarily for cases in
sub-Saharan Africa and southern Asia 178. Antibiotic treatment for shigellosis can rapidly improve
patient outcomes

178

. However, many of the recommended antibiotics are expensive and

increasingly ineffective due to bacterial resistance to antibiotics, making them difficult to
implement with limited health services

178

. Thus, shigellosis remains a persistent cause of

mortality, particularly for young children, with insufficient practical options for disease
management. Therefore, alternatives to expensive and logistically challenging antibiotic
treatments for shigellosis could valuably reduce disease burden, especially in children.
As the rates of antibiotic resistance in bacteria continue to increase alarmingly,
complementary treatments to control bacterial infections are quickly being considered. One such
treatment is phage therapy, the clinical use of bacteriophages (phages), viruses that specifically
infect bacteria, to treat bacterial infections

179

. In particular, lytic phages are considered good
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candidates for phage therapy due to their predator-like effect on susceptible host bacteria. The
lifecycle of a lytic phage involves attachment to one or more receptors on the surface of a
bacterium, introduction of genomic material to the cytoplasm, intracellular replication,
transcription and translation of phage genes, assembly of new phage particles, and lysis of the
bacterial host to repeat the cycle 179. There are recent reports of implementation of phage therapy
to treat refractory bacterial infections, particularly those that are resistant to multiple antibiotics 13,
83, 180

. While phage therapy has demonstrated potential and promise as a complementary therapy

to antibiotics, it is expected that these viruses should select for evolution of phage-resistance in
target bacteria. Therefore, it is crucial to design rational phage treatments, so that evolution of
phage resistance is leveraged as a possible benefit, rather than necessarily constituting a barrier to
effective treatment.
The concept of evolutionary trade-offs permeates evolutionary biology. Trade-offs occur
when an organism evolves a new phenotype that improves fitness in a certain environment at the
cost of decreased fitness in another environment 47. In the context of phage therapy, it should be
possible to identify phages that direct the evolution of their host bacteria, such that evolution of
phage resistance, on average, results in a clinically-useful fitness trade-off. In particular, by
choosing a lytic phage that exerts selection pressure on an antibiotic-resistance and/or virulence
mechanism, the phage-susceptible bacteria are killed while the remaining population is enriched
for phage-resistant variants with reduced drug resistance and/or virulence

49

. In either case, the

phage treatment would cause evolution of phage resistance to be a benefit, rather than a liability.
To implement a rationally designed phage treatment that selects for a virulence trade-off
in bacteria, a surface-expressed virulence factor must be identified that the phage uses for binding.
Intercellular spread of S. flexneri contributes greatly to tissue damage and its accompanying
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symptoms, while providing the bacteria refuge from immune system detection and from antibiotics
that poorly transit across eukaryotic cell membranes. One of the plasmid-encoded virulence factors
of S. flexneri, IcsA, recruits and polymerizes host cell actin on one end of the bacterium to create
actin tails

181

. These actin tails move the bacterium around the host cytoplasm, occasionally

propelling the bacterium into the membrane, causing protrusions which can lead to spread of the
bacterium to a neighboring host cell 182. IcsA is both surface-expressed and essential for S. flexneri
virulence, suggesting its potential usefulness as a binding receptor for a phage therapy candidate.
However, IcsA is plasmid-encoded 183, indicating that this virulence factor might be spontaneously
lost from target bacteria during cell division, and may be capable of horizontally transferring into
cells of non-target bacteria. For this reason, a better strategy would be to discover a phage that
interacts with a known chromosomally-encoded virulence factor of S. flexneri bacteria, rather than
targeting a genetic element that could be more easily gained or lost. Recent reports have implicated
other outer membrane proteins 184, 185 as necessary for intercellular spread of S. flexneri, including
OmpA, a highly conserved outer-membrane porin: a pore or channel in Gram-negative bacteria
that translocates small molecules across the membrane. In S. flexneri, OmpA is surface-expressed,
required for virulence, and chromosomally encoded; these three properties make it an attractive
target for testing our hypothesis due to its potential as a phage receptor 186 that could be leveraged
to select against virulence in this pathogen.
In this study, we describe the recently-isolated lytic phage A1-1, a dsDNA virus discovered
in a waste water sample obtained in Cuatro Cienegas, Mexico, a geographic region renowned for
its extreme microbial diversity 187. Characterization of phage A1-1 revealed that it was a member
of the Myoviridae family, and that the virus naturally used OmpA as a binding receptor to infect
susceptible S. flexneri bacterial cells. We hypothesized that phage A1-1would kill its host bacteria
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while selecting for evolution of resistance in the bacterial population, to cause a trade-off in
decreased virulence (i.e., reduced capacity for phage-resistant mutants to undergo intercellular
spread). We randomly isolated five spontaneous phage-resistant mutants, and results of our
phenotypic and genotypic characterizations revealed that these strains could be placed generally
into two different groups. Nevertheless, our data confirmed that all isolated mutants suffered the
predicted trade-off: these bacteria could invade and replicate in mammalian-derived cells in a
tissue culture model of S. flexneri infection, but the evolved phage resistance was always
associated with attenuated virulence because the mutants were incapable of intercellular spread.
Results
Novel lytic phage A1-1 is a Myoviridae virus that binds to OmpA of Shigella flexneri
We predicted that naturally-occurring lytic phages of S. flexneri have evolved to exploit OmpA as
a receptor. We sought to isolate such a phage from water samples, assuming that these contained
high levels of microbial biodiversity. From waste water obtained in Cuatro Cienegas, Mexico,
phage A1-1 was purified on S. flexneri strain PE577 using classical phage-isolation techniques,
and was then grown using S. flexneri strain M90T as a host in the below experiments.
We used SPAdes 188 for de novo assembly of the phage A1-1 genome, and results showed
a tentative genome size of 104,552 base pairs. Phage A1-1 was observed to have a GC content of
35.89%, whereas the host bacteria had a GC content of 50.9%. Preliminary annotation of phage
genes using PHASTER 189 revealed 139 coding regions (Figure 4.1A) with no indication that genes
for lysogeny (temperate phage life cycle) were present. Sequence alignment suggested that phage
A1-1 was similar to myoviruses known to infect Escherichia coli. Transmission electron
microscopy (TEM) revealed that phage A1-1 had a long, contractile tail (Figure 4.1B); this
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morphology is consistent with the typical structure of virus particles of the Myoviridae family of
dsDNA viruses.
We then conducted phage growth curves, in triplicate, that estimated key features of the
phage A1-1 lytic reproductive cycle, and tested its ability versus inability to infect wild-type and
OmpA knockout strains of S. flexneri, respectively. Results showed that phage A1-1 had a latent
and eclipse period of approximately 30 minutes, and a burst size of roughly 12 phage particles per
lysed bacterial cell (Supplemental Figure S4.1A). Furthermore, these data confirmed that phage
A1-1 was able to grow on M90T bacteria, but was unable to infect M90TDompA lacking the
putative OmpA binding site.
To determine conclusively whether phage A1-1 required OmpA to bind and infect S.
flexneri cells, we performed adsorption assays to measure cell binding, and efficiency of plaquing
(EOP) assays to measure infectivity of phage A1-1. Results of replicated (n = 3) adsorption assays
showed that phage A1-1 was unable to adsorb to both M90TDompA and M90TDompA:pSF-vector
(empty vector control); in both cases, the slope of the linear regression for observed plaque forming
units (PFU) over time was not statistically significantly different than zero. However, we observed
that phage A1-1 was able to adsorb to wild-type M90T as well as M90TDompA:pSF-ompA, (Figure
4.1C). Similarly, EOP assays performed in triplicate (Supplemental Figure S4.1B) showed that
phage A1-1 was able to infect M90TDompA:pSF-ompA with an EOP of 0.365±0.15 (mean ± sem),
but unable to infect M90TDompA or M90TDompA:pSF-vector with EOPs below the limit of
detection (200 PFU/mL) on both strains. Finally, we examined growth kinetics of S. flexneri in the
presence of phage A1-1 using bacterial growth curves. As expected, growth of the susceptible
wild-type strain, M90T, was completely suppressed in the presence of phage over the 15-hour
assay (Supplemental Figure S4.1C). Conversely, growth of M90TDompA and M90TDompA:pSF115

vector strains were both unimpacted by phage A1-1 (Supplemental Figure S4.1C). While growth
of M90TDompA:pSF-ompA was suppressed by phage presence, the reduced growth was less severe
compared to the M90T wild-type, likely due to differences in chromosomal versus exogeneous
expression of OmpA (Supplemental Figure S4.1C). Taken together, the above results showed that
phage A1-1 was a naturally-occurring virus that could be isolated and characterized as requiring
OmpA to bind and initiate infection of S. flexneri host bacteria.
Phage A1-1 selects for two different phenotypes of phage-resistant mutants
Since the above results showed phage A1-1 used OmpA to infect S. flexneri, we hypothesized that
phage resistance would involve modification of the phage receptor and that phage-resistant
mutants would be phenotypically similar to M90TDompA. Fluctuation assays revealed that phage
A1-1 selected for phage-resistant mutants of M90T at a frequency of 4.18·10-7±1.22·10-7 (mean ±
sd). Five spontaneous phage-resistant mutants (hereafter, R1, R2, R3, R4 and R5) were
independently isolated and randomly chosen for further characterization.
Using similar assays as above, we sought to confirm that all five mutants showed traits
associated with phage resistance. As expected, phage A1-1 had an EOP below the limit of detection
(200 PFU/mL) on each resistant mutant (Figure 4.2A). Similar to data for M90TDompA presented
above, all five resistant mutants did not support phage adsorption, indicated by the slopes of linear
regressions that were not statistically significantly different than zero (Figure 4.2B). Also, growth
of the phage-resistant mutants was not visibly altered by the presence of phage A1-1, while growth
of wild-type M90T was completely suppressed by phage A1-1 (Figure 4.2C). We noted that
mutants R1 and R2 grew to final densities similar to the M90T ancestor, but mutants R3, R4 and
R5 reached final densities that were roughly two-fold less than the wild-type (Figure 4.2C).
Furthermore, R1 and R2 produced phenotypically ‘smooth’ colonies on agar, while R3, R4, and
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R5 grew as ‘rough’ colonies on agar, indicating that the latter mutants were potentially altered for
lipopolysaccharide (LPS) production. In summary, these results confirmed that all of the mutants
had phenotypic traits consistent with resistance to phage A1-1 infection, but the strains could be
separated into two groups (R1 and R2; R3, R4 and R5).
To further characterize the five phage-resistant mutants, we used assays that investigated
membrane permeability, LPS quantity per cell and resistance to several antibiotics, because
changes (relative to wild-type) in these traits were anticipated if phage resistance was conferred
by altering OmpA and/or LPS. Using membrane-integrity assays as proxies for cell permeability,
results showed that permeability of resistant mutants R1, R3 and R5 was statistically significantly
lower than that of the M90T wild-type (Figure 4.3A). Total LPS measurements revealed that while
R1 and R2 had similar amounts of LPS per colony forming unit (CFU) compared to M90T and
M90TDompA, R3, R4 and R5 showed almost an order of magnitude more LPS per CFU (Figure
4.3B). It was expected that alterations to OmpA and LPS would result in changes in minimum
inhibitory concentration (MIC) for certain antibiotics. Mutants R3, R4 and R5 showed a significant
decrease in mean fold change (as compared to wild-type) in MIC of erythromycin (R3:
0.042±0.015 sem; R4: 0.056±0.009 sem; R5: 0.071±0.012 sem) (Figure 4.3C). Mutant R5
presented a significantly decreased fold change in ciprofloxacin MIC, 0.667±0.083 sem (Figure
4.3D). Mutant R1 showed a significantly decreased fold change in vancomycin MIC, 0.438±0.188
sem, while mutants R3 – R5 had significantly increased fold changes in vancomycin MICs (R3:
2.33±0.417 sem; R4: 2.25±0.334 sem; R5: 2.25±0.334 sem) (Figure 4.3E). Fold change in MIC of
tetracycline was not different from wild-type for all five mutants (Figure 4.3F). We further
concluded that phage A1-1 tended to select for phage-resistant mutants in two groups; R1 and R2
likely have mutations affecting OmpA, while R3, R4 and R5 likely have mutations altering LPS.
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To further investigate the potential role for LPS in phage resistance, EOPs were measured
on E. coli knockout strains 113 for genes involved in LPS biosynthesis 190. The EOP of phage A11 was below the limit of detection when the following fifteen E. coli genes were knocked out:
ompA, galU, waaC, gmhA, gmhB, gmhC, gmhD, waaF, waaQ, waaP, waaY, waaG, waaO, waaJ,
and waaB (Supplemental Figure S4.2). EOP measurements for phage A1-1 on BW25113DicdC
and BW25113DompC controls, as well as on BW25113DwaaS and BW25113DwaaL knockouts,
were not statistically different from phage ability to grow on wild-type BW25113 (Supplemental
Figure S4.2). In contrast, the EOP of phage A1-1 on BW25113DwaaZ was slightly improved,
compared to wild-type BW25113 (Supplemental Figure S4.2). These results suggested that LPS
biosynthesis genes waaS, waaL, and waaZ were not determinants of phage A1-1 growth. From
these results, we concluded that portions of S. flexneri LPS were required somehow for phage A11 infection.
Since our earlier results showed that phage A1-1 used OmpA to bind and initiate infection
of S. flexneri, we anticipated that the genetics underlying phage resistance should be governed by
alterations of OmpA, and not by changes in LPS. While results above (Figure 4.1) hinted that
OmpA might be the only receptor for phage A1-1, EOP data from the E. coli LPS knockout strains
implied that further tests were needed to examine whether LPS also served as a receptor. To that
end, we tested whether resistance to phage A1-1 additionally altered susceptibilities of the resistant
mutants to previously-characterized phages 60B and T7. Phage 60B putatively requires OmpC as
a receptor. Our results showed that wild-type M90T, and mutants R1 and R2 were susceptible to
phage 60B infection, indicating that this constituted the ancestral phenotype, whereas our data
found that mutants R3, R4 and R5 displayed resistance to phage 60B (Supplemental Table S4.1).
E. coli phage T7 uses the inner core of LPS as a receptor 126. Results showed that wild-type M90T,
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R1 and R2 were resistant to phage T7, indicating this was the ancestral phenotype; while R3, R4
and R5 were susceptible to phage T7 (Supplemental Table S4.1). Differences in phage T7
resistance again suggested that there were putative LPS changes conferring phage A1-1 resistance
in mutants R3, R4, and R5. Moreover, the differences in phage 60B resistance for these strains
compared to wild-type suggested that LPS changes may be broadly affecting the structure of
different outer membrane porins. Therefore, we hypothesized that while LPS might be necessary
for A1-1 infection, it was not serving as a receptor; rather, LPS could serve to maintain the
appropriate structure of the phage A1-1 binding receptor OmpA.
Western blots were used to determine whether the five resistant mutants expressed OmpA.
Blots for OmpA of whole cell lysates showed that resistant mutants R1 and R2 did not express
OmpA; however, R3, R4 and R5 expressed OmpA to a similar degree as the wild-type control
(Figure 4.4A). Furthermore, western blots of fractioned cell lysates revealed that R3, R4 and R5
expressed OmpA at the membrane (Figure 4.4B). These results supported our hypothesis that LPS
was likely not a receptor for phage A1-1, but instead was maintaining a conformation of OmpA
that was required for phage A1-1 binding.
Based on differing results of observed colony morphologies, MICs of various antibiotics,
phage A1-1 infection ability on LPS mutants of E. coli, and western blots for OmpA, we concluded
that phage-resistant mutants R1 and R2 phenotypically resembled the M90TDompA knockout and
did not express this OmpA, while R3, R4 and R5 appeared to be phage A1-1 resistant due to LPS
deficiencies.
Whole genome sequencing reveals underlying mutations conferring resistance
Whole genome sequencing was used to determine whether the genotypes of the resistant mutants
matched our inferences based on the above-described phenotypes. Genomes of all five resistant
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mutants were sequenced, aligned to the reference genome for the wild-type M90T ancestor
(GenBank # CM001474.1), and GATK was used to identify variants. Results showed that both R1
and R2 had a nonsense mutation in ompA, resulting in a premature stop codon after amino acid
172 (Figure 4.5). R3 had a nonsense mutation in gmhA that resulted in a premature stop codon
after amino acid 176 (Figure 4.5). R4 had a transversion at base pair 787 of gmhC. Finally, R5 had
a 29,645 base pair deletion between two insertion sequence 1 (IS1) elements at positions 303,277
and 332,873; this deletion included 27 genes, one of which was gmhA (Figure 4.5). The EOP of
phage A1-1 was restored to levels observed on wild-type S. flexneri, when R1 and R2 were
complemented with plasmid pSF-ompA, R3 and R5 harbored plasmid pSF-gmhA, and R4
contained plasmid pSF-gmhC (Figure 4.2A). Altogether, whole genome sequencing and EOP
assays confirmed that R1 and R2 were ompA mutants, while R3, R4 and R5 were LPS-deficient
mutants.
Phage-resistant mutants are attenuated for intercellular spread
We originally sought to test the prediction that a phage requiring OmpA to bind and infect S.
flexneri would select for phage-resistant mutants that were attenuated for intercellular spread.
Virulence of phage-resistant mutants was assayed using intracellular replication assays and plaque
assays in primate-derived Vero cells grown in laboratory tissue culture. As expected, M90T and
M90TDompA bacteria were capable of invading and replicating in Vero cells, while the negative
control, M90TDmxiH, a knockout for the type III secretion system needle, was unable to invade
(Figure 4.6A). All five of the phage-resistant mutants were able to invade and replicate
intracellularly; R1, R2, R3 and R5 replicated to levels similar to M90T at the 7-hour timepoint
while R4 replicated 10-fold less than M90T by this time (Figure 4.6A). Plaque assays revealed
that wild-type M90T (Figure 4.6B) could spread intercellularly; in contrast, neither M90TDompA
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nor M90TDmxiH (Figure 4.6B,C) could spread intercellularly, and none of the phage-resistant
mutants (Figure 4.6D-I) could spread between cells. Therefore, although all five resistant mutants
were able to invade and replicate intracellularly, as predicted they were unable to spread
intercellularly, indicating that resistance to phage A1-1 led to evolution of reduced virulence in S.
flexneri.
Discussion
Classical phage biology assays, including adsorption assays, EOPs and growth curves suggest that
phage A1-1 uses OmpA as a receptor. A1-1 selected for two different phenotypes of phageresistant mutants. R1 and R2 formed smooth colonies, exhibited decreased membrane permeability
as compared to wild-type, and were more sensitive than wild-type to vancomycin; R3, R4 and R5
formed rough colonies, exhibited decreased membrane permeability as compared to wild-type,
were more sensitive than wild-type to erythromycin, were more resistant than wild-type to
vancomycin, had greater total LPS per CFU than wild-type, and showed altered phage resistance
profiles to phages 60B and T7. Whole genome sequencing revealed that A1-1 selected for resistant
mutants with mutations in ompA (R1 and R2). However, A1-1 also selected for resistant mutants
in gmhA (R3 and R5) and gmhC (R4), two genes involved in the biosynthesis of the heptose sugars
that make up the inner core of LPS 121. Resistant mutants R3, R4 and R5 all express OmpA on the
membrane and phage A1-1 fails to adsorb to these resistant mutants. This leads to two possibilities:
phage A1-1 both OmpA and LPS as co-receptors, or phage A1-1 uses OmpA as a receptor and
LPS is somehow required for binding but is not a receptor.
While the first possibility cannot be ruled out in this study, it is worth noting that plaques
of A1-1 were never observed on M90TDompA even when high titers of A1-1 were plated. If both
OmpA and LPS are receptors for A1-1, selective pressure to make more progeny and standing
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genetic variation would likely lead to variants of phage A1-1 that could plaque on M90TDompA,
using only LPS as a receptor. This was not observed; instead, it seems likely that A1-1 uses OmpA
as a primary receptor and that LPS is required for binding either as a secondary receptor or to
maintain the proper conformation of OmpA for A1-1 binding. Since resistant mutants R3, R4 and
R5 all express OmpA and no phage adsorption to these resistant mutants was observed, it seems
unlikely that LPS is being used as a secondary receptor by phage A1-1. Therefore, perhaps LPS is
involved in maintaining a particular conformation of OmpA that is necessary for phage binding.
Indeed, it has been previously observed that complex interactions between LPS and outer
membrane proteins (OMPs) are involved in both OMP biogenesis and stabilization of particular
conformations of various OMPs 191-193. Three different conformations of E. coli OmpA have been
proposed: a monomeric narrow pore conformation with two domains (an eight stranded β-barrel
and a periplasmic domain), a monomeric large pore conformation with a single domain (sixteen
stranded β-barrel), and a dimer of the two-domain narrow pore structure 194-196. OmpA in M90T
appears to be localized to both the periplasm and membrane fractions (Figure 4.3B), indicating
that perhaps the two-domain narrow pore structure with the periplasmic domain is the main
conformation of OmpA in S. flexneri. Interestingly, OmpA in resistant mutants R3, R4 and R5 is
localized more in the membrane fraction than in the periplasmic fraction (Figure 4.3B), possibly
indicating that the single domain large pore structure dominates the conformation state of OmpA
in these LPS-deficient mutants. Indeed, it has been previously suggested that core LPS plays a role
in maintaining the conformation of OmpA. Experiments in the current study seem to support this
hypothesis.
When S. flexneri invades and replicates within human host cells, it is known to spread
intercellularly via actin-based motility which occurs through polymerization of host actin by

122

unipolar IcsA on the bacteria. It is previously demonstrated that O-antigen null mutants (i.e., those
with truncated LPS) are attenuated for intercellular spread 197. Therefore, it is perhaps unsurprising
that the phage-resistant LPS mutants R3, R4 and R5 are capable of intracellular invasion and
replication but not intercellular spread. However, the mechanism behind why O-antigen confers
the ability for S. flexneri to spread intercellularly has not been fully elucidated. Furthermore, prior
work shows that OmpA is required for intercellular spread
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; as expected, our isolated phage-

resistant mutants with OmpA changes, R1 and R2, are similarly defective for this virulence trait.
Interestingly, the shared ompA mutation that likely confers phage resistance in R1 and R2 is in the
region that likely composes the final predicted extracellular loop of the eight-stranded β-barrel
conformation and truncates OmpA at position 174. It is observed that OmpA residues 188-190
interact with a periplasmic protein, PhoN2, to maintain polarity of IcsA 198. Therefore, if these two
resistant mutants express a partial peptide of OmpA, where residues 1-169 are wild-type and 170173 are frameshifted, this partial protein likely is neither suitable for phage A1-1 adsorption nor
has the region predicted to interact with PhoN2 to maintain polarity of IcsA. This perhaps explains
the observed defect in intercellular spread observed for phage-resistant mutants R1 and R2.
It is unsurprising that ompA mutants and rough mutants of S. flexneri in the current study
are attenuated for intercellular spread based on the previous literature, but it is noteworthy that
these mutants were obtained strictly via selection for resistance to phage A1-1. In all five
randomly-chosen mutants, phage resistance led to attenuation for intercellular spread; thus,
selection for resistance to phage A1-1 in S. flexneri consistently traded off with maintenance of a
key virulence factor in this biomedically-important pathogen. While this interesting result yields
insights into possible S. flexneri interactions with lytic phages, expectations for phage-bacteria
interactions in natural environments and in the context of clinical infection are harder to predict.
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The epidemiology of S. flexneri typically involves colonization of an index human case
(presumably via consumption of contaminated food or water) which then can be fecal-orally
transmitted to household members and other nearby individuals. As a facultative intracellular
pathogen, S. flexneri is capable of growth inside of human host cells, but can also exist as “freeliving” bacteria in the natural environment. During clinical infections, bacteria are presumably
protected from phage attack while replicating inside colonic epithelial cells; however, during fecaloral transmission, bacteria are free-living and once again vulnerable to phage. This is an example
of an alternating environment with intermittently-changing selection pressures experienced by the
bacteria. That is, aside from other possible selection pressures such as escape from host immunity,
a population of S. flexneri may sometimes experience selection to avoid phage infection, and at
other times can experience absence of this selection if intracellular invasion provides a refuge from
phage exposure. Under such complex conditions, selection would positively favor evolution of
phage resistance in free-living bacteria; in this ecology, the mutations underlying phage resistance
would be beneficial and positively selected. However, inside intestinal epithelial cells, the ecology
presents a different target for selection; here, the mutations for phage resistance observed in this
study would be deleterious because of the trade-off we observed between phage resistance and
intercellular spread.
This scenario stimulates two predictions: (1) evolution of phage resistance (i.e., positive
vs. negative selection for this trait) should occur differently for facultative intracellular pathogens
such as S. flexneri, depending whether the bacterial population is growing inside versus outside of
the human host; and (2) the particular phage-resistant mutants in the current study should
experience a net fitness cost if the frequency of environmental fluctuations necessitate intracellular
growth and spread during infection of human host cells. The first prediction is the subject of
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ongoing studies in our laboratory to examine spontaneous phage-resistant mutants of S. flexneri
selected under simultaneous selection pressures of phage A1-1 and intracellular growth constraints
in Vero cells. The second prediction can be examined by subjecting the phage-resistant mutants in
the current study to experimental evolution that toggles between batch culture and tissue culture
environments. Here, the outcome can be informed by previous studies of microbial evolution in
fluctuating environments. For example, it is observed that phages subjected to elevatedtemperature selection (i.e., heat shocks) outside of bacterial cells results in evolution of greater
thermotolerance (increased particle stability) to withstand degradation in elevated temperatures,
despite the deleterious nature of these mutations for phage reproduction in benign temperature
environments

199

. Thus, antagonistically-pleiotropic mutations can evolve in microbes, even

though these changes confer high fitness in only a portion of the selective environment. We might
expect that a fluctuating environment would cause the particular phage-resistant mutants in our
study to undergo further evolution, such as compensation for their complete inability to spread
intercellularly, to perhaps maintain some degree of phage resistance while also achieving minimal
intercellular spread (a compromise). In contrast, our study may reveal that evolution of phage
resistance creates a strong evolutionary constraint, whereby acquisition of phage A1-1 resistance
prevents S. flexneri from readily undergoing compensatory evolution, thus effectively confining
the bacteria to the free-living ‘ecology’ when faced with selection to avoid phage attack. If this
result holds true for the system presented in the current study, it might be possible to select for
long-lasting phage-resistant S. flexneri strains that are attenuated for virulence, an important step
toward developing phage treatments for this important human pathogen.
Conclusion
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Phage A1-1 is a newly isolated Myoviridae phage that uses OmpA as a receptor to infect S. flexneri.
Mutants resistant to phage A1-1 have altered membrane permeability, changes in antibiotic
resistance profiles, and do not support adsorption of phage A1-1. A combination of whole genome
sequencing and targeted Sanger sequencing reveal that two of these resistant mutants have a
mutation in ompA, two resistant mutants have mutations in gmhA and one has a mutation in gmhC.
EOP assays with complemented strains confirm that these mutations confer resistance to phage
A1-1. While phage A1-1 does not appear to use LPS as a receptor, we hypothesize that interactions
between OmpA and LPS are required to maintain a particular confirmation of OmpA to allow for
phage attachment and will investigate this further in future studies. Finally, all five phage-resistant
mutants tested in this study are attenuated for virulence; while they can still invade and replicate
intracellularly, they are unable to spread intercellularly in a tissue culture model of infection. This
study demonstrates that it is possible to find phage that select for a trade-off between phage
resistance and virulence in bacteria.
Materials and Methods
Strains and culture conditions
Bacteria, phage and plasmid strains used in this study are listed in Supplemental Table S4.2. S.
flexneri was grown in 0.1% congo-red tryptic soy (CR-TS) medium (10g tryptone, 5g soytone,
10g NaCl, 0.1g congo red dye per L) unless otherwise noted. E. coli was grown in Lysogeny Broth
(LB) medium (10g tryptone, 5g yeast extract, 10g NaCl per L). Phage A1-1 was amplified to high
titer on M90T unless otherwise noted. Bacteria were grown on 1.5% agar plates and phages were
grown on plates in 0.75% agar top layer. Plasmids were maintained using 100ug/mL of
carbenicillin and expression was induced with 1mM IPTG. Lambda-red recombination
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was

used to engineer bacterial strains M90TDompAKanr and M90TDmxiHKanr, and plasmid pCP20
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was used to remove the Kanr cassette from each of these strains to create strains M90TDompA and
M90TDmxiH.
Assays to characterize phage
Adsorption assays to estimate phage cell-binding ability were performed as described by Kropinski
(2009)
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. Efficiency-of-plating assays to estimate phage infectability on challenge bacteria

relative to that on a permissive host strain, and phage growth curves to estimate virus traits (i.e.,
latent period, exponential growth rate, burst size) were performed as previously described
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Bacterial growth curves were performed at multiplicity of infection (MOI; ratio of phage particles
to bacterial cells) of approximately 100. Transmission electron microscopy (TEM) was performed
using uranyl acetate-stained phages on 300 mesh carbon film copper grids, and phage particles
were visualized on a FEI Tecnai Biotwin microscope.
LPS extractions
Lipopolysaccharide (LPS) was extracted from bacteria using an LPS extraction kit (Abcam
ab239718) and LPS was quantified using a carbohydrate quantification assay (Abcam ab155891).
LPS was extracted following the instructions provided in the kit. Briefly, bacteria were grown
overnight on LB agar, scraped into PBS, centrifuged for 5 min at 5,000g at 4°C, resuspended in
extraction buffer, sonicated and incubated on ice for 10 minutes to allow for full lysis. Any unlysed
cells were removed via centrifugation (5 min at 5,000g at 4°C) and the supernatant was treated
with proteinase K at 60°C for one hour. Any remaining debris was removed via centrifugation (5
min at 5,000g at 4°C). Total carbohydrate content (grams/CFU) in the supernatant was quantified
following the instructions of the carbohydrate quantification assay.
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MIC measurements
Minimum inhibitory concentration (MIC) was measured using Etest strips (Biomerieux). Briefly,
overnight cultures of bacteria were spread on Mueller Hinton Agar (MHA, 2g beef extract, 17.5g
casein hydrolysate, 1.5g starch, 17.0g agar per L) plates and test strips were plated. After overnight
incubation, MIC values were determined by the lowest concentration at which the bacterial growth
was inhibited. These measurements were conducted with three-fold replication.
Membrane permeability assay
Membrane permeability of cells grown in LB was assayed using the Live/Dead BacLight kit
(ThermoFisher L34856) using a microplate reader (Tecan Infinite F500) following the
manufacturer instructions.
Cell fractionation, protein gels and western blots
Whole cell lysates were made by centrifuging cells (5 minutes at 5,000g), resuspending in 1x
Laemmli buffer (Biorad) and boiling at 100°C for 15 minutes. Cell fractions were made following
the previously published protocols 201. Briefly, late log cultures were centrifuged at 5,000g for 5
minutes and gently resuspended in 200 µL of TES buffer (200mM Tris-HCl pH 8.0, 0.5mM
EDTA, 0.5M sucrose). Lysozyme (10 µg/mL final) was added to the resuspended cells followed
by 720 µL of TES buffer that had been diluted 1:1 in water. The lysate was incubated for 30
minutes on ice with gentle inversion to mix and then centrifuged at 5,000g for 5 minutes at 4°C.
The supernatant was saved as the periplasmic fraction. The spheroplast fraction, the pellet, was
resuspended in TES buffer diluted 1:1 in water containing 2mM phenylmethylsulfonyl fluoride
(PMSF), 2mM MgCl2 and 10 µg/mL of DNAseI and lysed via four cycles of freeze thaws from 273°C to 37°C. Unlysed spheroplasts were removed via centrifugation at 2,000g for 5 minutes at
4°C. Finally, the supernatant was ultracentrifuged at 120,000g for 45 minutes at 4°C. The
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supernatant was saved as the cytoplasmic fraction, and the pellet was resuspended in TES buffer
diluted 1:1 in water and saved as the membrane fraction. Whole cell lysates and fractions were run
at 200V for 45 minutes on a 10% Tris-Glycine polyacrylamide gel and transferred to a PVDF
membrane (90V for 60 minutes) and blotted with an anti-OmpA antibody (Biorbyt orb241331).
Sequencing and analysis
Genomes were extracted as previously described
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. Sequencing libraries were made using

NexteraXT library preparation kits (FC-131-1096, Illumina). Samples were run paired-end 150bp
reads on the Illumina HiSeq 2500 platform. Reads were aligned to reference genomes for M90T
(Genbank Accession # CM001474.1) and the virulence plasmid, pWR501 (Genbank Accession #
NC_002698.1) using Bowtie2 143 and variants were called using GATK 174.
Bacteria intracellular growth curves
Intracellular growth curves of S. flexneri were performed as described by Hale and Formal (1981)
with some modifications 202. Briefly, 24 hours prior to assay, Vero cells were plated in Dulbecco’s
Modified Eagle Medium (DMEM) with 5% fetal bovine serum (FBS) to 90% confluency in a 24well dish. On the day of the assay, overnight bacterial cultures were diluted 1:100 and grown to
mid-late log. Cultures were centrifuged (5 minutes at 5,000g) and resuspended in DMEM with 5%
FBS. Vero cells were washed once with PBS prior to infection. Bacteria were added to each well
to an MOI of 10 and the plate was centrifuged at 200 rpm for 5 minutes. Plates were incubated for
30 minutes at 37°C and 5% CO2. Wells were washed three times with PBS, DMEM with 5% FBS
and 100 µg/ml gentamicin was added to each well, and plates were incubated at 37°C and 5% CO2
for the duration of the assay. At five time points (0, 1, 3, 5 and 7 hours), plates were destructively
sampled, supernatant was aspirated, wells were washed 3 times with PBS, Vero cells were lysed
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with sterile, deionized water and gentle pipetting, and bacterial CFU was enumerated via plating
on CR-TS agar plates.
Bacterial plaque assays
Plaque assays were performed as described by Oakes et al. (1985) with some modifications 203.
Briefly, 24 hours prior to infection, Vero cells were plated to 90% confluency in a 6-well dish in
DMEM with 5% FBS. On the day of the assay, overnight bacterial cultures were diluted 1:100 and
grown to mid-late log. Cultures were centrifuged (5 minutes at 8,000g) and resuspended in DMEM
with 5% FBS to achieve a range of MOI’s between 100 and 0.1. Vero cells were washed once with
PBS. Bacterial suspensions were plated on Vero cells and allowed to attach and invade for one
hour at 37°C and 5% CO2 with gentle rocking every 15 minutes. After the incubation, 2x Minimum
Essential Media (MEM) complete (10X MEM, 100X L-Glutamine, 100xVitamins, 100X NEAA,
7.5% sodium-bicarbonate added to sterile distilled water to a final concentration of 2x with 200
µg/ml gentamicin) was mixed with an equal volume of molten 1% agarose in water and FBS to
5%, added to each well, and allowed to solidify. Plates were incubated for 48 hours at 37°C and
5% CO2. An additional top layer of 2% neutral red stain (MilliporeSigma N2889) in PBS with
0.5% agarose was added to each well. After 24 hours of incubation, plates were visualized for
plaques.
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Chapter 4 Figures & Tables
Figure 4.1 Basic characterization of newly-discovered lytic phage A1-1

Basic characterization of newly-discovered lytic phage A1-1 on host, Shigella flexneri. A. Genome annotation of
phage A1-1 using PHASTER. Plate proteins are shown in purple, fiber proteins shown in yellow, coat proteins shown
in blue, phage-like proteins shown in red and hypothetical proteins are shown in grey. B. TEM image of phage A1-1
(200 nm scale bar). C. Adsorption assay of phage A1-1 on bacterial hosts: M90T (purple), M90TDompA (yellow),
M90TDompA:pSF_vector (grey) and M90TDompA:pSF_ompA (black). Error bars show standard deviations of the
mean of three biological replicates. Significance determined by testing whether slope of the linear regression line
deviates from zero. (* indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001).
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Figure 4.2 Characterization of phage resistance

Characterization of phage resistance A. Efficiency of plaquing (EOP) assay of phage A1-1 on various strains. Dashed
line at 1 indicates EOP on M90T. DL indicates the EOP was below the limit of detection (~10-9). B. Adsorption assay
of phage A1-1 on bacterial hosts: M90T (purple), R1 (yellow), R2 (grey), R3 (black), R4 (blue) and R5 (red). Error
bars show standard deviations of the mean of three biological replicates. Significance determined by testing whether
slope of the linear regression line deviates from zero. C. Growth curves of M90T (purple), R1 (yellow), R2 (grey), R3
(black) R4 (blue), and R5 (red). Solid lines indicate bacteria growing in absence of phage; dashed lines indicate phage
A1-1 presence (MOI=10). (* indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001).
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Figure 4.3 Phenotypic characterization of five spontaneous phage-resistant mutants

Phenotypic characterization of five spontaneous phage-resistant mutants of S. flexneri. A. Membrane permeability
measured as a linear regression of the ratio of green to red fluorescence of different suspensions of live and dead cells
stained with SYTO 9 dye and propidium iodide. Error bars show standard deviations of the mean of three biological
replicates. Significance determined using a student’s t-test comparing the slopes of the linear regressions to that of
wild-type bacteria. B. Total LPS measured as µg per CFU. Error bars show standard deviations of the mean of three
biological replicates. C-F. Fold change in MIC compared to MIC of wild-type M90T for erythromycin, ciprofloxacin,
vancomycin (shaded region indicates limit of detection) and tetracycline. Error bars show standard errors of the
average of three biological replicates. Unless otherwise noted significance determined using a student t-test. (*
indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001).
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Figure 4.4 OmpA expression in phage-resistant mutants

OmpA expression in phage-resistant mutants of S. flexneri, compared to controls. A. Western blot for OmpA of whole
bacterial cell extract of M90T, M90TDompA, R1, R2, R3, R4 and R5. B. Western blot for OmpA of cytoplasmic (C),
periplasmic (P) and membrane (M) fractions of M90T, R3, R4 and R5.
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Figure 4.5 Diagram of mutations

Diagram of mutations identified via whole-genome sequencing. The chromosome of wild-type M90T is 4,580,866
base pairs. Mutations were identified in all five phage-resistant mutants. R1 and R2 have identical single base pair
insertions at position 507 in ompA (yellow). R3 has a single base pair insertion in gmhA (blue) at position 400. R4 has
a transversion at position 787 of gmhC (red). R5 has a 29,645 base pair deletion spanning 27 genes, including gmhA
(blue) between two IS1 elements (black).
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Figure 4.6 Virulence of phage-resistant mutants

Virulence of phage-resistant mutants, relative to controls, in a tissue-culture model of S. flexneri pathogenicity A.
Representative intracellular growth curves of wild-type M90T (purple), M90TDompA (yellow), M90TDmxiH (red),
R1 (black circle), R2 (black square), R3 (black triangle), R4 (black inverted triangle), and R5 (black diamond) bacteria.
Error bars show standard deviations of the mean of three technical replicates. B-I. Representative plaque assays of
wild-type M90T, M90TDompA, M90TDmxiH, R1, R2, R3, R4 and R5, respectively, on monolayers of Vero cells at
MOI = 5 (bacteria CFU relative to Vero cells) after 72 hour incubation.
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Chapter 4 Appendix
Supplemental Figure S4.1 Further characterization of newly-discovered lytic phage A1-1

Further characterization of newly-discovered lytic phage A1-1 on host, Shigella flexneri. A. Phage growth curve of
A1-1 on M90T (purple) and M90TDompA (yellow). Titers of filtered and chloroformed conditions are indicated with
solid and dashed lines respectively. Error bars show standard deviation of three biological replicates. B. Efficiency of
plaquing (EOP) assay of phage A1-1 on various strains. Dashed line at 1 indicates EOP on M90T. DL indicates that
the EOP was below the limit of detection (~10-9). C. Bacterial growth curves of M90T (purple), M90TDompA
(yellow), M90TDompA:pSF_vector (grey), M90TDompA:pSF_ompA (black) and M90TDompA:pSF_ompA171 (blue).
Solid lines indicate bacteria growing in absence of phage; dashed lines indicate phage A1-1 presence (MOI=10).
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Supplemental Figure S4.2 EOP of phage A1-1 on LPS knockouts

Efficiency of plaquing of phage A1-1 on LPS knockouts. A. EOP assay of A1-1 on various strains. Dashed line at 1
indicates EOP on M90T. Yellow shaded knockouts are genes involved in synthesis of KDO sugars. Red shaded
knockouts are genes involved in synthesis of the inner core LPS. Purple shaded knockouts are genes involved in
synthesis of outer core LPS and O-antigen. DL indicates that the EOP was below the limit of detection (~10-9).
Significance determined using a student t-test between B25113 and test strains. (* indicates p < 0.05, ** indicates p
< 0.01, *** indicates p < 0.001) B. Diagram of M90T LPS with lipidA (grey), KDO region (yellow), inner core LPS
(red) and outer core LPS (purple). Abbreviations as follows phosphoryl group (P), N-acetylglucosamine (GlcN), KDO
sugar (Kdo), heptose sugar (Hep), glucose (Glc), and galactose (Gal).
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Supplemental Table S4.1 Phage resistance profile of various strains to phages 60B and T7

Phage 60B Phage T7
M90T
S
R
M90T∆ompA
S
R
R1
S
R
R2
S
R
R3
R
S
R4
R
S
R5
R
S
S, phage sensitive; R, phage resistant
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Supplemental Table S4.2 Bacterial strains, phage strains and plasmids used in this chapter

Bacterial Strains
PE577
M90T
M90T∆ompA KanR
M90T∆ompA
M90T∆mxiH KanR
M90T∆mxiH
BW25113
BW25113 ∆icdC
BW25113 ∆ompA
BW25113 ∆ompC
BW25113 ∆galU
BW25113 ∆waaC
BW25113 ∆gmhA
BW25113 ∆gmhB
BW25113 ∆gmhC
BW25113 ∆gmhD
BW25113 ∆waaF
BW25113 ∆waaQ
BW25113 ∆waaP
BW25113 ∆waaY
BW25113 ∆waaG
BW25113 ∆waaO
BW25113 ∆waaJ
BW25113 ∆waaB
BW25113 ∆waaS
BW25113 ∆waaL

Species
S. flexneri
S. flexneri
S. flexneri
S. flexneri
S. flexneri
S. flexneri
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli

Antibiotic
Resistance
SmR
SmR, KanR
SmR
SmR, KanR
SmR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR
KanR

Reference or
Source
186
ATCC BAA-2402
This study
This study
This study
This study
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC
113; CGSC

Phage
A1-1
60B
T7

Host Species
S. flexneri
S. flexneri
E. coli

Reference or
Source
This study
This study
J. Wertz (Yale U)

Plasmid
pSF-vector
pSF-ompA

Antibiotic
Resistance
AmpR
AmpR

Source
Oxford Genetics (OGS634)
This study

KanR, Kanamycin resistance; SmR, Streptomycin resistance; AmpR, Ampicillin
resistance; CGSC, Coli Genetic Stock Center
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Chapter 5: Evolution of bacterial cross-resistance to lytic phages and albicidin antibiotic
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Abstract
Due to concerns over the global increase of antibiotic-resistant bacteria, alternative antibacterial
strategies, such as phage therapy, are increasingly being considered. However, evolution of
bacterial resistance to new therapeutics is almost a certainty; indeed, it is possible that resistance
to alternative treatments might result in an evolved trade-up such as enhanced antibiotic resistance.
Here, we hypothesize that selection for Escherichia coli bacteria to resist phage T6, phage U115,
or albicidin will result in a pleiotropic trade-up in the form of cross-resistance, because all three
antibacterial agents interact with the Tsx porin. Selection imposed by any one of the antibacterials
resulted in cross-resistance to all three of them, in 29 spontaneous bacterial mutants examined in
this study. Furthermore, cross-resistance did not cause measurable fitness deficiencies under
normal growth conditions for any of the bacterial mutants. A combination of whole-genome and
targeted sequencing confirmed that mutants differed from wild-type E. coli via change(s) in the
tsx gene. Our results indicate that evolution of cross-resistance occurs frequently in E. coli
subjected to independent selection by phage T6, phage U115 or albicidin. This study cautions that
deployment of new antibacterial therapies such as phage therapy, should be preceded by a thorough
investigation of evolutionary consequences of the treatment, to avoid the potential for evolved
trade-ups.
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Chapter Introduction
As global concerns grow over the widespread emergence of antibiotic-resistant bacteria, attention
has increasingly turned to antibiotic alternatives such as phage therapy: the use of bacteria-specific
viruses, bacteriophages (phages), to treat bacterial infections. Although phage therapy is frequently
seen as a novel medical technology, the approach originated in the early 20th century soon after
phages were discovered24, 28. Less than a decade after the discovery of phages, penicillin was
discovered and focus shifted to research and deployment of new antibiotics 204. Recently, interest
in phage therapy has resurged as a tool for treating antibiotic resistant infections 179; however, just
as antibiotics select for the evolution of antibiotic resistance, phages select for the evolution of
phage resistance 16, 205. To avoid the historical mistakes that resulted in multi- and even pan-drug
resistant strains, the evolutionary consequences of phage therapy need to be considered and
investigated prior to its widespread use 206.
While the evolution of phage resistance in bacteria is perhaps inevitable, phage therapy
strategies can be devised to leverage the evolution of phage resistance as an asset, rather than a
limitation

179

. In particular, by using lytic phages that interact with bacterial mechanisms of

virulence and antibiotic resistance, these phages should kill bacteria while selecting for phage
resistance that may compromise – or pleiotropically “trade-off” with – virulence or antibioticresistance traits

179

. Theory, experiments and emergency patient treatment provide evidence that

certain phages can direct favorable “trade-off” outcomes, where the therapy kills the target
pathogen while selecting for reduced virulence or increased antibiotic sensitivity in the remaining
bacterial population

13, 207, 208

. This approach exemplifies one goal of evolutionary medicine:

applying “evolution thinking” to improve the effectiveness of therapy 209, 210.
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However, not all bacterial mutations underlying the evolution of phage resistance result in
genetic changes with extreme fitness costs that result in a trade-off 211. Instead, the opposite may
happen whereby evolution of phage resistance results in an additional fitness gain, also known as
a “trade-up”. Indeed, it is possible that the fitness effects of evolved phage resistance might
pleiotropically trade-up with virulence or antibiotic resistance 212, 213. To examine this possibility,
here we studied the interactions of Escherichia coli with two lytic phages and an antibiotic that all
require the Tsx porin to enter the cell. Tsx is a substrate-specific outer-membrane porin, which
uptakes nucleosides and deoxynucleotides into the periplasmic space 214. Phages T6 and U115 are
shown to use the Tsx porin as a receptor for binding to E. coli

215

. Additionally, the Tsx porin

uptakes the antibiotic albicidin, a phytotoxic DNA-gyrase inhibitor produced by Xanthomonas
albilineans, an agriculturally important pathogen that causes leaf scald in sugar cane grasses 216219

. We hypothesized that selection for E. coli resistance to phage T6, phage U115, or albicidin

should tend to produce cross-resistance to the other antibacterial agents, due to converging
selection at the tsx locus.
Our results confirmed that the predicted pleiotropic trade-ups evolved frequently; selection
exerted by any one of the antibacterials led to perfect (100%) cross-resistance of E. coli mutants
to all three antibacterials. Moreover, we observed that cross-resistance was generally “cost-free”,
evidenced by equivalent growth of bacterial mutants relative to their wild-type ancestor in the
absence of the phages and albicidin. In addition, we used sequence analysis to show that a wide
variety of mutations at the tsx locus of E. coli may govern cross-resistance. Our study suggests that
prior characterization of evolutionary consequences of antibacterial treatments, particularly the
mechanistic interactions of lytic phages and antibiotics with target bacteria, can be used to inform
treatment strategies that potentially avoid the evolution of undesired trade-ups.
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Results
Phages T6 and U115 each select for cross-resistance to the other phage and to albicidin
Because phages T6 and U115 both rely on the Tsx porin for cell-binding, we predicted that
evolution of resistance to one phage should often lead to cross-resistance against the other phage.
To test this idea, we used a classic fluctuation analysis (see Methods) to obtain a collection of
spontaneous mutants of E. coli that were resistant to each phage individually. We used a paired
approach, where each of 10 independently-grown bacterial cultures were used to isolate one T6resistant and one U115-resistant strain (20 mutants total). Results for efficiency of plaquing (EOP)
assays (see Methods) confirmed that growth of phage T6 on each of the 10 T6-resistant mutants
(T6R1 through T6R10) was below the limit of detection, compared to normal infectivity of the
phage on wild-type bacteria (Supplemental Table S5.1). Similarly, EOP experiments showed that
phage U115 was unable to grow on each of the 10 U115-resistant mutants (U115R1 through
U115R10), relative to expected infectivity on the wild-type (Supplemental Table S5.1).
Furthermore, we found positive support for our hypothesis; in all 20 cases, evolved bacterial
resistance to phage T6 provided cross-resistance to phage U115 using EOP assays, and vice versa
(Supplemental Table S5.1). We concluded that independent selection for E. coli resistance to one
phage provided cross-resistance to the other phage.
We then used antibiotic-resistance assays (see Methods) to test the prediction that evolution
of phage resistance would lead to cross-resistance to the antibiotic albicidin. We first used E. coli
strains BW25113 and BW25113∆icdC as two positive controls, to confirm that these albicidinsensitive bacteria fail to form confluent lawns (i.e., they show zones of inhibited growth) when
exposed to albicidin-producing X. albilineans strain XA23, but grow normally on X. albilineans
strain LS126 which does not produce albicidin. Results (Figure 5.1) showed that the controls
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behaved as expected, with zones of growth inhibition around XA23 indicating sensitivity of both
bacterial strains to albicidin. We estimated that wild-type BW25113 had a mean clearing ratio (a
ratio of the zone of clearing divided by the area of the X. albilineans spot) of 4.88 ± 0.47 s.d. in
the presence of XA23 albicidin-producing bacteria, and that BW25113∆icdC bacteria showed a
mean clearing ratio of 5.094 ± 0.524 s.d. (Supplemental Figure S5.1 A). As a negative control, the
Tsx knockout, BW25113∆tsx, had no zone of inhibited growth on either XA23 or LS126 (Figure
5.1); in both cases the mean clearing ratio of BW25113∆tsx was 1.0 ± 0.0 s.d. (Supplemental
Figure S5.1 A). A test of the hypothesis confirmed our prediction was correct; all 20 phageresistant mutants showed no zones of growth inhibition around XA23 or LS126 (Figure 5.1 and
Supplemental Figure S5.1 B) and presented mean clearing ratios of 1.0 ± 0.0 s.d. on XA23 and
LS126 (Supplemental Figure S5.1 A), indicating that all the phage-resistant mutants were
completely resistant to albicidin as well.
Selection for albicidin resistance confers cross-resistance to phages T6 and U115
We used albicidin selection (see Chapter 5 Methods) to isolate 9 independent spontaneous
mutants of E. coli (albR1 through albR9). Using the above-described growth challenges on X.
albilineans strains XA23 and LS126, our results confirmed that each mutant was albicidin resistant
(Figure 5.1 and Supplemental Figures S5.1 A,B). We then tested whether the albicidin-resistant
mutants were cross-resistant to infection with phage T6 and phage U115. Results showed that in
all 9 strains tested, acquisition of albicidin resistance conferred cross-resistance to both phages T6
and U115 (Supplemental Table S5.1). We concluded that the evolution of cross-resistance was
absolute in this study system, such that evolution of resistance to one of the three antibacterials
provided perfect cross-resistance to all of the selective agents.
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Cross-resistance to albicidin and phages T6 and U115 is cost-free for E. coli
To further examine the evolution of antibacterial cross-resistance, bacterial growth assays (see
Methods) were performed with replication (n = 3) in LB medium. Controls confirmed that wildtype E. coli strain BW25113 showed no discernable growth in the presence of either phage T6 or
U115 (Figure 5.2 A), and that growth of the tsx-knockout strain, BW25113∆tsx, was similar in the
presence and absence of each phage (Figure 5.2 B). In contrast, all 10 of the T6-resistant mutants
grew normally in the presence and absence of phage T6 (representative data shown in Figure 5.2
C,D; see Supplemental Figure S5.2 B-I for all results). Similarly, growth of all 10 U115-resistant
mutants was unaffected by presence or absence of phage U115 (representative data in Figure 5.2
E,F; see Supplemental Figure S5.2 J-Q for all results). Lastly, the 9 albicidin-resistant mutants
were capable of approximately equivalent growth in the presence and absence of either phage T6
or U115 (representative data in Figure 5.2 G,H; see Supplemental Figure S5.2 R-X for all results).
A visual comparison of the growth-curve results suggested that all the resistant mutants
grew similarly to wild-type strain BW25113 in the absence of each phage (Figure 5.2 and
Supplemental Figure S5.2). To examine this outcome more closely, we analyzed the growth data
with GrowthCurver 220 to estimate intrinsic growth rate (r) as a proxy for bacterial fitness (Figure
5.2 I). None of the resistant mutants had an r that was differed significantly from that of BW25113.
These results suggested that there are no appreciable growth costs associated with bacterial
evolution of resistance to phage T6, phage U115 and albicidin. While resistance to any of the
antibacterials did not affect bacterial fitness under the tested conditions, we could not eliminate
the possibility that our growth assays failed to detect minor fitness differences.
Thus, we conducted additional experiments, in an attempt to measure more subtle fitness
differences among bacterial strains. To do so, we performed replicated (n = 3) competition assays
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(see Chapter 5 Methods) for each test strain to gauge its fitness relative to a genetically-marked
wild-type strain (BW25113∆icdC) under normal growth conditions. Competitive indexes were
calculated as the ratio of resistant-mutant colony forming units (CFU) to CFU of the common
competitor strain, BW25113∆icdC, to the ratio of BW25113∆icdC CFU to wild-type, BW25113,
CFU. Each ratio was normalized by the starting ratio each competing strain. Results showed no
significant differences in competitive indexes of the resistant mutants as compared to the common
competitor (Figure 5.3). Therefore, it appeared that all T6-resistant, U115-resistant and albicidinresistant mutants suffered no fitness deficits, compared to non-resistant bacteria under normal
growth conditions.
All phage-resistant and albicidin-resistant mutants have mutations in tsx
Owing to the importance of the Tsx porin in the interactions of all three antibacterials with cells,
evolution of E. coli cross-resistance suggested that genetic changes in the tsx gene were likely
involved. To examine this idea, we conducted whole genome sequencing (WGS) of all 29 strains.
While some strains showed some single nucleotide variants (SNVs) and short insertions or
deletions (indels) in tsx, many strains had no observable mutations in any genes using multiple
variant calling pipelines including GATK
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and breseq
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. While WGS and variant calling

pipelines are amenable for detecting SNVs and short indels, structural variants (SVs), including
movement of transposable elements, are not easily detected 222. Therefore, we conducted targeted
Sanger sequencing of tsx in all 29 resistant mutants. As expected, results for the wild-type showed
no mutations in tsx; however, mutations in tsx were identified in all 29 resistant mutants. For the
10 T6-resistant strains we observed the following mutations in the tsx gene: 3 insertion sequence
(IS) elements, 3 deletions, 3 nonsense mutations and 1 missense mutation (Figure 5.4 A,
Supplemental Table S5.2). For the 10 U115-resistant strains, we documented the following in tsx:
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4 IS elements, 2 deletions, 1 insertion, 2 missense mutations, and 2 nonsense mutations (Figure
5.4 A, Supplemental Table S5.2). Interestingly, of the 10 pairs of phage-resistant mutants isolated
from the same parent culture, only 3 pairs (T6R4/U115R4; T6R8/U115R8; T6R10/U115R10)
showed identical mutations in tsx (Figure 5.4 B, Supplemental Table S5.2). For the 9 albicidinresistant mutants we observed 6 IS elements, 2 deletions, and 1 missense mutation in tsx (Figure
5.4 A). In addition, our data showed that eight of the 29 mutations in tsx clustered within the region
spanning base pairs 375 to 435 (Figure 5.4 B). While it is likely that these mutations are conferring
resistance to phage T6, phage U115 and albicidin, this was not experimentally confirmed via
recombinant genetics because the work fell outside the scope of the current study.
Discussion and Conclusion
The phage life cycle relies on surface-exposed molecules to initiate infection and bacterial
metabolism to replicate inside cells. Since phages T6 and U115 both require Tsx as a primary
receptor, it is not surprising that spontaneous mutants to one phage confer resistance to the other
phage 215. However, it is interesting that all 20 phage-resistant mutants are also cross-resistant to
albicidin and that all 9 albicidin resistant mutants are cross-resistant to both phages. It was
previously observed that T6-resistant mutants maintained their sensitivity to colicin-K, another
antibiotic that enters via the Tsx porin 106. While all three antibacterials used in the current study
require Tsx as a receptor, it is unclear whether replication of phages T6 and U115 and the
mechanism of action of albicidin also converge on the same gene to confer resistance. Albicidin
is a DNA gyrase inhibitor that blocks topoisomerase II, an enzyme which cleaves both strands of
DNA to modulate supercoiling during DNA replication, gene regulation, and transcription
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.

Phages require the DNA replication machinery of the host bacterial cell to make viral progeny
within the cell; however, many phages, including T6, encode their own topoisomerases

223

.
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Furthermore, the minimum inhibitory concentrations (MICs) of ciprofloxacin (another DNA
gyrase inhibitor) and ampicillin for wild-type BW25113 bacteria and for each of the 29 resistant
mutants did not differ statistically (Supplemental Table S5.3). These observations of unchanged
phenotypes imply that selection by phage T6, phage U115, and albicidin seems to evolutionarily
converge on the tsx locus, rather than involving changes at other loci. Indeed, the results of the
targeted sequencing indicated this possibility, because each mutant was observed to undergo a
change in the tsx gene (i.e., as opposed to no mutation at this locus, suggesting resistance occurred
via a different mechanism). While the identified mutations were not validated as the causative
mutations of resistance, it seems likely that the 29 different mutations found in tsx were conferring
resistance to phage T6, phage U115, and albicidin. The combination of tsx mutations observed in
all 29 resistant mutants and the lack of detectable fitness defects in these strains indicate that Tsx
may be superfluous for E. coli in the laboratory environment.
The 29 observed mutations in tsx fall within the promoter region, as well as various other
locations along the gene. However, there seems to be a cluster of ‘hotspots’ for mutational changes
in the region spanning 332 to 435 base pairs. These residues make up a surface exposed alpha helix
and a beta sheet that spans the outer membrane of the bacteria. All of the mutations in this region
were observed in phage-resistant strains, indicating that perhaps amino acid residues 88 through
123 are important for phage binding, but not albicidin entry.
Moreover, of the 10 “paired” phage-resistant mutants, only 3 of the pairs (T6R4/U115R4;
T6R8/U115R8; T6R10/U115R10) showed the same tsx mutation. This means that even in a clonal
population of E. coli, there are often multiple spontaneous mutants with different changes in tsx.
This finding indicates that the number of resistant mutants observed to arise during fluctuation
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assays cannot be used to compute a rate of spontaneous mutation; instead, these data should only
be used to calculate a rate of spontaneous phenotypic resistance.
It is also interesting that the profile of tsx mutations was different for the phage-selected
resistant mutants, compared with the antibiotic-selected resistant mutants. There were 6 albicidinresistant mutants with an IS element inserted in tsx, while 3 of each of the phage-resistant mutants
showed IS-element changes in tsx. This observation could be due either to a difference in selection
pressures of phages versus antibiotics, or to a difference in the method of selection to amass these
mutants. Underlying these possibilities are two opposing ideas. It has been previously assumed
that insertion and excision of IS elements are stochastic events. However, recent evidence suggests
that IS movement may actually be a form of directed mutagenesis in which IS elements target
specific chromosomal loci to reduce stress under certain environmental conditions
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. The

isolation of phage-resistant mutants in this study relied on spontaneous mutations accumulated in
an overnight culture, while the isolation of antibiotic-resistant mutants allowed for both selection
of spontaneous resistant mutants as well as evolution in the presence of albicidin. This difference
suggests that the larger proportion of IS element insertions in tsx found in the set of albicidinresistant mutants might be caused by direct targeting of tsx by IS elements under stressful
conditions. Without further experiments that use the same method to select for spontaneous phage
and albicidin resistant mutants, we cannot rule out that a difference in selection pressures between
phages and the antibiotic resulted in the skew of IS-element-insertion changes in tsx found in the
albicidin-resistant mutants.
Finally, it is worth noting that all 29 resistant mutants have gained fitness relative to wildtype in the presence of albicidin or phage, with no appreciable fitness cost in an ordinary
environment. Antibiotic cross-resistance has extreme clinical relevance as selected resistance to a
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single antibiotic can also result in evolution of multi-drug resistance. Here, we showed that phage
resistance can result in antibiotic resistance, and vice versa, at no fitness cost. This highlights a
potential pitfall of the future therapeutic use of any antimicrobial whether it be phage or antibiotics.
Without a clear understanding of the evolutionary implications of treatment, antimicrobial
selection can result in both resistance and cross-resistance at no fitness cost to the bacteria.
Materials and Methods
Strains and culture conditions
Strains in this study are listed in Supplemental Table S5.4. E. coli strains were cultured for 24
hours with shaking incubation at 37ºC in lysogeny broth 16. The Tsx knockout, BW25113∆tsx, was
used as a negative control in many experiments. A pseudogene knockout, BW25113∆icdC, was
used as a control for the KanR cassette and as a marked competitor in the competition assays.
Where appropriate, LB was supplemented with kanamycin at 30 µg/mL (LB Kan30). X.
albilineans strains (provided by D. Gabriel, U Florida) were cultured for 48 hours with shaking at
30ºC in Modified Wilbrinks (MW) medium 225. Lysates of phages T6 and U115 were obtained by
mixing each phage with E. coli strain BW25113 in LB medium and culturing for 24 hours at 37ºC,
followed by filtration (0.22 µm) to remove bacteria.
Isolation of phage-resistant bacterial mutants
Ten cultures of E. coli strain BW25113 were grown independently as described above, and diluted
samples were spread on LB agar (1.5% agar) plates, pre-saturated with either phage T6 or phage
U115. After overnight incubation at 37ºC, one colony was chosen randomly from each plate and
colony-purified three times. For each of the 20 isolated mutants, phage resistance was confirmed
via efficiency of plaquing (EOP) assays, which compared plaquing ability of phage T6 or U115
on the test mutant relative to growth on wild-type strain BW25113.
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Isolation of antibiotic-resistant bacterial mutants
X. albilineans strain XA23 was cultured as described above, and a 10 µL sample was spotted onto
each of ten Sucrose Peptone agar (SPA) plates that were incubated for 5 days at 30ºC 226. A sample
from each of ten independently-grown cultures of BW25113 was then overlaid on one of the SPA
plates, and incubated overnight at 37ºC. Colonies that appeared in the zone of growth inhibition
around the XA23 spot represented spontaneous E. coli mutants that were resistant to albicidin. One
plate was lost due to contamination; from each of the remaining 9 plates, one colony was randomly
chosen and colony-purified three times. Albicidin resistance of each mutant was verified by plating
a sample of a grown-up culture of the isolate on an XA23 spot, as described above.
Antibiotic-resistance assays
X. albilineans strains XA23 and LS126 were each cultured for 48 hours at 30ºC, and their optical
densities at wavelength l = 600 nm (OD600) were estimated via spectrophotometry. Each culture
was then diluted in MW medium, to obtain OD600 = 0.25. Then, a 10 µL sample of each diluted
culture was spotted on a SPA plate, allowed to dry completely and then incubated for 5 days at
30ºC. SPA plates were overlaid with 4 mL of LB top agar (0.75%) with 1 mL of a test E. coli strain
at OD600 = 0.25, and incubated overnight at 37ºC. The next day, plates were imaged. Images were
quantified using ImageJ, by thresholding until either the X. albilineans spots or E. coli clearings
were outlined and the area within the outline was quantified. The ratio of the area of the zone of
clearing to the area of the X. albilineans spot was used to define albicidin sensitivity: a ratio of
greater than 1.0 indicates albicidin sensitivity, while a ratio of 1.0 indicates albicidin resistance.
Minimum inhibitory concentrations (MICs) of ampicillin and ciprofloxacin were determined using
the two-fold dilution method 227.
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Bacterial growth curves
E. coli bacteria were cultured overnight as described above. Dilutions of a test strain in LB medium
were placed in wells of a flat-bottomed 96-well plate, in the absence of phage or mixed with phage
at a multiplicity-of-infection (MOI; ratio of phage particles to host cells) of ~10. Plates were
incubated with shaking for 18 hours in an automated spectrophotometer at 37ºC, and OD600
measurements were obtained every 10 minutes. Growth curve data were fit to a logarithmic curve
using GrowthCurver and growth parameters were extracted

220

. All growth curve data will be

deposited on Dryad (doi:10.5061/dryad.ghx3ffbmn).
Bacterial competition assays
Replicated (n = 3) competition assays were conducted in LB medium by mixing two bacterial
strains at a 1:1 initial ratio, and serially passaging (1:100 dilution) every 24 hours for 72 hours
total. At the end, a diluted sample of each competition was plated on LB agar to measure viable
bacterial density (colony-forming units; CFU), and on LB Kan30 agar to estimate the CFU of a
KanR competitor; the density of the KanS competitor was estimated by subtraction. Competitive
indexes were calculated as the ratio of resistant-mutant CFU to the CFU of BW25113∆icdC
divided by the ratio of BW25113∆icdC CFU to BW25113 CFU. Each ratio was normalized by the
starting ratio each competing strain.
Sequencing
Sequencing libraries were prepared using Illumina’s Nextera prep kit. Whole genome sequencing
was done using paired-end 150bp reads on the Illumina NextSeq platform or paired-end 300bp
reads

on

the

Illumina

HiSeq

platform.

For

targeted

sequencing,

primers

(5’-

CTGTGAAACGAAACATATTTTTG-3’ and 5’-CGTGCTTTTGTTGGC-3’) were designed
~100 base pairs upstream and downstream of E. coli gene tsx, and used to amplify tsx of each

155

resistant mutant and the ancestral BW25113 strain. Amplicons were Sanger sequenced at the Yale
DNA Analysis Facility on Science Hill. Mutations were identified by comparing sequencing reads
to tsx loci of the reference strain GenBank CP009273.1
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Chapter 5 Figures & Tables
Figure 5.1 Tests of albicidin resistance

Tests of albicidin resistance for representative spontaneous mutants of E. coli, selected for resistance to phage T6,
phage U115, or albicidin. Wild-type BW25113 and the positive-control BW25113DicdC showed inhibited growth on
agar plates with albicidin-producing X. albilineans (XA23), and normal growth on the non-producer, LS126. In
contrast, mutants (T6R1, T6R2, U115R5, U115R6, albR4, albR7) and negative-control BW25113Dtsx grew equally
well in the presence/absence of albicidin-producing bacteria.
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Figure 5.2 Growth dynamics of representative E. coli mutants

Growth dynamics of representative E. coli mutants selected for resistance to phage T6, phage U115, or albicidin, in
environments with and without each phage. A-B Wild-type BW25113 bacteria grew only in phage absence (solid
line), whereas Tsx knockout strain BW25113Dtsx grew similarly in phage-free as well as T6 (dashed line) and U115
(dotted line) environments. C-H Each of the representative resistant mutants grew similarly in the presence/absence
of phages T6 and U115, regardless of their prior selection for phage or albicidin resistance. I Intrinsic growth rate (r;
proxy for fitness) estimates from growth-curve data (A-H and Supplemental Figure S5.2) showed that each strain
did not differ statistically from BW25113 (P > 0.05; unpaired t-tests).
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Figure 5.3 Competition assays

Competition assays showed that E. coli mutants resistant to phage T6 A phage U115 B or albicidin C did not
measurably differ in fitness, relative to a non-resistant wild-type strain. Each point represents results from independent
competition assays (n = 3), and statistical significance was determined using a t-test comparing competitive index of
the resistant mutant relative to the competitive index of BW25113DicdC.
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Figure 5.4 Mutations in tsx

Mutations in tsx A Proportions of tsx mutations observed in sets of E. coli strains, selected for spontaneous resistance
to either phage T6, phage U115 or albicidin. Mutations were due to insertion sequence elements (blue), deletions (red),
insertions (yellow), missense mutations (purple) and nonsense mutations (orange). B Locations of tsx mutations for
each resistant mutant.
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Chapter 5 Appendix
Supplemental Figure S5.1 Tests of albicidin resistance for spontaneous mutants of E. coli

Tests of albicidin resistance for spontaneous mutants of E. coli not described in main text, selected for resistance to
phage T6, phage U115 or albicidin antibiotic. A Quantification of albicidin resistance (ratio of cleared zone to area
of X. albilineans growth) showed that each mutant and the Tsx-knockout strain, BW25113Dtsx, were albicidinresistant (ratio = 1.0), whereas wild-type BW25113 and positive-control BW25113DicdC bacteria were albicidinsensitive (ratio > 1.0). B In all cases, mutant growth on agar plates was not inhibited by albicidin-producing X.
albilineans (XA23), and growth was normal on non-producer strain LS126 controls.
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Supplemental Figure S5.2 Growth dynamics of E. coli mutants

Growth dynamics of E. coli mutants selected for resistance to phage T6, phage U115, or albicidin, in environments
with phage T6 (dashed line), with phage U115 (dotted line), and without phages (solid line). A-X In all cases, mutants
grew similarly in presence/absence of phages T6 and U115, regardless of their prior selection for phage or albicidin
resistance.
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Supplemental Table S5.1 Efficiency of plaquing
Efficiency of Plaquing
Phage T6
BW25113 ∆icdC
1.11 ± 0.55
BW25113 ∆tsx
0*

Phage U115

T6 R1

0*

1.32 ± 0.16
0*
0*

T6 R2
T6 R3
T6 R4
T6 R5
T6 R6
T6 R7
T6 R8

0*
0*
0*
0* ^
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*

0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*

0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*

0*
0*
0*
0*
0*
0*
0*
0*
0*
0*
0*

T6 R9
T6 R10
U115 R1
U115 R2
U115 R3
U115 R4
U115 R5
U115 R6
U115 R7
U115 R8
U115 R9
U115 R10
alb R1
alb R2
alb R3
alb R4
alb R5
alb R6
alb R7
alb R8
alb R9

Efficiency of plaquing (EOP) for phages T6 and U115 on challenge strains of E. coli, selected for spontaneous
resistance to each phage or to albicidin. EOP is defined as phage titer (PFU/mL) on the test strain divided by that on
wild-type BW25113; EOP = 0 indicates phage growth on the challenge is below the limit of detection (<100 PFU/mL).
Positive (BW25113DicdC) and negative (BW25113Dtsx) controls confirm expected susceptibility and resistance to
each phage in replicate (n = 3) assays, whereas, all 29 mutants show cross-resistance to phage infection. Statistical
significance (*; P < 0.05) indicates result of an unpaired t-test comparing three replicate measures to the EOP on
BW25113DicdC. The ‘^’ indicates a phage with observable turbid clearing of the challenge-bacteria lawn, without
making visible plaques.
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Supplemental Table S5.2 Mutations in tsx
Strain

Mutation Type

Position Notes

T6 R1

Deletion

291-321 31 base pair deletion, new stop codon at residue 101

T6 R2

Insertional Element -75

T6 R3

Deletion

402-733 332 base pair deletion

T6 R4

Nonsense

773

T6 R5

Insertional Element 403

IS2 with sequence [GGTCGTA] repeated

T6 R6

Nonsense

G435A (W146Stop)

T6 R7

Insertional Element 165

IS2 with sequence [GGAAC] repeated

T6 R8

Missense

725

* T725G (L242R)

T6 R9

Nonsense

535

G535T (E179Stop)

T6 R10

Deletion

410-420 * 11 base air deletion, new stop codon at residue 24

U115 R1

Insertional Element 400

IS3 with sequence [ATG] repeated

U115 R2

Insertion

1 base pair insertion at position 53, new stop codon at residue 24

U115 R3

Insertional Element 774

IS1 with sequence [GACAGCGGT] repeated

U115 R4

Nonsense

773

* G773A (W258Stop)

U115 R5

Missense

31

U115 R6

Insertional Element 161

T31A (V11E)
IS2 with sequence [GCAAC] repeated

U115 R7

Nonsense

375

C375G (Y125Stop)

U115 R8

Missense

725

* T725G (L242R)

U115 R9

Deletion

429-435 7 base pair deletion, new stop codon at residue 157

U115 R10

Deletion

410-420 * 11 base air deletion, new stop codon at residue 24

alb R1

Insertional Element -3

IS1 with sequence [CATATGAAA] repeated

alb R2

Insertional Element 344

IS1 with sequence [ACCTTAGCTTCGGT] repeated

alb R3

Deletion

1 base pair deletion, new stop codon at residue 111

alb R4

Insertional Element 116

IS5 with sequence [TTAA] repeated

alb R5

Insertional Element 665

IS2 with sequence [GTAAC] repeated

alb R6

Insertional Element 692

IS1 with sequence [TAAGACCCG] repeated

alb R7

Insertional Element -16

IS1 with sequence [GGGATTTC] repeated

alb R8

Missense

161

G161C (R54P)

alb R9

Deletion

4

1 base pair deletion, new stop codon at residue 111

435

53

64

IS2 with sequence [AGGCTCCTC] repeated
* G773A (W258Stop)

* Indicates paired phage resistant mutants with the same mutation

Putative resistance mutations in the tsx gene, for each E. coli mutant selected for spontaneous resistance to either
phage T6, phage U115, or albicidin.
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Supplemental Table S5.3 Minimum inhibitory concentrations of ciprofloxacin and ampicillin
Ampicillin
(µg/mL)

Ciprofloxacin
(ng/mL)

20 ± 0
20 ± 0
20 ± 0
20 ± 0

11.67 ± 7.64
11.67 ± 7.64
13.33 ± 5.77
13.33 ± 5.77

BW25113 ∆tsx

20 ± 0
26.67 ± 11.55

6.67 ± 2.89
10 ± 0

T6 R1
T6 R2

20 ± 0
20 ± 0

6.67 ± 2.89
10 ± 0

T6 R3
T6 R4

20 ± 0
20 ± 0

8.33 ± 2.89
8.33 ± 2.89

T6 R5
T6 R6

20 ± 0
20 ± 0
20 ± 0

10 ± 0
8.33 ± 2.89
11.67 ± 7.64

T6 R9
T6 R10

20 ± 0
20 ± 0
20 ± 0

8.33 ± 2.89
13.33 ± 5.77
13.33 ± 5.77

U115 R1
U115 R2

20 ± 0
20 ± 0

10 ± 0
10 ± 0

U115 R3
U115 R4

20 ± 0
20 ± 0
20 ± 0

10 ± 0
8.33 ± 2.89
8.33 ± 2.89

U115 R7
U115 R8

20 ± 0
20 ± 0
10 ± 0

6.67 ± 2.89
8.33 ± 2.89
8.33 ± 2.89

U115 R9
U115 R10

20 ± 0
20 ± 0

11.67 ± 7.64
8.33 ± 2.89

alb R1
alb R2

20 ± 0
20 ± 0
20 ± 0

11.67 ± 7.64
13.33 ± 5.77
13.33 ± 5.77

alb R5
alb R6

20 ± 0
20 ± 0
20 ± 0

13.33 ± 5.77
8.33 ± 2.89
8.33 ± 2.89

alb R7
alb R8

20 ± 0
20 ± 0

8.33 ± 2.89
13.33 ± 5.77

albR9

20 ± 0

10 ± 0

Strain
BW25113
BW25113 ∆icdC

T6 R7
T6 R8

U115 R5
U115 R6

alb R3
alb R4
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Supplemental Table S5.4 Strains used in this chapter

Antibiotic
Reference or
Resistance Cassette Source

Strains
BW25113
BW25113 ∆icdC
BW25113 ∆tsx
T6 R1
T6 R2
T6 R3
T6 R4
T6 R5
T6 R6
T6 R7
T6 R8
T6 R9
T6 R10
U115 R1
U115 R2
U115 R3
U115 R4
U115 R5
U115 R6
U115 R7
U115 R8
U115 R9
U115 R10
alb R1
alb R2
alb R3
alb R4
alb R5
alb R6
alb R7
alb R8
alb R9
XA23
LS126

Species
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
X. albilineans
X. albilineans

Phage
T6
U115

Reference or Source
J. Wertz (Yale U)
215

KanR
KanR
KanR, StR

CGSC
CGSC
CGSC
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
219
219

KanR, Kanamycin resistance; StR, Streptomycin resistance; CGSC, Coli Genetic
Stock Center
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